













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 





Biocatalytic application of rare PLP-
dependent aminotransferases for the 










A Thesis Submitted for the Degree of  
Doctor of Philosophy 
The University of Edinburgh 
2018 
 







Traditional chemical approaches for the production of compounds often rely on harsh 
conditions such as high temperature and pressure and create toxic waste and pollutants. 
Moreover, these reactions are often non efficient, creating unwanted side products that 
need to be disposed of. A very important branch of chemistry, called green chemistry, 
supports the design of products and processes that use the least amount of dangerous 
substances as they can.  An important aspect of green chemistry is biocatalysis, which 
consists of the use of biological systems, either whole cells or enzymes for the production 
of compounds. Indeed, enzymes represent a very valid alternative for the production of 
chemicals in a more ‘green’, eco-friendly way. Enzymes have the main advantage of 
requiring mild conditions (room temperature, atmospheric pressure) and being extremely 
efficient, minimizing the production of unwanted side products. Moreover, enzymes are 
biodegradable which means that they are degraded over time.   
An important class of compounds that find a broad range of applications from 
pharmaceuticals to personal care products are the chiral amines. The traditional chemical 
approach for their production requires dangerous metals and is very inefficient. A very valid 
alternative for their production is represented by aminotransferase enzymes that are able 
to yield the desired product in high purity. 
In this work two aminotransferases, the D-Phenylgylcine aminotransferase (D-PhgAT) 
and the amino-pentol aminotransferase FumI are explored as tools for the production of 
high value compounds. These compounds are the D-phenylglycines, which are key 
molecules for the production of antibiotics and the fatty amines that are used as detergents 
















Optically active amines and amino acids are ubiquitously distributed in nature where they 
play many crucial roles. Moreover, it was recently estimated that around 40% of 
blockbuster drugs and 20% of agrochemicals contain chiral amines in their structure, thus 
there has been considerable effort in developing efficient, low cost and widely-applicable 
methods for their production. Compared to classical chemical synthesis, aminotransferase 
(AT) enzymes have been widely explored as a more efficient and sustainable method for 
the preparation of optically pure amines from the corresponding ketones. In several cases 
these biocatalysts have replaced the existing chemical catalysts, which are limited by their 
high cost and poor regio- and stereoselectivity. 
Two very interesting, distantly-related class III bacterial ATs have been investigated 
in this study: the D-phenylglycine (D-Phg) aminotransferase (D-PhgAT) and the amino-
pentol AT (FumI). The D-PhgAT from Pseudomonas stutzeri ST-201 catalyses the reversible 
transamination from L-glutamic acid to benzoylformate, yielding α-ketoglutarate and D-Phg 
with high (>99%) enantiomeric excess (% ee). The D-PhgAT possesses the unique feature 
that the amino acid donor and amino acid product display an inverted absolute 
configuration. Thus, D-PhgAT is a very promising biocatalyst as it yields high value D-amino 
acids from inexpensive L-amino acid donors.  
By carrying out a detailed kinetic analysis of recombinant D-PhgAT the best 
substrates were identified and an optimized method, delivering a range of enantiopure 
aromatic D-amino acids at 1 g scale, has been developed. Moreover, the x-ray crystal 
structure of D-PhgAT at 2.25 Å resolution has been determined with its pyridoxal 5’-
phosphate (PLP) cofactor bound as an internal aldimine. The active site architecture 
highlights various residues potentially involved in catalysis and illuminates the basis of the 
exquisite enantioselectivity of this unique member of the AT superfamily. These studies 
promote D-PhgAT as a useful tool for the sustainable production of high value, aromatic D-
amino acids. 
Fatty amines (C8-C20) are high value products with a wide variety of applications in 
fabric softeners, detergents and cosmetic formulations. The unusual Sphingopyxis FumI 
detoxifies the C20 mycotoxin natural product fumonisin B1 (FB1). FumI catalyses 
 






transamination at the C2 position of a hydrolyzed fumonisin B1 (HFB1) derivative with 
pyruvate as the amino acceptor. A screen of prochiral C2 ketones of varying chain length 
(C3-C17 2K) with L-alanine as amino donor has revealed that the recombinant FumI is 
capable of producing alkyl-amines of various chain lengths (C3-C17) by working in the 
reverse direction. Chiral HPLC analysis has revealed that the enzyme generates (S)-amines 
with high ee (>99%). The regioselectivity of FumI was also determined using prochiral keto-
substrates with substitutions along the chain (such as 3-decanone (C10-3K) and 5-decanone 
(C10-5K)). Interestingly, C10-3K, but not C10-5K, was converted to the corresponding 
amine. A range of long chain aldehydes (C10-C20) were also converted by FumI to the 
corresponding amines with L-Ala as the amino donor. The x-ray crystal structure of the PLP-
bound, internal aldimine form of FumI was solved to a resolution of 1.6 Å by molecular 
replacement using a Bacillus subtilis AT as a model. The structure suggested residues 
potentially involved in catalysis and revealed a potential hydrophobic binding site for the 
long alkyl chain substrates. The combination of aldehyde and ketone alkyl chain substrate 
promiscuity, the high enantioselectivity and the 3D structures of this rare AT suggests that 
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1 Introduction  
1.1 Biocatalysis 
1.1.1 A Background to biocatalysis 
Biocatalysis, or the practise of using enzymes to catalyse reactions between organic 
components, has a long history. Indeed, the first use of enzymes can be dated back to 5000 
B.C. when the ancient Egyptians used them for the preservation and production of food 
and alcoholic drinks.1 At that time there was no concept of enzymes and the science behind 
those transformations was a mystery to our ancestors. The relationship between humans 
and enzymes has evolved since then and now enzymes are used to carry out a wide variety 
of chemical biotransformations, defining the field of biocatalysis.2–4  
The biocatalysis field has flourished in recent years due to an array of factors. 
Unlike homo- and heterogeneous catalysts that rely on harsh and energy-intensive 
processing, enzymes are renewable, biodegradable and biocompatible. Enzymes require 
mild reaction conditions; a typical enzyme-catalysed procedure is usually carried out at 
room temperature, neutral pH and atmospheric pressure, without requirement of 
particular instruments (such as high pressure hydrogenation equipment).5–7 Biocatalysts 
also possess chemo-, regio- and enantio-selectivity, ensuring that the desired product is 
produced in one step and without the need for protection and deprotection steps, common 
in enantio- and regioselective organic synthesis.  Biocatalysis therefore has features that 
are very attractive in the context of green chemistry and sustainable development.8 
Biocatalysis has reached its present relevance through waves of innovation and 
technology development. In 2012, Bornscheuer and colleagues described the development 
of modern biocatalysis over three main periods of times, named the ‘three waves of 
biocatalysis’.9 The first wave can be traced back to over a century ago (1910-1980) when 
plants, animal tissue extracts or microbial strains having the enzymatic activity of interest 
were applied to useful chemical transformations such as the hydroxylation of steroids using 
different microorganisms.10 The second wave of biocatalysis, which began in the 1980s, saw 
the expanding of the number of gene sequences and the determination and submission of 
 






high resolution protein structures to the Protein Data Bank (PDB). Initial protein 
engineering, typically structure based, allowed the expansion of the substrate scope of 
enzymes and the synthesis of unusual intermediates. The third wave of biocatalysis started 
in 1990s and runs until today. It is defined by the development of pioneering molecular 
biology techniques by Stemmer and Arnold.11 These techniques, known as directed 
evolution, mimic the Darwinian process of natural selection to evolve proteins to a user 
defined goal. Thanks to the continued development of these techniques, the timescale for 
the development of enhanced biocatalysts is now measured in months rather than in 
years.12 At the Biocatalysis Gordon Research Conference (GRC), held in Maine on July 2018, 
speculations to what will constitute the ‘fourth wave of biocatalysis’ have been made, 
suspecting that it will be focused on the development of combinations of multiple enzymes 
together which are linked via cascade processes or metabolic engineering and by 
combining chemo- and biocatalytic approaches.13  
In a broad spectrum of modern industrial applications there is a continual increase 
in the use of biocatalytic processes, not only in pharmaceuticals but also in food, feed and 
fine chemical sectors.12–14 The global enzyme market in 2018 has been estimated at $4.4bn 
and is shared between a wide varieties of sectors, from organic synthesis to personal care 
(Figure 1.1, Table 1.1).17   
 
Figure 1.1 Industrial application of enzymes according to their sector.  
Currently, well over 500 distinct industrial products are made using enzymes and 
approximately 150 industrial processes use enzymes or whole cells catalysis.18 One such 
example is the manufacture of acrylamide, a key monomer for non-ionic and ionic 
 






polyacrylamides. The chemical synthesis of acrylamide requires a copper catalyst, but this 
has been completely supplanted by a biocatalytic approach based on the use of a nitrile 
hydratase enzyme, conducted on a scale of tens of thousands of metric tons per year 
(Figure 1.2).19,20 Other examples include the production of semisynthetic penicillin by 
employing penicillin amidases21 or the production of high corn syrup by the action of xylose 
isomerase22 (Table 1.1). 
 
Figure 1.2 Example of a bulk chemical produced by enzymatic catalysis. This process, used for the 
commercial production of pure acrylamide has been developed by Nitto Chemical Industry 
Company. 
Table 1.1 Biotransformation on industrial scales. Adapted from Sánchez-Carrón.17 
T/a Product Enzyme 
> 1,000,000 High-fructose corn syrup Glucose isomerase 
> 100,000 Lactose-free milk Lactase 
> 10,000 Acrylamide Nitrilase 
 Cocoa butter Lipase 
> 1,000 Nicotinamide Itrilase 
 D-Pantothenic acid Aldonolactonase 
 (S)-Chloropropionic acid Lipase 
 6-Aminopenillanic acid Penicillin amidase 
 Aspartame Thermolysin 
 L-Aspartate Aspartase 
 D-Phenylglycine Hydantoinase 
 4-hydroxy-D-Phenylglycine Hydantoinase 
>100 Ampicillin Penicillin amidase 
 L-Methionine, L-Valine Aminoacylase 
 L-Carnitine Dehydratase/hydroxylase 
 L-DOPA B-Tyrosinase 
 L-Malic acid Fumarase 
 (S)-Methoxyisopropyl-amine Lipase 
 (R)-Mandelic acid Nitrilase 
 L-Alanine L-Aspartate-β-decarboxylase 
 
 






1.1.2 The biocatalysis cycle 
The development of a biocatalytic process can be illustrated as the ‘biocatalytic cycle’ 
(Figure 1.3).17,23 The starting point usually consists of the identification of a product of 
interest, which ideally can be produced biosynthetically using different enzymes.  Such 
enzymes can either be commercially available/described in the literature or identified by 
screening for organisms (cultured or uncultured) catalysing the desired reaction. The genes 
encoding the desired enzymes can be codon optimised for expression in the selected host 
organism and purchased (e.g. GenScript). Once one or more biocatalysts are obtained, a 
kinetic characterisation is carried out and structural information are acquired by solving of 
the 3D structure or by homology modelling.  
 
Figure 1.3 The biocatalysis cycle. Adapted from Sánchez-Carrón and Schmid et al.17,23 
The biocatalyst and the biocatalytic process are then engineered for optimal performances 
at the level of the enzyme and/or the process. Commonly, iterative cycles of protein 
engineering are required to improve a specific enzyme to the desired standards (activity, 
substrate range, etc.). Once the biocatalyst has the desired characteristic other issues such 
as stability, cofactor recycling and/or biocatalyst recovery can be addressed. The reaction 
medium, consisting of an aqueous, organic or two-liquid phase system is usually optimised 
to dissolve the components of the reaction while retaining enzyme activity. Many 
biocatalysts are used in immobilized form as it eliminates the drawbacks associated with 
 






substrate and product inhibition and allows a very easy product separation.24,25 If 
immobilised, the enzyme can be re-used multiple times, drastically reducing the reaction 
costs. This biocatalytic cycle can be iterated multiple times to reach an efficient industrial 
process that meets the requirements in terms of catalyst stability, conversion and cost-
efficiency.17,23 
1.1.3 Case study - sitagliptin manufacture:  a tale of biocatalysis  
For a given biotransformation, the performances of the wild type (WT) enzymes with the 
target compounds under the desired reaction conditions are often not satisfactory and 
enzyme evolution is frequently necessary. Indeed, in several cases, the WT enzyme does 
not show any activity towards the desired substrate whatsoever and several rounds of 
evolution are necessary to achieve conversions up to industrial standards.26 
A spectacular example of a biocatalyst redesigned by directed evolution for the 
production of the active pharmaceutical ingredient (API) is the ATA-117 for Sitagliptin 
manufacture. Sitagliptin is the active ingredient of Januvia™, a top selling drug for type II 
diabetes developed by Merck and synthesised by high pressure rhodium mediated 
asymmetric hydrogenation.27 The Rh mediated process was highly stereospecific (> 97% 
enantiomeric excess (ee)) but the residual catalyst required removal upon carbon 
treatment and the overall process was not ‘green’.  
Merck, together with the leading biocatalysis company Codexis, investigated the 
use of an aminotransferase (AT) for the conversion of the key pro-sitagliptin ketone into the 
sitagliptin amine. An (R)-selective AT (ATA-117) from Arthrobacter sp. was selected for 
enzyme evolution using a combined in silico design and directed evolution approach. 
Several rounds of mutagenesis were required to achieve a satisfying conversion of the 
bulky pro-sitagliptin ketone under the desired reaction conditions (40,000-fold activity 
increase in 50% DMSO, 40 °C). The final variant, which held 27 mutations, was able to 
convert 200 g L-1 prositagliptin with 99.95% ee at 92% yield (Figure 1.4).28 These 27 
mutations are found in several positions, not only in the active site but also at the enzyme 
dimer interface which most likely stabilise the dimeric form of the enzyme under conditions 
(such as 50% DMSO) that would normally cause enzyme denaturation.27,28 
 






The biocatalytic approach has several benefits compared to the chemocatalytic 
process, such as a productivity increase of 50%, waste reduction of 19%, heavy metal 
elimination and overall cost reduction. Furthermore, no high-pressure hydrogenation 
equipment was needed. This 2010 study still represents one of the flagship applications of 
an industrial biocatalyst today, highlighting the advantages of adopting the biocatalytic 
strategy over the chemical counterpart and was recognized with the 2010 Presidential 
Greener Reaction Conditions Award from the United States Environmental Protection 
Agency. 
 
Figure 1.4 Comparison between the A) chemocatalytic and B) biocatalytic route for sitagliptin 
manufacturing. The prositagliptin ketone is converted into the Sitagliptin amine in high yield and ee 
Adapted from Savile et al.27 
 
 






1.1.4 Limitations of biocatalysis  
Despite the advantages of biocatalysis and its increased application in many sectors, there 
are still a number of drawbacks associated with biocatalysis as a generally applicable 
technique. Problems such as limited stability of the biocatalysts under operative conditions, 
an insufficient number of well-characterised, ready-to-use enzymes and high development 
costs have to be addressed.29,30 Due to the existence of well-developed chemical tools, the 
improvement and optimisation of traditional chemical transformations are generally still 
faster when compared to the biocatalytic approach. There is still a lack of optimal, off-the-
shelf biocatalysts that can be used for multiple biotransformations and protein engineering 
is usually necessary to ensure an enzyme works for a given substrate and in the desired 
reaction conditions (e.g. high solvent, high temperature). Thus, for a biocatalytic process to 
be established it should bring significant improvements and typically represents a second-
generation method, supplanting a pre-existing chemical process.   
For some reactions, such as the enzymatic reduction of ketones, biocatalytic 
processes are competitive with their chemical counterparts. However, for many others, the 
chemical approach is still preferred. Despite this, the use of enzymes is broadening and is 
already quite prominent in the production of fine-chemicals and pharmaceuticals (Table 
1.1). Opportunities are available for combining chemo- and bio-catalysis and overcoming 
some of the limits associated with both approaches.  
Currently, a growing number of companies see biocatalysis as an appealing option 
and are investing in developing a core suite of biocatalytic tools to optimise production 
schemes. In particular, enzyme panels from different suppliers (e.g. Prozomix, Codexis) are 
increasingly becoming available to allow for screening of interesting enzyme activities, 
which could be useful for the synthesis of APIs. Biocatalysis is poised to play an ever-
increasing role in the manufacture of chemicals, and in the next decade more processes are 
expected to adopt it. This paradigm shift will be facilitated by high throughput screening 
(HTS), which will be crucial for testing large libraries of mutant enzymes in short time 
frames. Additionally, bioinformatic software that will accurately predict hot spots for 
mutations will reduce the time required to obtain new biocatalysts and improved 
variants.31 
 






1.2 The importance of chirality  
1.2.1 Chiral drugs 
Biocatalysis is gaining increased attention for its ability to perform stereoselective 
transformations in an environmentally friendly way.32 The creation of a stereogenic centre 
via organic synthesis is not trivial, and multiple approaches have been described based on 
organometallic and organocatalytic methods.33,34 In 2006, 90% of the Food and Drug 
Administration (FDA) approved drugs were chiral compounds and thus the development of 
novel, green approaches to the synthesis of chiral centres is of paramount importance.35 As 
such, the intrinsic chirality of enzymes makes them a powerful tool for the development of 
stereoselective transformations.  
Drug isomerism is a crucial consideration in drug development. This is because 
although isomers have the same chemical structure, most drug isomers exhibit differences 
with respect to the pharmacology, toxicology, pharmacokinetics, and metabolism.36 This is 
exemplified by the tragic history of thalidomide (thalidomid, Contergan), which shows why 
chiral separation and enantioselectivity is crucial in drug development chemistry.37 
Thalidomide was a racemic sedative launched in 1957 and prescribed to pregnant women 
to alleviate morning sickness. Unfortunately fetuses exposed to thalidomide were born 
with catastrophic limb malformation (phocomelia). This was compounded by a mortality 
rate of 50%. These horrific side effects were found to be due to one of the two enantiomers 
of thalidomide, which has a stereogenic carbon atom on the glutarimide ring adjacent to 
succinamide ring. The (S)-enantiomer of the drug has the teratogenicity effect while the (R)-
enantiomer has the pharmacologic effect (Figure 1.5).37   
 
Figure 1.5 The two enantiomers of thalidomide, (S)-thalidomide was found to cause malformations 
in embryos while (R)-thalidomide relieved the symptoms of morning sickness. 
This painful episode illustrates the importance of chiral separation and enantioselective 
production of drugs. As a consequence, in 1992, the FDA required that if approval for a 
 






racemic drug is being sought, then both enantiomers must be tested for their 
pharmacological effects. Following this, in 1997 a fast track program was introduced by the 
FDA, which allowed faster approval of a single enantiomer. This translated into the general 
decision for synthesising and marketing single enantiomer drugs. Additionally, a lower 
dosage is required to achieve the desired effects, and single enantiomer drugs present 
better pharmacological profiles in comparison to their racemates.36 The most pertinent 
example of this is the pain relief drug ibuprofen, which was switched to a single-enantiomer 
because of the increased effectiveness of the (S) enantiomer, which is over 100-fold more 
potent as an inhibitor of cyclo-oxygenase 1 than the (R)-ibuprofen enantiomer. Ibuprofen 
was followed by ketoprofen and fifteen other drugs in the period between 1994 and 2011 
in the so called ‘chiral switching’. Thus the demand for enantiopure drugs is continuously 
increasing, and the development of methods for their production is vital.38   
1.2.2 Chiral amines 
Optically active amines and amino acids are ubiquitously distributed in nature where they 
play a central role in living systems. L-amino acids, for instance, are the building blocks of 
proteins, function as precursors of DNA and RNA bases, and are involved in the biosynthesis 
of all the fundamental biological macromolecules.39 They are also involved in secondary 
metabolism and signaling pathways. Chiral amines are highly biologically active; this is 
thought to be due to the density of structural information they carry and their ability to 
hydrogen bond with targets.39 Thus, it is not surprising that chiral amines are key scaffolds 
for the synthesis of natural products, pharmaceuticals and agrochemicals. It was recently 
estimated that currently around 40% of pharmaceuticals and 20% of agrochemicals contain 
a chiral amine moiety in their structure.40 Pharmaceutical compounds containing a chiral 
amine moiety have a broad range of applications, treating conditions such as pain, 
depression, HIV, obesity and Alzheimer’s (Figure 1.6).41 
However, their application is not limited to the pharmaceutical and agrochemical 
sectors, they also find application as chiral resolving agents and chiral auxiliaries. Thus, due 
to their crucial roles, the demand for chiral amines is steadily increasing and high chemical 
and enantiomeric purity (>99%) are usually required, but their synthesis with chemo-, 
regio- , diastero- and enantiocontrol is still challenging. 
 








Figure 1.6 Example chiral amine pharmaceutical drugs. These find application to treat several kinds 
of condition such as Alzheimer’s, depression, obesity and HIV.   
1.2.2.1 Organic Synthesis of chiral amines 
The importance of chiral amines and the strong need for enantiomerically pure substances 
has led to the development of a pool of methodologies for their synthesis. Two main 
chemical approaches can be listed for the preparation of optically pure chiral amines: (1) 
resolution of racemates and (2) asymmetric synthesis. The resolution technique is the 
‘classical’ route to an enantiopure product. It differs from the asymmetric synthesis as it 
separates two enantiomers rather than aiming to produce a single enantiomer from the 
beginning.  Although the major drawback is a maximum yield of 50%, classical resolution 
via the formation of diastereomeric salt pairs and precipitation of the least soluble salt is 
still used industrially to produce optically active pure amines as it is relatively inexpensive 
and can be easily scaled-up.42 In this approach a racemate interacts with an enantiopure 
compound to form a diastereomeric salt which, unlike the enantiomer crystals, can be 
easily separated while the other enantiomer is generally discarded. This leads to poor atom 
economy and so asymmetric synthesis is usually preferred as it can yield 100% of the 
desired product. This can be generally achieved by imine and enamide reduction (Figure 
1.7).39 
 







Figure 1.7 Most used chemical approaches for the synthesis of chiral amines: imine and enamide 
reduction. 
The imine reduction process requires multiple steps: (1) condensation with an N-source to 
generate the imine, (2) reduction to generate an amine and (3) cleavage of the auxiliary 
group to release the free amine. A similar alternative approach is enamide reduction. 
However, both these methods require the use of expensive metal catalysts and the removal 
of auxiliary groups to give the free amine can be problematic. 
1.2.2.2 Biocatalytic route to non-racemic chiral amines  
Several biocatalytic approaches are available for the production of enantiopure amines. As 
for the chemical approach, two main strategies are commonly used: (1) enzymatic kinetic 
resolution of racemates and (2) enzymatic asymmetric synthesis from prochiral substrates 
(Figure 1.8).43 In the enzymatic kinetic resolution approach, two enantiomers react with the 
biocatalysts with different reaction rates, yielding an enantio-enriched sample of the less 
reactive enantiomer (1) (Figure 1.8A). The main limitation of this process is a maximum 
theoretical yield of 50%. In order to overcome this technical limitation and achieve a yield 
of 100%, the addition of an extra enzyme, a racemase, is necessary to convert the 
unwanted enantiomer and facilitate a dynamic kinetic resolution (DKR) (Figure 1.8A). Using 
 






this approach, several enzymes such as lipases, hydantoinases and amidases have been 
successfully employed for the production of a wide range of chiral amines. Alternatively, 
enzymatic asymmetric synthesis can be employed (2), allowing the direct conversion of a 
prochiral substrate into the desired single enantiomer in one step (Figure 1.8B). This 
provides the greatest atom economy and higher efficiency than the alternative DKR 
approach as no requirement of additional enzyme is necessary to achieve a potential yield 
of 100%.  
 
Figure 1.8 A) Enzymatic kinetic resolution and B) enzymatic asymmetric synthesis approaches for the 
production of chiral amines. Adapted from Xue et al. 43 
Nature has evolved a wide variety of enzymes which can be used to produce enantiopure 
chiral amines from various starting materials using both approaches outlined above. These 
include lipases (1), amine oxidases (AOs) (2), amine dehydrogenases (AmDHs) (3), imine 
reductases (IReds) (4), reductive aminases (RedAms) (5) and aminotransferases (ATs or TAs) 
(6) (Figure 1.9).41 Amongst the principal methods for the enzymatic synthesis of chiral 
amines, depicted in Figure 1.9, the most widely applied strategy is the resolution of racemic 
starting material (low cost, produced from inexpensive bulk chemicals) employing 
hydrolytic enzymes (e.g. lipases, 1).41 However, in the past decade ATs have started to 
become the elected biocatalyst for the production of primary amines.  
 







Figure 1.9 Different biocatalyst that catalyse the production of amines: lipases (1), amine oxidases 
(AOs) (2), amine dehydrogenases (AmDHs) (3), imine reductases (IReds) (4), reductive aminases 
(RedAms) (5) and aminotransferases (ATs or TAs) (6). 
Lipases (1) 
Lipases belong to the hydrolase family that catalyse the formation or cleavage of esters and 
amides. Lipases have found their application in industry in the production of optically pure 
aliphatic amines, benzyl amines and amino alcohols. They are widely employed for their 
flexibility as they are not restricted to the 20 proteogenic amino acids, but they also accept 
non-natural analogues. They are the first enzymes to have been applied on an industrial 
scale for the enantioselective acylation of racemic amines.44,45 
Amine oxidases (AOs) (2) 
The AOs catalyse the oxidation of amines to imines with simultaneous reduction of oxygen 
to hydrogen peroxide. They are divided in two classes according to the cofactor used: type I 
AOs are copper dependent whilst type II AOs are flavin dependent. The AOs represent a 
valuable alternative to lipase mediated kinetic resolution and de-racemization of racemic 
amines.46,47 
 






Amine dehydrogenases (AmDHs) (3)  
The ADHs catalyse the NAD(P)H dependent reversible asymmetric reductive amination of 
ketones with ammonia to yield amines.48 Even though the AmDH reaction is reversible, the 
equilibrium reaction is in favour of amination (1014<Keq< 1018). The main drawback in 
utilising AmDHs is the requirement of expensive cofactor such as NADH and NADPH. For 
industrial applications, in situ cofactor regeneration is essential for the production of chiral 
amines, allowing their use in catalytic amounts. For the cofactor recycling system, formate 
dehydrogenase (FDH) is often used, which catalyses the oxidation of formate to carbon 
dioxide with the concurrent reduction of NAD+ to NADH (Figure 1.10A). Alternatively, 
glucose dehydrogenase (GDH) is also commonly used for its ability to accept both NADH 
and NADPH substrates 49 (Figure 1.10B).  
 
Figure 1.10 Reaction scheme for NADH and NADPH recycling systems employing (A) formate 
dehydrogenase (FDH) (B) glucose dehydrogenase (GDH). 
Imine reductases (IREDs) (4) and reductive aminases (RedAms) (5) 
The IREDs are a recently discovered class of NAD(P)H dependent enzymes that catalyse the 
asymmetric reduction of imines to amines via oxidoreduction. A breakthrough in their 
application was the identification of an IRED homologue from Aspergillus oryzae by Turner 
and colleagues displaying remarkable activity for reductive amination (RedAm).50,51 This 
RedAm is able to accept a wide range of carbonyl acceptors and amine nucleophiles and 
hints at the potential application of these IRED homologues for the reductive amination of 
a wide range of substrates such as aliphatic, cyclic and aromatic ketones. Since they require 
NADH and/or NADPH, recycling systems would be necessary for their industrial application. 
 






Aminotransferases (6) (ATs or TAs) 
The ATs are pyridoxal 5’-phosphate (PLP) dependent enzymes that catalyse the reversible 
transfer of an amine group to a carbonyl containing compound (amino acceptor) such as 
ketones, aldehydes and ketoacids.52 Unlike other biocatalysts used for the preparation of 
chiral amines, TAs have the main advantage of not relying on a costly cofactor that requires 
in situ regeneration. TAs can be used for the asymmetric synthesis of amines from the 
corresponding ketone or kinetic resolution of racemic amines. The first process is usually 
preferred as it offers the potential of achieving 100% yield. However, problems such as 
unfavourable reaction equilibrium, and substrate and/or (co)product inhibition have 
hampered the widespread use of ATs in industry.53 
1.3 Aminotransferases, a class of PLP-dependent enzymes 
1.3.1 Vitamin B6 vitamers 
Vitamin B6 is one of nature’s most versatile organic enzyme cofactors. Six biologically 
interconvertible compounds constitute the vitamin B6 group: pyridoxine (PN), pyridoxamine 
(PM), pyridoxal (PL) and the phosphorylated forms pyridoxine 5’-phosphate (PNP), 
pyridoxamine 5’-phosphate (PMP) and pyridoxal 5’-phosphate (PLP).54,55,56 These differ from 
each other in the functional group present at the 4’ position of the pyridine ring (Figure 
1.11).57,58 Amongst them, PLP is the biologically active form of vitamin B6, which catalyses 
over 100 reactions inside the human body, including the production and degradation of 
several neurotransmitters.59–61 
 
Figure 1.11 Structures of the six vitamin B6 derivatives and their phosphorylated forms.  
 






PLP dependent enzymes are principally involved in the biosynthesis of amino acids and 
amino acid derivatives, but also in the biosynthesis of amino sugars and other amine-
containing compounds.57,59 As they are widespread in cellular processes, many of them 
have been identified as drug targets. Indeed, ϒ aminobutyric acid AT is the target of 
inhibitors to treat epilepsy, serine hydroxyl methyltransferase is a cancer target and L-3,4-
dihydroxyphenylalanine carboxylase is a target for the treatment of Parkinson’s disease.61,62 
Genetic defects affecting PLP dependent enzymes are implicated in a variety of 
diseases such as primary hyperoxaluria type I and autonomic neuropathy type 1 (HSAN1) 
and inadequate levels of PLP in the brain have been shown to causes neurological 
dysfunctions like epilepsy.63,64 The versatility of the PLP as cofactor, derived from its 
excellent electron sink properties, has also inspired  the development of biomimetic 
catalysts such as N-quaternized catalyst for the production of amines.65 
1.3.2 The chemistry of PLP 
PLP-dependent enzymes are found in five of the six classes defined by the Enzyme 
Commission (EC), and catalyse a multitude of different reaction representing 4% of all 
enzyme activities.66 Despite the variety of PLP-catalysed reactions, the chemical mechanism 
is broadly consistent. PLP acts upon amino containing substrates (mostly amino acids) and 
its aldehyde group is invariably bound to the ε- amine group of an active site lysine residue 
through a Schiff base linkage, forming the internal aldimine species.67,68 This represents the 
holo-form of the enzyme while the lack of the cofactor is referred to as the apo-form.69 The 
internal aldimine can be distributed between two tautomeric forms, the ketoenamine form 
when the imine nitrogen is protonated (400-420 nm) and the enolimine form when the 
alcohol oxygen is protonated (320-340 nm) (Figure 1.12).70 
 
Figure 1.12 Enolimine and ketoenamine equilibrium.  
 






The ketoenamine and enolimine distribution is characteristic of each PLP dependent 
enzyme and depends on the active site environment. Upon addition of an amino acid, the 
lysine residue is exchanged for the amino group of the substrate via a transaldimination 
reaction, forming a non-covalently bound external aldimine.  This causes a change in the 
ketoenamine-enolimine equilibrium. These changes in the UV-Vis spectrum can be used to 
monitor external aldimine formation and offer a window into the biochemistry of PLP 
dependent enzymes.71  
PLP’s reaction versatility arises from this common external aldimine intermediate 
as is followed by cleavage of one of the bonds adjacent to the Cα atom (α, β or γ). PLP 
catalysed reactions can therefore be subgrouped according the position at which the net 
reaction occurs (the α, β or ϒ carbon of the amino acid substrate) (Figure 1.13).  Reactions at 
the α-position include transamination, decarboxylation, racemization, elimination and 
replacement of an electrophilic R group. Reactions at the β or ϒ position include elimination 
or replacement.72  
The precision architecture of the enzyme active site and organisation of the PLP 
cofactor allow only one reaction to occur and prevent all other possible reactions. This is 
described by the Dunathan hypothesis (Figure 1.14).73 In 1966, Dunathan proposed that the 
specific reaction of a PLP-dependent enzyme is controlled by the orientation of the 
substrate. The bond (α, β or ϒ) to be broken will be the one perpendicular to the plane of 
the conjugated π system of the PLP ring (Figure 1.14A and B).73  The only exception is 
represented by the PLP-dependent glycogen phosphorylases, which use a different type of 
PLP chemistry, utilising the phosphate group of the PLP cofactor for catalysis.74,75 The bond 
breaking steps are facilitated by the formation of a carbanion that is stabilised by the 
electron sink property of the pyridine ring of the PLP cofactor (Figure 1.14C).76,77 The 
stabilised carbanion is described as a quinonoid as its structure resembles a quinone and 
can be monitored spectrophotometrically as it has a strong absorption at 500 nm.78,79 
 
 






Figure 1.13  PLP dependent enzymes catalyse a variety of chemical reactions after the substrate 
forms a covalent aldimine intermediate with PLP. Different bonds can be broken (shown in different 





Figure 1.14  Illustration of Dunathan hypothesis. (A) Stereoelectronic control of reaction specificity in 
PLP-catalysed reactions. (B) Possible conformation of the external aldimine after cleavage of the 
three possible bonds adjacent to the Cα. (C) Carbanion and quinonoid resonance forms obtained 
after the external aldimine deprotonation 
 






1.3.3 PLP enzyme classification 
Despite the variety of the PLP-catalysed reactions, all structurally characterised PLP-
dependent enzymes have been classified into seven structural groups, presumably 
corresponding to independent evolutionary lineages.59,60 The capability of proteins with 
similar structures to catalyse such a diverse range of chemical reactions represents a 
remarkable example of divergent evolution.59 
Several classification schemes have been proposed for PLP enzymes.80 However, 
the commonly accepted classification scheme is the one proposed by Goldsmith81 and 
recently redefined by Peracchi et al.60, in which PLP-enzymes are divided into five different 
fold types based on sequence similarity and 3D structures (Figure 1.15).55 Individual folds 
are named according to the enzyme first identified with such a fold and consist of: the 
aspartate aminotransferases (AspAT, fold type I), the tryptophan β-synthase (fold type II), 
the alanine racemase (fold type III), the D-amino acid aminotransferase (fold type IV) and 
the glycogen phosphorylase (fold type V) families. Two additional clusters have 
subsequently been added and include the lysine 5, 6 aminomutase (fold type VI) and the 
lysine 2, 3 aminomutase (VII) familes, whose structures have been recently determined and 
found to differ from other fold types (Figure 1.15). Amongst the PLP superfamily, the vast 
majority (approximately two-thirds) of enzymes belong to fold type I, followed by group II 
and group IV. Group V PLP enzymes are rare whilst groups VI and VII are almost absent.  
The aspartate aminotransferase family (fold type I) 
The group I PLP fold, also known as the AspAT family, is structurally the most well 
characterised fold in the PLP superfamily. Enzymes in this class are catalytically active as 
homodimers, where each subunit consists of two domains: a large domain, in which the 
central feature is a seven stranded β sheet and a small domain consisting of a three-
stranded β sheet packed against helices on one side. The PLP cofactor is covalently 
attached to the large domain via a lysine residue at the N-terminus, with the active site 
located in a cleft between the two domains. Residues from both domains/subunits are 
involved in cofactor binding and stabilisation.  Structural analysis of the members of this 
fold has revealed differences between the N-terminal domains, dividing the fold type I into 
 






six subclasses of which three are aminotransferases subclasses as defined by Grishin et al.81 
and Metha et al. and will be discussed in detail later.82 
 
Figure 1.15 Classification of PLP dependent enzymes based on fold types. The fold type I and IV 
include transaminases and are highlighted in bright yellow. Adapted from Slabu et al.83 
The tryptophan synthase β family (fold type II) 
The tryptophan synthase family includes the tryptophan synthase β subunit, threonine 
deaminase and O-acetylserine sulfhydrilase. The catalytic unit of these type II PLP enzymes 
is composed entirely of residues from one monomer. Each monomer consists of a PLP-
binding site in the N-terminal domain which forms the catalytic part, and a regulatory 
domain situated at the C-terminus. However the functional form is either homodimeric or a 
higher-order oligomer. 
The alanine racemase family (fold type III) 
Fold type III, known as the alanine racemase superfamily, includes amino acid racemases 
and decarboxylases. Enzymes of this group are homodimers with each monomer containing 
two domains, one with an α/β barrel and the other mainly comprising β strands. 
 






Interestingly the mode of binding of PLP is similar to other fold types, with the phosphate 
group anchored at the N-terminus of an α-helix and residues from both monomers 
contributing to the active site formation. 
The D-amino acid aminotransferase family (fold type IV) 
Not only does the fold type IV family include D-amino acid ATs, but also lyases. Fold type IV 
enzymes are superficially similar to fold type I, as they function as homodimers and the 
catalytic unit of each monomer is composed of a small and large domain. In addition, the 
active sites of D-amino acid transferases are mirror images of the active sites of the fold 
type I aminotransferases such that the re-face rather than the si-face of the PLP cofactor is 
solvent exposed (where the re- and si-faces are defined in relation to the C-4’ of the 
cofactor as the centre of the plane).84 
Glycogen phosphorylase family (fold type V)  
Fold type V PLP enzymes are multidomain proteins which contain three distinctive domains; 
the C- and N-terminal domains and a glycogen-binding domain. The C-terminal domain 
binds PLP and also has a dinucleotide-binding fold. Type V enzymes are strikingly different 
from the other PLP families as they utilise the phosphate group of PLP for catalysis.  
Lysine 5, 6 aminomutase (fold type VI) 
The overall structure of type VI PLP enzymes is an α2β2 tetramer. In this structure, a 
Rossmann domain covalently binds the PLP cofactor while simultaneously positioning the 
other cofactor, adenosylcobalamin (coenzyme B12) far from the active site in order to 
prevent radical generation in absence of substrate.85  
Lysine 2, 3 aminomutase (fold type VII) 
Lysine 2, 3 aminomutase is a homotetramer consisting of a dimer of tightly associated 
dimers.  The subunits of the dimers are linked through a zinc ion which coordinates 
residues from both subunits, with the PLP located at the N-terminus of the channel. Each 
subunit consists of three domains, the C-terminal domain, the central globular domain and 
the N-terminal domain.86 
 
 







Figure 1.16 PLP fold type examples. Type I Aspartate aminotransferase from Gallus gallus (PDB code: 
1IVR),87 Type II tryptophan β-synthase from Salmonella typhimurium (PDB code: 2RHG), Type III 
Alanine racemase from Geobacillus stearothermophilus (PDB code: 1SFT),88 Type IV D-amino acid 
aminotransferase from Bacillus sp. (strain YM-1) (PDB code: 1DAA),89 Type V Glycogen 
phosphorylase from Oryctolagus cuniculus (PDB code: 1GPA),90 Type VI lysine 5, 6 aminomutase 
(PDB code: 1XRS),85 Type VII the lysine 2, 3 aminomutase (PDB code: 2A5H).86 Monomer A is 
coloured in magenta while monomer B in blue. PLP is shown as sticks and highlighted in yellow.  
 







ATs are enzymes which catalyse the interconversion of amino acids and oxoacids by 
transfer of the amino group. The catalytic mechanism can be split in two half reactions that 
see PLP recycling between its aldehyde and amino forms (Figure 1.17).69 
 
Figure 1.17 Schematic view of the AT reaction. In the first half-reaction (1) an amino donor donates 
the amino group to the cofactor, generating PMP and a keto co-product. In the second half of the 
reaction (2) the PMP acts as amino donor, transaminating a keto substrate, generating the final 
amine product (which can also be a donor in the reverse direction) and regenerating the PLP 
cofactor. 
Based on the position of the transferred amino group, ATs can be grouped into α-ATs and 
ω- AT subfamilies; α-ATs only accept substrates with the amino group in the α-position to 
the carbonyl carbon while ω-AT have a much broader substrate scope as they accept 
substrates with at least one methylene group between the α-carbon and the carboxylate 
moiety (Figure 1.18).  
 
Figure 1.18 ATs are divided into α-ATs (A) and ω-ATs (B) according to whether the transfer of the 
amino group occurs at the α-carbon (α-ATs) or further away from the carboxylic moiety (ω-ATs). 
 






For this reason ω-ATs are more appealing for industrial biocatalysis as they have a broader 
substrate range and are not limited to α-amino acids. A further distinction based on the 
product enantioselectivity can also be made, defined as (S)-AT and (R)-AT. Several (S)-ATs 
have been characterised, while a more limited number of (R)-AT isoforms have been 
identified.91–93  
The application of ATs for the stereoselective amination of prochiral ketones 
represents an environmentally benign and economically appealing alternative to transition 
metal catalysed asymmetric synthesis.51–54 ATs display high enantio- and regio-selectivity, 
broad substrate specificity and high reaction rate and stability, all attractive qualities for 
industrial applications. Because of these features, ATs have been widely used in recent 
years for the production of a wide range of products such as natural and unnatural amino 
acids, amino alcohols, amino sugars and chiral amines.59,63–65 
The application of an engineered AT for the synthesis of ‘blockbuster’ drugs such as 
Januvia™(Sitagliptin) (Figure 1.4) has shown the enormous power and efficiency of this 
important class of biocatalysts. However, despite the enormous potential of ATs, challenges 
associated with substrate and co-product inhibition, challenging reaction equilibria and 
substrate scope have limited the widespread use of ATs. Many researchers are addressing 
these problems from different angles, trying to expand substrate scope and develop amine 
donors which can drive the equilibrium towards product formation.52,101–105 Some of these 
developments will be addressed in section 3.3.4.  
Although significant progress has been made towards expanding the 
substrate/product scope and overcoming the unfavourable equilibrium of ATs, there is still 
a list of challenging substrates which would be exciting to aminate (from a both commercial 
and scientific perspective) using this class of biocatalysts. The discovery of novel ATs 
through metagenomic approaches, combined with enzyme evolution will most likely 
expand the application of ATs. Moreover, the availability of structural information will no 
doubt help to further open the door to the expansion of the AT substrate scope. 
1.4.1 Reaction mechanism 
ATs are assumed to follow a ping-pong bi-bi mechanism. This means that the first substrate 
(amino donor) enters in the active site and only after the first product leaves the active site, 
 






the second substrate (amino acceptor) can bind generating the second product and 
regenerating the enzyme. A detailed AT reaction mechanism is described in Figure 1.19. In 
the resting state, the ε group of catalytic lysine is covalently bound to the PLP cofactor to 
form an internal aldimine. In the first half-reaction an amino donor, generally an amino 
acid, displaces the internal aldimine via a transaldimination reaction to form the external 
aldimine. The released lysine residue can now act as a catalytic base in the next step 
abstracting the α-proton from the external aldimine to form a planar quinonoid. After 
hydrolysis, a keto co-product and pyridoxamine 5'-phosphate (PMP) are formed. In the 
second half-reaction the inverse of the first half reaction occurs, where after deprotonation 
by the lysine residue, the amino acceptor reacts with PMP to form a second quinonoid and 
water. In the last step, the chiral amine forms an internal aldimine and the final chiral 
product is released and the cofactor regenerated. Each of the steps in this reaction are 
reversible resulting in an equilibrium between the products and reactants. 
Figure 1.19 AT reaction mechanism. Steps include, transaldimination, deprotonation of the 
substrate, protonation of PLP, hydrolysis of the amino donor to yield PMP, condensation of the 
amino acceptor, deprotonation of PLP, protonation of the product and transaldimination to release 
the product.  
 






The stereospecificity of ATs depends on the position of the catalytic lysine residue in 
comparison with PLP. According to the reaction mechanism of ATs, the reaction proceeds 
via a planar quinonoid intermediate, and the stereocenter is formed by protonation from 
the catalytic lysine on either the si- or the re-face of PLP (Figure 1.20). The catalytic lysine in 
(S)-ATs (fold type I) acts from below the quinonoid intermediate on the si-face, while the 
catalytic lysine in (R)-ATs and in branched-chain ATs (fold type IV) acts on the re- face above 
the quinonoid intermediate.106 
 
Figure 1.20 The position of the lysine compared to PLP determines the stereospecificity of the AT 
catalysed reaction. In (S)-AT the catalytic Lys acts from below the quinonoid intermediate on the si- 
face, thus yielding the (S)-enantiomer. In contrast, in (R)-AT the Lys acts from above the quinonoid 
intermediate on the re-face, producing the (R)-enantiomer. 
1.4.2 Structural analysis of transaminases 
TAs are found in the fold types I and IV families of PLP enzymes, where fold-type I is the 
most common fold for ATs and includes aspartate, ornithine, and ω-amino acid ATs. D-
amino acid ATs and branched-chain ATs belong to the fold type IV. In addition to the 
traditional classification of PLP enzyme fold types, Mehta et al. further classified ATs into 
four subgroups based on sequence similarity and secondary structure predictions. 
Subgroup I ATs comprise aspartate, alanine, tyrosine, histidinol-phosphate-, and 
phenylalanine- ATs; subgroup II consists of acetylornithine, ornithine, 4-aminobutyrate and 
diaminopelargonate ATs; subgroup III contains D-alanine and branched-chain amino acid 
ATs, and finally subgroup IV comprises of serine and phosphoserine ATs.82  
More recently, Steffen-Munsberg et al. have proposed a new classification of ATs 
based on sequence and structural similarity and grouped ATs in six subgroups or classes; 
 






class I: L-aspartate ATs; class II: L-alanine ATs; class III: ω-ATs; class IV: D-amino acid ATs and 
branched chain ATs (BCAT); class V: L-serine ATs; class VI: sugar ATs.107,108 This classification 
will be adopted in this thesis, focusing on the class III, ornithine-like, AT family as it presents 
features attractive for industrial biocatalysis such as broader substrate scope.  
ATs are interesting enzymes as they are able to accommodate different substrates 
in their active site while discriminating against all others. This phenomena is referred as 
‘dual substrate recognition’.109,110 This dual specificity could either be achieved by 
movements of the PLP cofactor between two different binding sites or by the movement of 
flexible side chains to accommodate different substrates. The latter has been observed for 
the first time in the E. coli aspartate AT (AspAT) and is achieved by the so called ‘arginine 
switch’. 113,114 The solving of the structure of a hexamutant of E.coli AspAT which displayed 
higher activity towards aromatic substrates, highlighted the movement of an active site 
arginine residue (Arg292) out of the active site. The Arg292 residue either shifted its 
position to directly interact with charged substrates or moved aside to allow access of 
aromatic ligands (Figure 1.21).69,111,112  
 
Figure 1.21 Schematic view of the arginine switch adopted by E. coli AspAT. (A) The γ carboxylate of 
L-Glu interacts with Arg292. (B) The Arg292 points out the active site when aromatic substrates such 
as L-Phe bind. The Arg386 interacts with the carboxylate of both substrates. This is how ATs display 
their dual substrate recognition and are capable of accepting both types of substrates. Adapted from 
Eliot et al.69 
In a more recent report, Steffen-Munsberg et al. identified an analogous ‘flipping’ arginine 
residue in Paracoccus denitrificans AT which plays the same role, directly interacting with  
 






the carboxylate of the substrates or providing a hydrophobic environment by moving out of 
the active site.104,113,114 
A typical class III AT is Chromobacterium violaceum AT (Cv-AT), which has been 
widely used for biocatalytic application as it displays a quite broad substrate scope. Its 
structure was successfully solved highlighting key features of this AT.115,116,117 Cv-AT is a 
homodimer in which the PLP cofactor lies at the dimer interface (Figure 1.22A).  Each 
monomer is composed of a small and a large domain (Figure 1.22B). A three-layered α/β/α 
sandwich comprising seven-stranded β-sheets constitutes the large domain. All the β-
sheets except one are parallel, with the catalytic Lys located in the loop preceding the only 
antiparallel strand.  The small domain consists of residues from both the C- and N-termini 
which can be divided into two lobes (Figure 1.22 B).  
 
Figure 1.22 Crystal structure of the Cv-AT obtained at 1.8 Å (PDB code: 4A6T). (A) Overall structure 
of Cv-AT, monomer A is highlighted in magenta while monomer B is in blue. (B) Monomer A of Cv-AT 
where the large subunit is in magenta, the C-terminal lobe of the small subunit is in light teal while 
the N-terminal lobe is in cyan. PLP is shown as sticks and highlighted in yellow. 
The interplay of residues from both monomers is crucial for cofactor stabilisation. Typical 
residues, highly conserved amongst the family, include the Tyr residue, perpendicular to 
the PLP cofactor and the Val residues that sandwich the PLP.  The electron sink nature of 
the cofactor is enhanced by a hydrogen bond interaction of the pyridinium nitrogen with an 
aspartic acid residue (D259), which maintains the cofactor in the protonated form. The 
phosphate group of the cofactor is coordinated by a series of hydrogen bonds with Ser118, 
 






Gly119 and Ser120 from one monomer and Thr320 and Phe319 from the other one, 
providing a very stable anchoring point for PLP also known as the ‘phosphate cup’.118 These 
general features are highly conserved amongst the class III family and will be further 
discussed in section 3.6 and 4.9.  
 
Figure 1.23 (A) Cv-AT PLP internal aldimine. The PLP internal aldimine and residues involved in 
cofactor stabilization are shown as stick representations, with carbon atoms shown in magenta and 
blue for the two monomers in the active dimer, oxygens are shown in red, nitrogen in blue and 
phosphorous in orange. Coordinated water molecules are shown as red spheres. The aromatic ring 
of PLP is sandwiched between Val261 and Tyr153. The nitrogen of the pyridine ring is fixed by 
hydrogen bond coordination to Asp259. The phosphate group is stabilized by a network of 
interactions with Ser118, Gly119, and Ser120 from Monomer A; and Phe319 and Thr320 from 
monomer B. (B) Hydrogen bonds, direct or through water molecules, are shown as dotted lines and 
distances (Å) in grey.   
1.5 Target compounds and biocatalysts 
This study is focused on the biocatalytic production of two main classes of molecules: the 
phenylglycine compounds and the fatty amines. These classes of molecules and the 
catalysts chosen for their biocatalytic production will be introduced in this section with 
details about the current synthetic methods and understanding of these enzymes. 
1.5.1 The phenylglycine family 
A noteworthy family of non-proteinogenic amino acids that occur in natural products, but 
also find broad application in synthetic compounds, is the phenylglycine family. This family 
includes D- phenylglycine (D-Phg) and D-4-hydroxyphenylglycine (D-Hpg).119 
 







Figure 1.24 D-Phg and D-Hpg structure. 
In contrast to proteinogenic amino acids, in phenylglycines the bulky aromatic sidechain is 
directly attached to the α-carbon. This strongly decreases the degrees of freedom of 
rotation for the aromatic side chain, structurally influencing phenylglycine containing 
peptides.  
Phenylglycine-type amino acids occur in a wide variety of peptide natural products, 
including glycopeptide antibiotics and biologically active linear and cyclic peptides. In 
vancomycin, for instance, D-Phg plays a crucial role in the structure and the function of the 
final glycopeptide. Similarly, synthetic drugs such as amoxicillin, one of the top-selling 
antibiotics developed by GSK, contain D-Hpg in its structure (Figure 1.25).  
 
Figure 1.25 Natural and synthetic compounds containing the D-Phg and D-Hpg moiety. (A) 
Vancomycin is a natural glycopeptide antibiotic produced by Amycolatopsis orientalis whilst (B) 
amoxicillin is an antibiotic produced by GSK.  
It is interesting to characterise how nature has evolved a biosynthetic pathway to produce 
these compounds. Despite the fact that Phg is structurally the simplest member of the 
phenylglycine family, its biosynthetic pathway has been only recently identified following 
the sequencing of the pristinamycin biosynthetic pathway in Streptomyces 
pristinaespiralis.120 An operon of five genes (plgA-E) was identified and their functions have 
 






been assigned. Bioinformatic analysis of the pathway suggests that synthesis starts from 
phenylpyruvic acid (PPA), which is converted into phenylacetyl-CoA (PA-CoA) by PlgB and 
PlgC, assumed to work as a pyruvate dehydrogenase complex. The hydroxylacyl-
dehydrogenase PlgA converts PA-CoA into benzoylformyl-CoA (BZF-CoA) before the 
thioesterase PlgD catalyses the hydrolysis of BZF-CoA, releasing BZF and CoA. The final step 
is an L-specific AT PlgE which yields L-Phg from the keto-acid substrate BZF (Figure 1.26). 
 
Figure 1.26 Biosynthesis pathway of L-Phg (Phg) hypotesized from the pristinamycin biosynthesis 
gene cluster (pglA, pglB, pglC, pglD and pglE) of Streptomyces pristinaespiralis. Adapted from Al 
Toma et al.121 
The Hpg synthetic pathway has been elucidated following sequencing of the 
chloroeremomycin biosynthetic cluster in Amycolaptosis orientalis.122,123 The first step is 
conversion of prephenate (PPA) into 4-hydroxyphenylpyruvic acid (HPPA) by the action of 
the prephenate dehydrogenase (Pdh). L-4-hydroxymandelate synthase (HmaS) then 
catalyses the conversion of HPPA into L-4-hydroxymandelate (L-HMA) by hydroxylating the 
benzylic position of HPPA. Subsequently L-HMA oxidase (HmO), a flavin mono-nucleotide 
(FMN) dependent enzyme, catalyses the oxidation of L-HMA to 4-hydroxybenzoylformate 
(HBF). Finally, a transamination reaction catalysed by L-Hpg AT (HpgT), which uses L-Tyr as 
amino donor (Figure 1.27) yields the final product L-Hpg.  
It is important to underline that both biosynthetic pathways produce the 
L-enantiomer of the desired product D-Phg/D-Hpg. An epimerization (E) domain is found in 
the non-ribosomal peptide synthetase (NRPS) module where the Phg residue is 
incorporated in the peptide as the D-isomer.  E-domains are structurally related to 
condensation domains that catalyse peptide bond formation and have been shown to 
epimerise the residue once it is incorporated within the peptide, explaining why D-
enantiomers are found in the final natural products.  
 







Figure 1.27 Hpg biosynthetic pathway in Amycolaptosis orientalis. Pdh: prephenate dehydrogenase, 
HmaS: L-4- hydroxymandelate synthase, HmO: L-4-hydroxymandelate oxidase, HpgT: 4-
hydroxybenzoylformate/L-4-tyrosine AT. Adapted from Al Toma et al.121 
Synthetically, the conventional preparation of D-Phg in industry, developed in the early 
1970’s, is a diastereomeric salt recrystallization of the phenylglycine racemic mixture using 
(+)-camphor-8-sulfonic acid (CSA) as the resolving agent (Figure 1.28, Route 1).124 This 
method, as described previously, presents the main disadvantage of a maximum theoretical 
yield of 50%.  
As D-Phg and D-Hpg are high value compounds, several biocatalytic approaches 
have been attempted for an efficient and enantioselective production of D-Phg and D-Hpg. 
Amongst these, the most widely used is a hydantoinase/carbomylase system.125 Here, a 
chemically synthesised racemic hydantoin is first hydrolysed by a hydantoinase to yield the 
corresponding carbamoyl derivative, which is subsequently cleaved by a carbamoylase to 
afford the desired optically pure amino acid. Incorporation of a hydantoin racemase to 
perform dynamic kinetic resolution (DKR) affords theoretically a 100% yield when starting 
from the racemate. The hydantoin process has the further advantage that nature has 
provided us with D- or L-selective hydantoinases/carbamoylases, with broad substrate 
specificity and hence access to either D-or L-amino acids, including non-proteinogenic 
 






derivatives, is possible. However, the substrate 5-phenylhydantoin has to be synthesized by 
a Bucherer–Bergs reaction with benzaldehyde, urea, and highly toxic cyanide, and the low 
solubility of 5-phenylhydantoin in aqueous solution results in a low overall reaction rate.  
         
Figure 1.28 Conventional routes for D-Phg production. Route (1) Phenlyglycine diastereomeric salt 
crystallization using CSA as the resolving agent. Route (2) D-hydantoinase/carbomylase approach for 
the synthesis of D-Phg. 
Several other DKR approaches have been reported applying lipases, nitrilases or amidases. 
However, all those methods fail to produce an ee greater than 88% and therefore are not 
suitable for direct applications.125,126 Similar approaches are used to produce D-Hpg. As all 
the current methods present several drawbacks, the development of an efficient 
alternative for the synthesis of these compounds would be very advantageous.  
1.5.1.1 The D-phenylglycine aminotransferase from Pseudomonas stutzeri 
The D-phenylglycine AT (D-PhgAT), isolated from the soil bacterium Pseudomonas stutzeri 
ST-201, catalyses the reversible transamination of L-glutamic acid (L-glu) with 
benzoylformate (BZF) and 4-hydoxybenzolyformate (HBF), as amino acceptors, yielding 
D-Phg and D-Hpg respectively, and α-ketoglutarate (AKG) (Figure 1.29).127 The unique 
feature of this AT is that it is a so-called ‘‘stereo-inverting’’ AT, a property whereby the 
 






amino donors (L-Glu and D-Phg) in this reversible reaction exhibit inverse absolute 
configuration.  
 
Figure 1.29 Reaction catalysed by the D-PhgAT. L-Glu donates the amino group to the pyridoxal 5’-
phosphate (PLP) cofactor generating pyridoxal amine (PMP) and α-ketoglutarate (AKG). In step 2, 
benzoyl formate (BZF) or its 4-hydroxy derivative (HBF) accepts the amino group from PMP yielding 
D-Phg or D-Hpg respectively. 
From a biocatalysis perspective, D-PhgAT has attractive features such as high turnover and 
stability and has been used in qualitative and quantitative analysis of L-Glu in food when 
coupled with L-glutamate dehydrogenase, and for quality control of amoxicillin in 
pharmaceuticals when coupled with a penicillin acylase.128,129 The homologous D-PhgAT 
from P. putida (82% sequence identity) has been successfully combined with HmaS and 
Hmo to engineer an E. coli strain that is able to produce D-Phg.130  
Wiyakrutta et al. have reported preliminary characterisation of D-PhgAT with the 
determination of KM for D-Phg and AKG (1.1 and 2.4 mM respectively). The optimum pH 
and temperature have been determined to be 9.5 and 35 °C, and it was found that 10 mM 
BZF was converted with a yield of 80% after 3 h. The substrate scope, however, has been 
only marginally explored, suggesting a very narrow substrate scope. In addition, an apo-
structure, lacking the PLP cofactor and several residues at the N-terminus has been 
deposited in the PDB in 2006 (PDB code: 2CY8, Figure 1.30).131 The enzyme is a homodimer, 
whose structure belongs to PLP fold type I and class III ATs and which displays the typical 
features of these families. However the lack of the cofactor and active site residues do not 












Figure 1.30 Incomplete structure (PDB code: 2CY8) of the apo-form of D-PhgAT deposited in the PDB 
database in 2006. Monomer A is shown in magenta while monomer B is shown in blue.  
The ability of D-PhgAT to use an L-amino acid substrates and yield a final D-amino acid 
product represents a great advantage for industrial biocatalysis and therefore D-PhgAT was 
chosen as target for the synthesis of high value D-amino acids (chapter 3). A structural 
understanding of the active site architecture is required to understand the 
enantioselectivity of this enzyme and enhance its directed evolution.  
1.5.2 Fatty amines 
Aliphatic long chain or ‘fatty’ amines are a class of primary, secondary and tertiary amines 
from C8 to C22.132 Fatty amines have a broad range of application but are predominately 
found in the manufacturing of emulsifying, cleaning and cosmetic formulations.133 The 
global fatty amine market size was estimated at 670 kilo tons in 2016 and the global 
demand for these compounds is expected to grow 
(https://www.grandviewresearch.com/industry-analysis/fatty-amines-market).  
Commercially available fatty amines consist of either a mixture of different carbon 
chain lengths or solely a specific chain length. Primary amines are the most common, but 
secondary and tertiary substitutions are also available. 
Two main production routes are used to prepare fatty amines. One route is the 
hydrogenation of nitriles, used since the 1940s.133 This involves the hydrolysis of naturally 
occurring materials such as fats and fatty oils at high temperatures (200-280 °C) to obtain 
saturated and unsaturated fatty acids and glycerol. A fatty nitrile intermediate produced 
 






using ammonia is then hydrogenated using a variety of catalysts, first to an imine and then 
to a primary amine. An alternative method uses fatty alcohols and ammonia. Natural fatty 
acids can be catalytically reduced to alcohols by high pressure (>20 MPa) and temperature 
(250–300 °C) hydrogenation using a copper chromite catalyst. Fatty amines can then be 
produced from the fatty alcohol using excess ammonia, at elevated temperature and high 
pressure (50-340 °C, 3.5 MPa). Neither of these approaches are eco-friendly and both 
require very harsh conditions. Thus, the development of a suitable biocatalytic alternative 
for their production would be of great interest. 
1.5.2.1 Fumonisin and the aminotransferase FumI 
Mycotoxins are secondary metabolites of fungi which are harmful to humans and animals. 
Ingestion of these mycotoxins causes mycotoxicoses, which can result in death.134  A 
particular class of mycotoxins, produced by the maize pathogen Fusarium verticilloides and 
other fungi, are the fumonisins.135 As their chemical structures resemble the sphingolipids, 
fumonisins are able to bind the mammalian ceramide synthase, disrupting sphingolipid 
metabolism.136,137 Amongst the fumonisins, fumonisin B1 (FB1) is the most abundant and has 
been shown to be carcinogenic, teratogenic and is suspected to cause oesophageal cancer 
(Figure 1.31).138,139  In addition, the FB1 degradation intermediate, hydrolysed FB1 (HFB1), is 
shown to cause defects in neonates.139 
In 2005, by studying the degradation of this harmful mycotoxin in the bacterium 
Sphingomonas sp. MTA14, two genes responsible for FB1 degradation were identified.140 
These genes, fumD and fumI, code for a carboxylesterase and an AT, respectively. 
Recombinant FumD was shown to catalyse the first step of FB1 degradation, the hydrolytic 
release of the two tricarballylic acid (TCA) side chain of FB1 to produce HFB1 while FumI was 
shown to catalyse the transfer of the 2-amino group from HFB1 to pyruvate, producing 2-
keto- HFB1 (Figure 1.31).141  
The research organization BIOMIN (Austria) has investigated the application of 
FumD and FumI as a tool for food detoxification and this application is covered by a patent 
(WO2004085624). Despite the interesting feature of FumI being able to accept long chain 
amines, the substrate scope of this interesting enzyme has not been examined.142,143 
Studies have been limited to the determination of its kinetic properties towards HFB1 and 
 






pyruvate, and the biosynthetic potential of this enzyme has not been explored.  Thus, the 
application of FumI for the synthesis of fatty amines from aldehydes and ketones 
represents an attractive alternative to the existing synthetic methods.  
 
Figure 1.31 Initial steps of the FB1 degradation pathway of Sphingopyxis sp. MTA144FB1. The 
carboxylesterase FumD catalyses the hydrolysis of FB1 to HFB1 and the aminotransferase FumI 
catalyses the transfer of the 2-amino group from HFB1 to pyruvate, producing 2-keto- HFB1. Adapted 










2 Aims  
 
The overall aim of this work is to investigate the substrate scope and the biosynthetic 
potential of the D-PhgAT and FumI by detailed structural and kinetic characterisation. As 
such, the main aims for each enzyme are as follows: 
 
1) D-PhgAT: 
• Express and purify recombinant P.stutzeri D-PhgAT 
• Characterise D-PhgAT for the natural reaction  
• Develop a suitable assay and optimise the biotransformation conditions  
• Explore the amino donor and amino acceptor scope 
• Use structural studies to understand the molecular basis of the unique ‘stereo-
inverting’ property of the enzyme 
• Immobilize D-PhgAT using a commercial resin to explore the possibility of recycling 
multiple times the catalyst 
 
2) FumI: 
• Express and purify recombinant Sphingopyxis FumI 
• Investigate the ‘reverse’ FumI reaction  
• Explore the ability of FumI to accept long chain alkyl ketones for the biosynthesis of 
high value fatty amines 
• Explore the substrate (C3-C20) chain length tolerance  















3 The D-Phenylglycine aminotransferase 
The D-Phenylglycine aminotransferase (D-PhgAT) was firstly isolated in 1997 from 
Pseudomonas stutzeri ST-201, a soil bacterium capable of utilising D-phenylglycine as the 
sole carbon and nitrogen source.127 D-PhgAT has the unique capability of catalysing a 
transamination reaction where the two amino donors L-Glu and D-phenylglycine (D-Phg) in 
the ‘forward’ and ‘reverse’ direction) exhibit opposite absolute configuration (Figure 3.1) 
and therefore is addressed in the literature as a ‘stereo-inverting’ AT. D-PhgAT channels the 
amino nitrogen directly between L-Glu and D-Phg without the requirement of additional 
enzymes (e.g. amino acid racemase for D-Phg or L-Glu). Thus, the enzyme represents an 
excellent target enzyme for the synthesis of enantiomerically pure D-Phg and derivatives 
such as D-4-hydroxyphenylglycine (D-Hpg) in a single step using a commercially available 
cheap amino donor such as L-Glu, providing a more concise and sustainable route to their 
biosynthesis than has previously been available. 
 
Figure 3.1  Schematic view of the reversible D-PhgAT reaction. In step 1 L-Glu (blue) donates the 
amino group to the 5’-pyridoxal phosphate (PLP) cofactor generating pyridoxal amine (PMP) and -
ketoglutarate (AKG) (red). In step 2 benzoyl formate (BZF) (red) or its 4-hydroxy derivative (HBF) 
accepts the amino group from PMP yielding D-Phg or D-Hpg respectively (blue). 
 







The aims of this project are to express, purify and characterise D-PhgAT and assess its 
suitability for the synthesis of high value, enantiopure products. Very limited information is 
available in the literature about transamination reactions between two amino acids with 
inverted absolute stereochemistry, therefore a crystallographic investigation is required in 
order to fully illuminate the mechanistic origin of the enantioselectivity of this unique 
member of the AT superfamily.  Determination of the 3D D-PhgAT structure will be central 
to expand and explore the biosynthetic potential of D-PhgAT, applying the enzyme to the 
synthesis of non-natural products.  
3.2 D-PhgAT aminotransferase expression and purification  
Full-length, codon optimized dpgA (Pseudomonas stutzeri ST-201, UNIPROT code: Q6VY99, 
Appendix 8.1) was purchased from GenScript and cloned into a pET-15b plasmid with NcoI/ 
BamHI  restriction sites, to give recombinant D-PhgAT with a non-cleavable N-terminal His6-
tag (pET15b-dpgA) (Appendix 8.2).  
Wiyakrutta et al. had reported that, in their hands, D-PhgAT exhibited low in vitro 
solubility and a tendency to aggregate and precipitate during purification, which limited its 
large-scale application.144 The dpgA gene over expression in E. coli was reported to yield 
D-PhgAT mostly in the insoluble fraction and subsequent expression in Pichia pastoris with 
chaperones improved the solubility by just 20%.145 In an effort to overcome this problem, 
different isopropyl β-D-1-thiogalactopyranoside (IPTG) concentrations and temperatures 
were tested in order to identify optimal conditions for protein expression.  However, in 
contrast to Wiyakrutta et al., good conditions for protein expression were found to be fairly 
standard 0.1 mM IPTG with 16 h induction at 20 °C.  Gene expression was induced under 
these conditions in 1 L of BL21 (DE3) E. coli cells.  
The protein was then purified from the cell lysate using nickel immobilized metal 
affinity chromatography (IMAC), where it eluted at a concentration of 100 mM imidazole. A 
second purification step, size exclusion chromatography (SEC), yielded a symmetrical peak 
with an elution volume of 78.0 mL (Figure 3.2B). Based on the calibration curve associated 
with the gel filtration column used (Superdex 16/60 S200, Appendix 8.5), D-PhgAT eluted at 
 






a retention volume corresponding to a homodimer (~ 100 kDa) in solution with the SDS-
PAGE analysis showing a monomeric mass of ~ 51 kDa (Figure 3.2 B). Typical yields were on 
the order of ~ 70 mg protein per litre of culture.  
To ensure the correct protein was expressed and purified, the mass of purified 
D-PhgAT was obtained using denaturing liquid chromatography electrospray – mass 
spectrometry (LC ESI-MS). The resulting spectrum displayed several peaks, representing the 
many charge states of the protein (Figure 3.3). The protein mass was deconvoluted from 
this spectrum using the maximum entropy (MaxEnt) algorithm from smoothed and 
centroided data. The observed mass of 50109.22 ± 0.53 Da was in keeping with the 
expected mass based on the recombinant protein sequence minus the initial methionine 
(50109.60 Da, Figure 3.3), calculated from the expressed protein sequence using ExPaSy 
ProtParam tool (https://web.expasy.org/protparam/). The loss of the methionine is very 
common as a post translational modification.146 An additional peak was also visible which is 
believed to correspond to the gluconoylation of the histidine tag (+ 178 Da), a very 
common phenomenon observed in recombinant proteins expressed in E. coli.147  A smaller 
additional peak can also be seen at each of the many charge states which corresponds to 
the PLP cofactor (230 Da). 
 
Figure 3.2 (A) Chromatogram from Superdex 16/60 S200 gel filtration chromatography of D-PhgAT. 
D-PhgAT elution volume corresponds to a dimer (79 mL). An aggregate is also visible at ~ 40 mL. (B) 
12% SDS-PAGE gel of D-PhgAT purification steps. Lane 1: low molecular weight (LMW) marker (GE), 
Lane 2: Soluble fraction of cell lysate Lane 3: D-PhgAT after IMAC, Lanes 4-9: elution fractions from 
SEC (3 mL fractions from 69-87 mL). 
 
 







Figure 3.3 Denaturing LC ESI-MS analysis of recombinant D-PhgAT (20 μM). The deconvoluted mass 
of 50109.22 ±0.53 Da agrees with the expected value based on the sequence of 50109.60 Da. The 
values are m/z with the charge states given in brackets.  
3.2.1 UV-Vis studies 
Binding of substrates to PLP-dependent enzymes can be monitored through ultraviolet–
visible (UV-Vis) spectroscopy of the PLP molecule where two absorbance maxima are 
usually observed. This is because the PLP molecule exists in two isoforms when bound as a 
Schiff base: the enolimine and ketoenamine forms (Figure 1.12). The enolimine form 
absorbs around 350 nm and the ketoenamine form around 420 nm. To investigate PLP 
binding, the enzyme was dialysed against buffer containing PLP (0.1 M CAPS, 150 mM NaCl, 
50 M PLP, pH 9.5) for 2 h in order to generate the holo-form of the enzyme. Excess PLP 
was then removed using a PD-10 desalting column and the resulting sample was analysed 
by UV-Vis spectroscopy.   
The enzyme shows a distinct UV-Vis spectroscopic profile with a max at 411 nm, 
indicative of PLP binding (Figure 3.4A). The formation of different intermediates results in 
distinct changes to the UV-Vis spectrum of PLP, allowing these intermediates to be followed 
spectroscopically. Upon addition of the amino donor (L-Glu), a shift towards 330 nm is 
 






observed in the first instance, corresponding to the formation of the external aldimine 
(Figure 3.4B). Over time, an additional shift toward 314 nm is observed, indicating the 
formation of the PMP intermediate (Figure 3.4C). Interestingly, if the amino acceptor (BZF) 
is added to the reaction mixture, a shift back towards 330 nm is observed suggesting that 
the PMP has donated the amino group to BZF and reverted to the PLP external aldimine 
(Figure 3.4D). An overview of all the spectral changes is shown in Figure 3.4. From these 
spectral changes, the reaction progress upon substrate addition can be monitored.  
 
Figure 3.4 (A) UV-Vis scans of D-PhgAT internal aldimine (E:PLP). (B) The PLP external aldimine 
profile after the addition of L-Glu (1mM). The 411 nm peak, corresponding to the internal aldimine, 
decreases and a new peak at 330 nm, corresponding to the external aldimine (PLP: L-Glu) is 
observed. (C) Over time a further shift towards 314 nm suggests the production of PMP (E:PMP). (D) 
Upon addition of BZF (1 mM) a shift back towards the 330 nm region is observed suggesting the 
formation of the external aldimine and the consumption of PMP (PLP:BZF).  
 






Using this approach, binding of different substrates, such as D-Phg and other amino 
donors/acids, can be followed. A general overview of the PLP profile upon amino donor 
binding is shown in Figure 3.5. Due to the fast enzyme turnover after substrate binding, 
calculation of the dissociation constant Kd (measurement of dissociation of the substrate 
from the ES complex) could not be achieved. This is because the fast shift towards the 
shorter wavelength would make the Kd calculation at 330 nm unreliable.   
 
Figure 3.5 Generic UV-Vis profile of D-PhgAT upon amino acid addition over time. The D-PhgAT 
internal aldimine displays an absorbance maximum at 411 nm. Upon amino donor addition a first 
shift towards external aldimine (330 nm) is observed. Over time (depending on the amino donor and 
the concentration used) a further shift, observed towards PMP at ~ 311 nm is observed, suggesting 
that the enzyme is turning over and the exchange of the amino group from the amino donor to the 
PLP cofactor.  
3.3 Enzyme assay 
Two different approaches were developed with the purpose of checking the enzyme 
activity and to determine the enantioselectivity of the enzyme. A spectrophotometric 
coupled assay, using a commercially available α-ketoglutarate dehydrogenase (AKGDH) 
from porcine heart, was developed as a quick method of validating enzyme activity. 
Additionally, a high-performance liquid chromatography (HPLC) based method was also 
developed. This was more time consuming but was necessary to determine the enzyme 
enantioselectivity. 
 






3.3.1 Coupled AKGDH assay (D-PhgAT/AKGDH) 
A high-throughput assay for D-PhgAT activity was developed by coupling the enzyme with 
AKGDH. AKGDH is a key enzyme in the citric acid cycle, crucial for human health as 
decreased activity can lead to neurodegenerative diseases such as Alzheimer’s disease.146 
AKGDH converts AKG into succinyl-CoA in presence of CoASH and NAD+. Appearance of 
NADH can be readily monitored at 340 nm (340 = 6220 M-1 cm-1), providing a fast route to 
measuring D-PhgAT activity. A scheme of the assay is show in Figure 3.6. 
                
                                                                                              
Figure 3.6 Reaction scheme of the D-PhgAT/AKGDH coupled assay. The AKG, product of the first half 
reaction, together with NAD+ and CoASH, are substrates of the AKGDH. The conversion of NAD+ to 
NADH can be easily monitored spectrophotometrically at 340 nm. 
A typical reaction profile of the NADH appearance at different L-Glu and BZF concentrations 
is shown in Figure 3.7, where a steeper gradient is observed at increasing substrate 
concentrations (Figure 3.7A and B). The initial rate (over the first 15 min) was used to 
determine kinetic parameters and obtain Michaelis-Menten plots (Figure 3.8, Table 3.1). 
Due to high background absorbance of HBF at 340 nm, the kinetic characterisation for the 
substrate was not achievable using the D-PhgAT/AKGDH assay.  
D-PhgAT exhibits a higher affinity towards BZF with a KM 5-fold lower than the KM 
for L-Glu (1.81 mM for BZF vs. 9.85 mM for L-Glu). Reported apparent KM values for D-Phg 
and AKG are 1.1 mM and 2.4 mM, but no kinetic parameters have been reported for the 
other half of the reaction, so no comparison is available for BZF and D-Phg. These are the 
first reported kinetic parameters for this reaction.127 Interestingly, the D-PhgAT enzyme 
 






Substrate KM (mM) kcat (s-1) kcat/KM (M-1 s-1) 
BZF 1.81 ± 0.57 0.39± 0.072 213.72± 0.49 
HBF NA NA NA 
L-Glu 9.85 ± 0.62 0.46 ±0.011 46.65 ±0.32 
 
shows a high catalytic efficiency (kcat/KM) towards the substrates and a fast turnover with a 
kcat in the order of sec. Thus, the enzyme has potential application in industrial biocatalysis. 
 
Figure 3.7 Typical raw data profile of NADH appearance at 340 nm obtained varying the (A) L-Glu 
concentration and (B) BZF concentrations. The initial rate (15 min) was used to calculate kinetic 
parameters using Graphpad Prism software. 
 
Figure 3.8 Michaelis–Menten plot of D-PhgAT for (A) the amino donor L-Glu and (B) the amino 
acceptor BZF. Data was analysed by non-linear regression using Graphpad Prism software.   
Table 3.1. Summary of the kinetic parameters obtained using the D-PhgAT/AKG assay. kcat values are 
in the order of sec. The same assay could not be applied (NA) for HBF due to high absorbance 
background at 340 nm.  
 






3.3.2 Chiral HPLC method development (cHPLC) 
The D-PhgAT/AKGDH assay presents many advantages, allowing a quick monitoring of 
kinetic parameters and enzyme activity. However, it cannot be used to fully characterise 
the enzyme. This is because the D-PhgAT/AKGDH assay directly monitors only the first half 
of the AT reaction and only indirectly D-Phg production.  Furthermore, the high background 
absorbance does not allow the calculation of kinetic parameters for other substrates, such 
as HBF.  
One of the major advantages of employing ATs is the possibility to produce chiral 
products. The D-PhgAT/AKGDH assay method does not allow the determination of enzyme 
enantioselectivity. As such, a stereospecific HPLC method was therefore developed to 
determine the chirality of the D-PhgAT reaction product. Initially, the protocol of 
Wiyakrutta S. et al was attempted, using a C18 column and a chiral mobile phase consisting 
of 2.4 mM copper acetate, 5 mM L-Pro and 3% Methanol (MeOH).127 However, this did not 
give the expected results as the D- and L-Phg were found to co-elute (data not shown).  
An alternative method, using a Chirobiotic T (Teicoplanin) column, was developed. 
This column had previously been used in our lab to resolve other amino acids.148 Using a 
mobile phase of 0.25% triethylammonium acetate (TEAA): MeOH (50:50) and a flow rate of 
1 mL min−1, the D- and L-Phg enantiomers were found to show distinct retention times (4.3 
min vs. 8.3 min).  Using the developed method, the production of the only D-Phg 
enantiomer can be observed in > 99% enantiomeric excess (ee) for the D-PhgAT catalysed 
reaction (Figure 3.9), where the ee is defined as the absolute difference between the mole 
fractions of two enantiomers as described in 5.9.1.149 
The exquisite D-PhgAT enantioselectivity is shown in Figure 3.9 were the HPLC trace 
for the D/L-Phg standards are overlaid with the HPLC trace for the D-PhgAT catalysed 
reaction. The specific formation of D-Phg for the D-PhgAT catalysed reaction can clearly be 
observed (Figure 3.9). Aliquots of single enantiomers of each amino acid (0-400 mM) were 
used to build a calibration curve to relate the area under the curve (AUC) with the amount 
of product formed over time (Appendix 8.6). Different enzyme concentrations (100 nM, 1 
M, and 10 M) were tested at different time points in saturating conditions in order to 
 






determine the range of linearity of the reaction and identify the ideal reaction conditions 
(Figure 3.10).  
 
Figure 3.9 Chiral HPLC (cHPLC) analysis on a calibrated Chirobiotic T column at  = 205 nm. The L- 
and D-Phg standards (10 mM, dash black line) are well resolved and the AT reaction carried out for 
18 h at 37 °C (10 mM L-Glu, 10 mM BZF) shows the formation of only the D-Phg enantiomer (red 
line). The retention times are 4.3 min for L-Phg and 8.3 min for D-Phg respectively.  
 
Figure 3.10 Reaction profile of three different enzyme concentrations (100 nM, 1 M and 10 M) at 
different time points at 37 °C under saturating conditions. Using D-PhgAT concentrations lower than 
10 M, the reaction is too slow to be monitored. Therefore 10 M was selected as the enzyme 
concentration for kinetic analysis. As 15 min is in the linear range of the plot it was chosen as the 
reaction time. 
 






Following the screening of these conditions, subsequent kinetic analyses were conducted 
with 10 M of D-PhgAT at 37 °C for 15 min after which the reaction was quenched by 
diluting the reaction 40-fold in the chiral mobile phase.  A typical chiral HPLC (cHPLC) profile 
of a kinetic experiment is shown in Figure 3.11 where a larger peak could be observed at 
increasing BZF concentrations. By relating the AUC with the amount of D-Phg/D-Hpg 
produced per unit of time, kinetic parameters could be calculated for each substrate, 
including HBF (Figure 3.11 B, Table 3.2). 
 
Figure 3.11 Representative chromatogram of D-PhgAT reactions at different BZF concentrations 
analysed by cHPLC. A bigger peak, corresponding to a larger amount of D-Phg produced is observed 
at increasing BZF concentrations. (B) Resulting Michaelis–Menten plot of D-PhgAT for BZF. Data was 
analysed by non-linear regression using Graphpad Prism software. 
As observed with the D-PhgAT/AKGDH assay, the enzyme shows a high turnover number 
confirming its industrial potential. The enzyme catalytic efficiency (kcat/KM) of HBF is ~ 3-fold 
greater than the BZF suggesting a preference of D-PhgAT for the 4’-hydroxy derivative 
(HBF) (899 vs. 302.80 M-1 s-1). 
Table 3.2 Summary of the D-PhgAT kinetic parameters calculated using the Chirobiotic HPLC 
method. 
Substrate KM (mM) kcat (s-1) kcat/KM (M-1 s-1) 
BZF 3.16 ± 0.46 0.95 ± 0.056 302.80 ± 0.10 
HBF 1.01 ± 0.07 0.91 ± 0.022 899.15 ± 0.27 
L-Glu 26.17 ± 3.63 1.65 ± 0.12 63.21 ± 0.78 
 
 






3.3.3  Comparison of D-PhgAT assays 
A comparison of the kinetic parameters calculated using both the D-PhgAT/AKGDH assay 
and the cHPLC method is shown in Table 3.3. All the calculated values are in the same order 
of magnitude. However, the values of the apparent KM determined using the cHPLC method 
are higher than those calculated with the spectrophotometric approach for both 
substrates.  
The apparent KM for BZF of the cHPLC method (3.16 mM) is 1.7-fold higher than that 
determined using the coupled assay (1.81 mM). A larger difference is observed for the 
kinetic parameters calculated for L-Glu with a 3-fold difference observed for the KM (9.85 
mM with AKG assay vs. 26.17 mM with cHPLC). 
Table 3.3. Summary of D-PhgAT kinetic parameters towards natural substrate calculated with both 
spectrophotometric and HPLC approaches. All kinetic parameters have been calculated using 
Graphpad Prism software. 
The AKGDH assay relies on the consumption of the transamination product of L-Glu, AKG, 
removing the ketone formed via a second enzyme and pushing the equilibrium towards 
product formation.  This likely results in the determination of an apparent KM lower than 
that calculated using the cHPLC approach, where the equilibrium is not altered by an 
additional enzyme. However, the parameters calculated with both approaches though 
different are comparable and for substrate comparison they could both be used. 
3.3.4 Exploring amino donor promiscuity 
In order to further characterise the D-PhgAT, substrate (BZF) conversion was assayed in the 
presence of all L- and D-amino acids and some industrially used amino donors (e.g. 
isopropylamine (IPA)). These were also tested to determine if a better amino donor could 
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be found to drive the AT reaction to completion. The amino donors were tested with BZF as 
amino acceptor as the product formation (D-Phg) can be easily monitored by cHPLC and the 
enantiopurity of the product can be assessed. Parallel reactions with 10 mM BZF and 10 
mM amino donor were incubated for 18 h at 37 °C.  Reactions were then quenched by 
diluting 40-fold into the mobile phase and analysed by cHPLC. According to the literature, 
no amino donors other than L-Glu are accepted by D-PhgAT, including L-Ala which has been 
shown to be accepted by the homologous D-PhgAT from P. putida (82% sequence 
identity).127 The different substrate scopes of these two homologous enzymes cannot be 
explained by sequence alignment alone.130  In contrast to reports in the literature,127 the D-
PhgAT used here displayed a much broader substrate scope, showing ability to use several 
L- and D-amino acids as substrates. The substrate scope is summarized in Figure 3.12, 
where BZF conversion (%) is normalized to L-Glu conversion which is the best amino donor.  
 
Figure 3.12   BZF conversion (%) when all L/D-amino acids are tested. All the reactions were carried 
out for 18 h in parallel. The percentage is an average of four experiments. The results are normalized 
by L-Glu conversion (70%). 
 






Regardless of whether L- or D- amino acids were used, the chirality of the final product 
remained unaffected, and the only detectable product was D-Phg. Interestingly, conversion 
was observed when D-Glu (7% conversion) was used as amino donor and with several D-
amino acids such as D-Met (75%), D-His (4.7%) and D- aromatic amino acids such as D-Phe, 
D Tyr and D-Trp (1.7%, 0.46% and 0.8% respectively). The second best amino donor after L-
Glu is (S)-α-methylbenzylamine (MBA) with 90% of conversion with respect to L-Glu 
conversion. The (R)-MBA enantiomer is still accepted by the AT, but with a much lower 
conversion (4.8%). D-PhgAT shows high activity towards L-Asp with a substrate conversion 
of 45%. Sulfur containing amino acids are accepted by D-PhgAT with 40% conversion when 
L- /D-Met are used as amino donors and 10% with L-Cys.  
3.3.4.1 Non-natural amino donors 
The application of ATs for the industrial synthesis of optically pure chiral amines still 
presents a number of challenges. One of the major drawbacks which has hampered the 
widespread use of ATs is the unfavourable reaction equilibrium. However, use of a large 
excess of the amino donor (if inexpensive) or removing the ketone by-products can be 
sufficient to shift the equilibrium towards product formation and achieve a satisfactory 
yield.102,150 The use of a large excess of amino donor combined with the by-product removal 
is often applied in small/medium scale reactions. The most widely employed system is the 
lactate dehydrogenase (LDH)/ glucose dehydrogenase (GDH) system (Figure 3.13, method 
1) which relies on the removal of the pyruvate by-product by using LDH, an enzyme that 
requires the expensive NADH cofactor, recycled using GDH. An alternative method, the 
alanine dehydrogenase (ADH)/GDH system (Figure 3.13, method 2) is used to both recycle 
the amino donor and shift the equilibrium towards product formation. However, both 
approaches require the use of expensive cofactor-dependent enzymes which are not 
sustainable for large scale reactions. Furthermore, the requirement of several enzymes 
could result in compromised conditions that are not optimal either for the AT or the 
enzyme(s) applied in the secondary irreversible reactions, resulting in sub-optimal enzyme 
performance in terms of activity and enantioselectivity. For this reason, industrially, the 
preferred amino donor is isopropylamine (IPA) since its keto co-product, acetone, is highly 
 






volatile and can be easily removed by in situ-evaporation (Figure 3.13, method 3).101,151 A 
summary of these approaches is shown in Figure 3.13.  
 
(A) Favored for small/medium-scale reactions 
 
(B) Favored for large-scale processes 
 
Figure 3.13 Most common approaches applied to overcome the unfavourable reaction equilibrium in 
TA applications. (A) Commonly, L-Ala is used as the amino donor as its keto by-product, pyruvate, 
can be removed from the reaction by applying the LDH. An additional enzyme, the GDH, is used in 
order to recycle the expensive NADH cofactor and therefore lower the amount of NADH required in 
the reaction. Alternatively the use of ADH has the double effect of driving the reaction towards 
product formation and recycling the L-Ala substrate. (B) In large scale processes the IPA method is 
preferred as the amino donor as its keto by-product acetone can be easily removed by in situ-
evaporation. Adapted from Gomm et al. and Truppo et al.101,151 
All these approaches have their limitations as they either involve additional enzymes, a 
costly cofactor or challenging by-product removal. The IPA method (Figure 3.13, method 3) 
has not been applied successfully for conversion of ketones with particularly challenging 
positions of equilibria.  
 






3.3.4.2 Ortho-xylylenediamine (OXD) 
In the last decade there has been significant interest in finding amino donors that could 
solve the issues related to unfavourable equilibrium position. This has led to the 
development of the so called ‘smart’ amine donors. The term ‘smart’ amine donor refers to 
amine donors whose keto by-products spontaneously and irreversibly transform into a 
different, more stable, compounds, shifting the equilibrium towards product formation.  
Amongst the ‘smart’ amine donors, the commercially available ortho-xylylene 
diamine (OXD) developed by Prof. N. Turner (University of Manchester) is of great interest 
as its cyclic imine by-product spontaneously converts into the more stable isoindole, 
removing the component from the system.152 The spontaneous polymerization of the 
isoindole causes the production of an insoluble purple derivative. The formation of a purple 
polymer has the double effect of displacing unfavourable reaction equilibria towards 
product formation whilst providing a substrate-independent high-throughput (HTP) 
screening method (Figure 3.14). Turner and co-worker successfully applied the OXD with a 
wide range of commercially available (R)- and (S)-ATs (Codexis) and amino acceptors 
suggesting the wide applicability of the ‘smart’ amine donor.152 However, higher 
conversions have been observed with (S)-AT rather than (R)-AT, suggesting a preference for 
(S)-ATs.  
Changes in the UV-Vis spectrum were observed when OXD was tested as amino 
donor for D-PhgAT, with a first shift towards the external aldimine and then to the PMP 
form (Figure 3.15). Overtime, an extra peak around ~ 550 nm was observed, suggesting the 
formation of the more stable isoindole product.  
The OXD amino donor was also successfully used in a solid phase assay. The 
formation of a purple/black precipitate was observed only in cells expressing the D-PhgAT 
(Figure 3.16). However, colonies turned black in a short period of time (a few hours), 
suggesting that it could not be used for screening in a directed evolution approach. This is 
thought to be due to high background combined with the high sensitivity which precludes 










Figure 3.14 General transamination reaction when OXD (1) is used as amino donor mode of action. 
The OXD keto by-product (2) spontaneously cyclizes into (3) that tautomerizes into the more stable 
isoindole (4). Compound (4) spontaneously polymerizes causing the production of a purple 
precipitate.  
 
Figure 3.15 D-PhgAT UV-Vis studies with OXD as amino donor at 1 mM. Over time the internal 
aldimine peak at 411 nm disappears and the PMP formation at ~ 311 nm is observed. An additional 
peak at ~ 550 nm corresponding to the isoindole formation is observed suggesting the progression of 
the AT reaction. The formation of a purple precipitate was observed after ~ 1 hr of reaction.  
 
 







Figure 3.16 Colony-based screen with OXD.  Cells expressing the dpgA gene turn dark in colour after 
~ 1 hr (middle). Cells lacking the dpgA gene remain colourless (left). After leaving the reaction ON 
the purple colour becomes more intense (right).  
A conversion comparison using the natural (L-Glu) and ‘smart’ amine donor (OXD) was 
carried out with 10 mM BZF over time (Figure 3.17) and analysed by cHPLC. Surprisingly L-
Glu showed a much higher conversion overtime (93% for L-Glu vs. 30% for OXD). Thus, 
the ’smart’ amino donor does not present any beneficial effect in either reaction time or 
percentage conversion for the D-PhgAT reaction. The ‘poor’ conversion observed with OXD 
as amino donor could be due to the reported preference of OXD for (S)-ATs as D-PhgAT is 
an unusual ‘stereoinverting’ AT.  
 
Figure 3.17 Time course comparison when OXD (purple line) and L-Glu (black line) are used as amino 
donor. The substrate conversion (%) was determined by cHPLC. OXD and L-Glu were used at a final 
concentration of 100 mM. 
 






3.3.4.3 Amino benzenes as ‘smart’ amino donors 
Recently, Prof. Helen Hailes (UCL) developed a range of ‘smart’ amine donors with a 
different mode of action compared to OXD.153 An example is shown in Figure 3.18, with 2-
(4-nitrophenyl) ethan-1-amine (4-NPEA) (3).  The aldehyde, (4), generated by the 4-NPEA 
(3) transamination reaction, reacts with the amine donor (3) forming the imine (5), which, 
after tautomerization, gives the conjugated red precipitate (6). The amine produced by the 
TA reaction (2) can also react with the amine donor 3 contributing to the observed colour. 
The use of a high excess of the amine donor should minimize this background colour.  
 
Figure 3.18 Mechanism of action of the 4-NPEA (3) amine donor. The 4-NPEA (3) conversion into 
aldehyde (4) and basic work up and deprotonation yields a highly conjugated structure (6) with 
absorbance in the UV-region. 
Prof. Helen Hailes and co-workers reported conversion using well characterised (S)-ATs 
such as Chromobacterium violaceum AT (Cv-AT) and Pseudomonas putida AT (Pp-TA) and 
(R)-AT such as Klebsiella pneumoniae KPN_00799 (Kp-TAm) showing the applicability of the 
assay to both (R)- and (S)-selective ATs.  
As the presence of the 4-nitroaryl electron withdrawing group (EWG) enhances the 
tendency to form the enamine, other commercially available amine donors with EWG were 
explored such as  4-(2-aminoethyl) benzonitrile (4-AEB) and 5-nitro-2, 3-dihydro-1H-inden-
2-amine (2,3-DHIA). Thus, 4-NPAE (3) ,4-AEB (7) and 2,3-DHIA (8) were tested with different 
amino acceptors such as BZF, AKG, benzaldehyde (BZALD) and n-butyraldehyde (NBA) as 
reported in the literature (Figure 3.19). The formation of a very pale orange/red 
precipitated could be observed with amine donors (3) and (8) with BZF as amino acceptor in 
 






comparison to the control (A3, A4; A5, A6) (Figure 3.19). However none of the amino donor 
screened seems suitable for the D-PhgAT reaction as no colour formation was observed.   
 
Figure 3.19 Screening of the amine donors 4-AEB (7) (lane 1, 2), 4-NAE (3) (lane 3, 4) and 2, 3-DHIA 
(8) (lane 5, 6) with different amino acceptors such as BZF (lane A), AKG (lane B), BZALD (lane C), NBA 
(lane D) with D-PhgAT (0.5 mg mL-1).  Amine donor were used at a final concentrations of 25 mM 
with amino acceptors at 10 mM, as suggested in the literature.153 For each reaction a control with no 
enzyme was performed (lane 2, 4, 6). Reactions were incubated for 18 h at 37 °C. A very pale red 
colour is observed for lane A3 and A5 with 4-NAE and 2, 3 DHIA and BZF.  
3.4 Biotransformation optimization/development 
Amongst all the tested amino donors, the natural substrate, L-Glu, was found to be the best 
amino donor and therefore was used in the following studies. The biocatalytic reaction was 
scaled up to a gram scale with BZF (1 g) in order to prove the applicability of the enzyme at 
an industrial level. A large excess of L-Glu (500 mM) was used in the reaction to shift the 
equilibrium towards product formation.  As the high pH (9.5) is crucial for the enzyme 
activity the highest L-Glu concentration achievable was 500 mM.  Therefore 1 g of BZF (~ 
133 mM) and 500 mM L-Glu were added to the reaction mixture (50 mL) and the pH was 
adjusted before addition of the catalyst.  
The catalyst concentration is a crucial factor for the biotransformation, therefore 
the reaction was carried out at 3 different D-PhgAT concentrations (0.2 mg mL-1, 0.4 mg mL-
1 and 1 mg mL-1) to identify the optimal conditions.  Samples were quenched at different 
 






time points from 15 min to 24 h. Reactions were quenched by diluting 40-fold into the 
cHPLC mobile phase and analysed by cHPLC. The results are summarized in Figure 3.20 
showing the substrate conversion at different time points for each enzyme concentration.  
A 93% BZF conversion is observed after just 3 h of reaction with an enzyme loading of 
1 mg mL-1. A 60% BZF conversion and 50% BZF conversion is observed at 0.4 mg mL-1 and 
0.2 mg mL-1 D-PhgAT, respectively. This yield is better than the previously reported 83% 
conversion with isolated enzyme.127 
 
Figure 3.20 Large scale biotransformations at different D-PhgAT concentrations (0.2, 0.4 
and 1 mg mL- 1). A control with all the reactants apart from the enzyme was carried out at each time 
point in order to prove that the reaction is enzyme catalysed. Reactions were quenched by diluting 
the sample (40-fold) into the mobile phase (50:50 MeOH: 0.025% TEAA). Samples were analysed by 
cHPLC at each time point in triplicate. 
Zhou Y. et al. 154 recently described the engineering of three recombinant E. coli strains that 
co-expressed four, seven and nine enzymes including P. stutzeri D-PhgAT as the final step. 
Thanks to these whole cell biotransformation approaches, the production of a wide range 
of D-Phg derivatives such as 4-bromo-, 4-fluoro-D-Phg is achieved in one pot from racemic 
mandelic acid, styrene and L-Phe starting materials. Using this approach, Zhou Y. et al. 
reported a yield of 93% for D-Phg which is consistent with our result.  
 






This reaction scale-up proves that D-PhgAT can be applied to a large-scale 
biosynthesis of D-Phg without requiring any additional engineering for the synthesis of D-
Phg. An excess of amino donor L-Glu (~ 20-fold KM) is enough to drive the reaction towards 
product formation. 
3.5 Exploring amino acceptor promiscuity 
Having established the best operative conditions for the D-PhgAT bioconversions in terms 
of both amino donor and enzyme concentrations, and demonstrated its efficiency for the 
natural catalysed reaction, screening of amino acceptors was carried out. This was done to 
identify other high value products that could be potentially synthesized using this promising 
biocatalyst.  
Non-proteinogenic D-amino acids such as D-phenylalanine (D-Phe), D-tyrosine (D-
Tyr) and D-tryptophan (D-Trp) are high value compound whose efficient synthesis would be 
extremely advantageous.155 Current biosynthetic methods still present several limitations 
such as either the requirement of multiple enzyme (e.g. L-amino acid ATs and a racemase 
or hydantoinase–carbamoylase system) or an expensive starting material (D-amino acids 
for D-AT).125,155  
D-PhgAT was therefore tested for its ability to use BZF, HBF, phenylpyruvic acid 
(PPA), 4-hydroxyphenylpyruvic acid (HPPA), and indole-3 pyruvic acid (IPyA) as amino 
acceptors in order to yield D-Phg, D-Hpg, D-Phenylalanine (D-Phe), D-Tryptophan (D-Trp) 
and D-Tyrosine (D-Tyr) respectively. A scheme of the tested reactions is shown in Figure 
3.21.  Surprisingly D-PhgAT was able to use all the aromatic compounds tested as amino 
acceptors, producing enantiopure high value D-amino acids. A summary of the cHPLC traces 
of the enantiopure synthesized D-amino acids is shown in Figure 3.22. These D-aromatic 
amino acids have a range of applications. D-Phe, for instance, has anti-depressant and 
analgesic activities.156 Furthermore D-Phe derivatives are high value building blocks for a 
wide range of pharmaceuticals from antibiotics to antidiabetics.156 D-Trp has been shown to 
be a product of probiotic bacteria, influencing the gut microbiome and chronic immune 
diseases.157 D-Tyr is a chiral precursor of potent inhibitors of human non-pancreatic 
secretory phospholipase A2 (IIa) with anti-inflammatory activity.158 
 







Figure 3.21 D-PhgAT reactions for the synthesis of aromatic D-amino acids. Reactions were analysed 
by cHPLC which was calibrated with a single enantiomer of each amino acid and used to build 
calibration curves.  
 
Figure 3.22 cHPLC traces of D-PhgAT production of D-Phg, D-Hpg, D-Trp, D-Phe and D-Tyr at  = 
205 nm. Reactions were carried out for 15 min and quenched by diluting the sample into the mobile 
phase (50:50 MeOH: 0.025% TEAA). Retention times are 4.6 min (D- Tyr), 5.4 min (D-Phe), 6.1 (D-
Trp), 7.6 min (D-Hpg) and 8.3 min (D-Phg). 
 
 






Kinetic parameters and % conversion were calculated for all amino acceptors up to 100 mg 
scale (Table 3.4). 
Table 3.4 Summary of product formation (%) and kinetic parameters of D-PhgAT for all the amino 
acceptor obtained using the cHPLC method. Kinetic parameters were calculated at 100 mM L-Glu at 
different amino acceptor concentrations (0-40 mM) with a reaction time of 15 min except for HPPA 
whose reaction was quenched after 30 min. Reactions were quenched by diluting the sample (40-
fold) into the mobile phase (50:50 MeOH: 0.025% TEAA). For the percentage of conversions, 
reactions were carried out at 100 mg scale as described in Material and Methods. The L-Glu 
concentration used was 500 mM to drive the reaction towards completion. 
The highest substrate conversion was observed with BZF as substrate (93%). However, 
good conversion was observed for PPA, with a 57% production of D-Phe, achieved after just 
3 h of reaction. The lowest substrate conversion was observed for HPPA (15%). This is 
consistent with the observed catalytic efficiency (kcat/KM) of D-PhgAT for HPPA, which is 
dramatically reduced compared to the other substrates (~ 5000-fold lower than BZF).  
According to the calculated kinetic parameters the best substrate (kcat/KM) is HBF, followed 
by BZF, IpyA, PPA and finally HPPA. Unsurprisingly, a decrease in the reaction rate (kcat) is 
observed for the non-natural amino acceptors. Thus, in order to apply these bioconversions 
on an industrial scale, approaches such as directed evolution/site directed mutagenesis will 
be necessary. Alternatively, approaches such as enzyme immobilization or biphasic systems 
could be applied to overcome problems such as substrate inhibition.159 As the position of 
the equilibrium is particularly challenging, especially for the 4-hydroxylated derivative of 
PPA, a range of ‘smart’ amine donors could also be tested to check improvement in 
percentage conversion. 










BZF D-Phg 93 >98 3.16 ± 0.46 0.95 ± 5.6 *10-2 302.80 ± 0.10 
HBF D-Hpg 50 >98 1.01 ± 0.07 0.91 ± 2.2 *10-2 899.15 ± 0.27 
PPA D-Phe 57 >98 6.91± 0.99 0.09 ± 8.5 *10-3 14.49± 0.819 
HPPA D-Tyr 15 >98 9.24 ± 2.4 5.95*10-4± 2.34 *10-4 0.0616 ± 0.011 
IPyA D-Trp 30 >98 0.39 ±0.19 0.10 ±1.4 *10-2 262.12 ± 0.13 
 
 






3.6 High resolution structural studies of D-PhgAT 
Determination of the 3D structure of D-PhgAT is fundamental for allowing an 
understanding of the molecular basis of the enzyme enantioselectivity and identifying 
residues crucial for substrate catalysis and conversion. These studies underpin future 
directed evolution/site-directed mutagenesis studies and optimisation of D-PhgAT as a 
biocatalyst. To this end, it was decided to determine the 3D structure of D-PhgAT from P. 
stutzeri ST-201 by X-ray crystallography. Previous attempts to solve the D-PhgAT structure 
are reported in the literature; a PDB file deposited under 2CY8 is available. However, this 
model is of ‘poor’ quality as it does not contain the PLP-cofactor and residues around the 
active site are not modelled, presumable due to their flexibility in the absence of the 
cofactor and ligand.131 
In collaboration with Dr Jon Marles-Wright (Newcastle University), crystal trials with 
purified D-PhgAT (See paragraph 5.13.1) were performed using a broad range of conditions 
from commercially available screens to identify hit conditions (PEG/ION, MIDAS, 
STRUCTURE, JCSG+ etc.). These screens were performed via vapour diffusion in 96 well 
plates format prepared with a Gryphon robot.  Crystals were observed under a handful of 
different conditions (C3, H10 PEG/Ion, B8 JCSG+, H4 MIDAS). These specific conditions were 
taken forward for further optimization. 
Following optimisation, suitable conditions were found to give monoclinic crystals 
with the ideal morphology. These were generated by vapour diffusion via the hanging drop 
method at room temperature (25°C) using 0.2 M ammonium citrate, polyethylene glycol 
15% (w/v) (PEG) 3350  (PEG/ION C3), pH 7 and a protein (9.1 mg mL-1): precipitant ratio of 
1:1 with the D-PhgAT in 50 mM Tris, 150 mM NaCl, 50 µM PLP, pH 9.5. These crystals were 
fished, frozen in cryoprotectant and sent to the Diamond Light synchrotron, Harwell for X-
ray diffraction analysis.  
Several diffraction-quality datasets were collected with the highest resolution being 
2.0 Å. Solution of the D-PhgAT structure from the electron density data was carried out by 
Dr Jon Marles-Wright (Newcastle University) by molecular replacement using the 
incomplete D-PhgAT structure with PDB code 2CY8. Unfortunately, the structure lacked the 
PLP cofactor in the active site Figure 3.24). The lack of PLP in both structures (2CY8 and 
 






ours) is probably caused by the buffer used (Tris) that, interacting with the cofactor, 
removes the PLP from the protein (Figure 3.23).  
 
Figure 3.23 Mechanism of interaction between PLP and Tris. The primary amine of Tris reacts with 
the cofactor forming an external aldimine, removing the PLP from the enzyme which results in an 
apo-structure. 
A second screen was performed, changing the protein buffer to 0.1 M CAPS, 150 mM NaCl, 
50 µM PLP, pH 9.5.  Yellow crystals were produced by adding 1 µL of 9.1 mg mL-1 D-PhgAT 
(in 0.1 M CAPS, 150 mM NaCl, 50 µM PLP, pH 9.5) to 1 µL of 0.1 M Tris, 0.2 M MgCl2, 10% 
(w/v) PEG 8000, pH 7.5 (Figure 3.25). Crystals were cryoprotected with a solution 
containing 0.1 M Tris, 0.2 M MgCl2, 10% (w/v) PEG 8000, pH 7.5, 20% (v/v) PEG 200 and 
then frozen by immersion in liquid nitrogen. Several diffraction-quality datasets were 
collected (Diamond Light) with the highest resolution of 2.25 Å undergoing full refinement 
to generate structural information (Appendix 8.7). 
 
 Figure 3.24 (A) Crystals morphology of the first attempt at obtaining diffraction quality D-PhgAT 
crystals. Conditions: 0.2 M ammonium citrate, 15%PEG 3350, pH 7 (Peg ION C3) and a protein (9.1 
mg mL-1): precipitant ratio of 1:1 with the D-PhgAT in 50 mM Tris, 150 mM NaCl, 50 µM PLP, pH 9.5. 
(B) Electron density map of the active site lacking the PLP cofactor contoured at 1.5 σ.  
 







Figure 3.25 (A) Crystal morphology of the second attempt of obtaining diffraction quality D-PhgAT 
crystals by changing the D-PhgAT purification buffer. Yellow crystals were produced by adding 1 µL 
of 9.1 mg mL-1 D-PhgAT in 0.1 M CAPS, 150 mM NaCl, 50 µM PLP, pH 9.5to 1 µL of 0.1 M Tris, 0.2 M 
MgCl2, 10% (w/v) PEG 8000, pH 7.5. (B) Electron density map of the active site containing the PLP 
cofactor contoured at 1.5 σ.  
Solving of the D-PhgAT structure was performed by Dr. Jon Marles-Wright (Newcastle 
University) using the same procedure describe above, using the 2CY8 structure as a 
template. The refined protein structure is deposited under the PDB code 6G1F. The final 
refined model contains three homodimers of D-PhgAT with the PLP cofactor present as an 
internal aldimine with residue Lys269 in each chain (Figure 3.26). 
Overall, our D-PhgAT structure conforms to the type I PLP-dependent fold seen in 
the group III of the aspartate AT (AspAT) family (Figure 3.27 A). The monomeric D-PhgAT 
structure can be subdivided into two distinct domains: a small discontinuous domain 
comprising the residues 1-72 and 336-453 (N- and C-terminal part of the polypeptide 
chain); and a large domain formed by residues 73 to 335 (Figure 3.27 B). The N-terminal 
portion of the small domain comprises a kinked α-helix followed by a three-stranded 
antiparallel β-sheet, while the C-terminal part consists of an α-helix followed by two 
antiparallel β-strands, an extended loop interspersed with a short α-helix that continues 
into a longer α-helix. This is followed by a β-strand that extends the N-terminal -sheet and 
an additional -strand which extends the C-terminal β-sheet, the structure finishes with a 
-helix opposed between to two other major helices in this domain (Figure 3.27 B).  
The large domain consists of a central seven-stranded β-sheet, with five parallel 
strands and two in an anti-parallel orientation. The β-sheet is connected by α-helices, which 
harbour the cofactor binding site and main dimerization interface (Figure 3.27 B). 
 







Figure 3.26  Final refined D-PhgAT model containing three homodimers of D-PhgAT with the PLP 
cofactor present as an internal aldimine with residue K279 in each chain. PLP is shown as sticks and 
highlighted in yellow. Monomer A is highlighted in red while monomer B is in blue. 
 
 
Figure 3.27 (A) Crystal structure of the D-PhgAT internal aldimine at 2.25 Å resolution. Monomer A is 
shown in red, monomer B in blue. (B) Large and small domain of monomer A are highlighted in 
bright and pale red. PLP is shown as sticks and highlighted in yellow. 
 






The PLP-binding site and the active site of D-PhgAT is located at the dimer interface with 
the PLP binding lysine (Lys269) located in the loop connecting strands β9 and β10. The 
aromatic ring of PLP is sandwiched between Val243 and Tyr149. The phosphate group of 
the cofactor is anchored by a series of hydrogen bonds with Ser121, Gly122, and Thr123 
from one monomer and Ser121, Glu124, Phe304 and Thr313 from the other, directly or 
through water molecules.118 Residues involved in cofactor binding/stabilization are 
highlighted in Figure 3.28.  
 
Figure 3.28  (A) D-PhgAT PLP internal aldimine. Residues involved in cofactor stabilization are shown 
as stick representations, with carbon atoms shown in cyan and green for the two monomers in the 
active dimer, oxygens are shown in red, nitrogens in blue and phosphorous in orange. Coordinated 
water molecules are shown as red spheres. The aromatic ring of PLP is sandwiched between Val243 
and Tyr149. The nitrogen of the pyridine ring is fixed by hydrogen bond coordination to Asp241 as is 
common in ATs. The phosphate group is stabilized by a network of interactions with Ser121, Gly122, 
and Thr123 from Monomer A; and Glu124, Phe304 and Thr313 from monomer B. A water molecule 
forms a bridge between one of the phosphate oxygens and the side chain carboxylic acid of Glu124; 
and another water molecule bridges a phosphate oxygen and the peptide nitrogen of Phe304. (B) 
Hydrogen bonds, direct or through water molecules, are shown as dotted lines and distances (Å) in 
grey.  
The large active site cavity is crucial to accommodate bulkier substrates such as 4-HBF and 
explains the reported ability of D-PhgAT to accept bulkier halogenated substituents like 
bromine and fluorine (Figure 3.29 A).154 The cavity extends from the surface of the protein 
and has a wide mouth with a constriction near the active site formed by Thr44, Phe74, 
His224, and Phe422 (Figure 3.29 B). This constriction accommodates hydrophobic side 
chains through π-stacking interactions, while orienting the keto substrate to accept the 
amine group from the PMP intermediate. 
 







Figure 3.29 (A) D-PhgAT surface coloured by electrostatic potential. Around the active site cavity a 
predominance of positively charged residues can be observed.  (B) The protein displays a wide cleft 
to accept a wide range of amino acid substrates. The cavity extends from the surface of the protein 
and has a wide mouth with a constriction near the active site formed by Thr44, Phe74, His224, and 
Phe422, highlighted as sticks. PLP is shown as yellow sticks.  
Comparison of the holo- and apo-forms of the P. stutzeri D-PhgAT highlights a number of 
key differences around the PLP-binding pocket.  The two structures align with an overall 
RMSD C of 1.29 Å, revealing three loop regions absent in the apo-structure and ordered in 
the holo-structure, due to PLP binding in the active site (Figure 3.30).  A loop between 
residues 149 and 174 directly contacts the pyridine ring, with Tyr149 opposed edge-on 
against the ring, with the hydroxyl group pointing towards the phosphate group. This 
interaction orders a stretch of residues from Tyr149 – Trp152 which provides a template to 
order the remainder of this loop. The phosphate group interacts closely to form a hydrogen 
bond with Thr313 of the partner chain to order a loop between residues 291 and 306, 
which stabilises the loop between residues 28-35 of the primary chain (Figure 3.30 B).  
 
Figure 3.30 (A) Comparison of the apo- (PDB code: 2CY8) and holo-form (PDB code: 6G1F) of the P. 
stutzeri D-PhgAT. The apo-structure is shown as a surface while the holo-structure is shown as 
 






ribbon. (B) Zoom into the active site reveals some of the key residues absents in the apo structure. 
Amongst them, the conserved Try149 involved in PLP stabilisation and Thr303 involved in the 
phosphate stabilisation.  
The highlighted residues missing in the apo-structure are conserved amongst the AT family 
as they are all involved in cofactor stabilisation. Amongst them the tyrosine residue, 
sandwiching the cofactor which is typically present in the class III ATs.  
In order to gain further insight into residues involved in substrate binding, co-
crystallization experiments and substrate soaking have been performed with several 
substrates, to attempt to trap an external aldimine structure. As the enzyme has a fast 
turnover rate, a D-PhgAT K269A variant was also produced to stop the enzyme from turning 
over and trap the external aldimine. Natural substrates (L-Glu and D-Phg), non-natural 
‘smart’ substrate (OXD) and substrate mimics, reported to inhibit ATs in the literature (such 
as L-Tyr hydrazide and L-Phe hydrazide and cycloserine) were also tried in co-crystallisation 
experiments. However, none of the approaches were successful and it was not possible to 
obtain the x-ray structure of an external aldimine of D-PhgAT.  
3.7 Characterisation of enzyme variants 
Concurrent with the determination of the D-PhgAT 3D structure, site-directed mutagenesis 
(SDM) experiments were undertaken in order to gain more insight into the residues 
involved in substrate binding and recognition. Looking at the residues around the active 
site, Gln300 was identified as a potential residue involved in the recognition of the 
carboxylic group of the BZF, crucial for the enzyme enantioselectivity (Figure 3.31A). This 
was identified by bioinformatic analysis as is not conserved amongst the other class III AT as 
highlighted in Figure 3.39. In order to confirm its role, SDM studies were undertaken, by 
mutating the residue to an asparagine (shortening the side chain length) and also to an 
alanine (completely disrupting the function).   
As Arginine residues are crucial for the dual substrate recognition displayed by ATs, 
a detailed analysis of Arg residues around the active site and the surface pocket was carried 
out.113 This analysis has led to the identification of Arg406 (Figure 3.31 B). This differs from 
the Arg348 suggested for the same role by Bornscheuer and co-workers which, in our 
structure, is very far from the active site pocket and surface.108 
 






Mutagenesis primers were designed to prepare D-PhgAT Q300N, Q300A and R406A 
via the method of Naismith and Liu.160 Using the original pET15b-dpgA plasmid as a 
template, the entire vector was PCR amplified with the relevant primer pairs incorporating 
the mutated residues into the gene sequence. Subsequent sequencing confirmed the 
mutations were present and that gene fidelity was otherwise maintained. 
 
Figure 3.31 Residues identified in substrate recognition. (A) Amongst the residues around the active 
site the Gln300 has been identified as the potential residue involved in the interaction with BZF. (B) 
On the enzyme surface an arginine residue, Arg406 is suggested to be important for substrate 
recognition. 
3.7.1 D-PhgAT Q300N and Q300A characterisation  
D-PhgAT mutants Q300N and Q300A were expressed and purified according to the 
established procedures. Both mutants were soluble and expressed in yield similar to the 
wild type (WT) enzyme (~ 70 mg per litre of culture). The SEC showed a profile comparable 
to the WT enzyme with an elution volume of 78.0 mL (Figure 3.32 A and Figure 3.33 B) 
corresponding to a homodimer in solution. SDS-PAGE analysis showed the pure protein 
with a monomeric mass of ~ 51 kDa (Figure 3.32 A and Figure 3.33 B). 
The presence of the designed mutation was further conformed by LC-MS as 
previously described and was is in keeping with the expected mass based on the predicted 
recombinant protein sequence minus the initial methionine(Figure 3.32 C and Figure 3.33 
C).   
 






As observed for the WT enzyme, multiple forms of the enzyme can be observed in the LC 
ESI-MS spectrum, including the loss of the methionine and gluconoylation of the histidine 
tag (+ 178 Da).  
 
Figure 3.32 (A) Chromatogram from Superdex 16/60 S200 gel filtration chromatography of D-PhgAT 
Q300N (B) 12% SDS-PAGE gel of D-PhgAT purification steps. Lane 1: LMW marker (GE), Lane 2: D-
PhgAT Q300N after nickel affinity purification, Lanes 3-8: elution fractions from SEC (3 mL fractions 
from 69-87 mL). (C)  Denaturing LC ESI-MS spectrum of recombinant D-PhgAT Q300N (20 μM) with a 
deconvoluted mass C of 50096.22 ±0.44 Da which agrees with the expected one for the recombinant 
protein of 50095.57 Da. The values are m/z with the charge states given in brackets.  
D-PhgAT Q300N and Q300A were successfully characterised by cHPLC, according to the 
established procedures. The Michaelis-Menten plots obtained for both mutants are shown 
in Figure 3.34. Since the Q300 residue was hypothesized to be involved in BZF recognition, a 
 






change in the enzyme enantioselectivity was expected by mutating this residue. However, 
the enzyme enantioselectivity was not affected by the mutation and both Q300N and 
Q300A mutants showed the production of only the D-enantiomer of Phg in >99% ee. 
 
Figure 3.33 Chromatogram from Superdex 16/60 S200 gel filtration chromatography of D-PhgAT 
Q300A. D-PhgAT elution volume corresponds to a dimer. An aggregate is also visible at ~ 40 mL. (B) 
12% SDS-PAGE gel of D-PhgAT purification steps. Lane 1: LMW marker (GE), Lane 2: D-PhgAT Q300A 
after nickel affinity purification, Lanes 3-8: elution fractions from SEC (3 mL fractions from 69-87 mL).  
(C) Denaturing LC ESI-MS spectrum of recombinant D-PhgAT Q300A (20 μM) with a deconvoluted 
mass of 50053.15 ±0.31 Da which agrees with the expected one for the recombinant protein of 
50052.55 Da. The values are m/z with the charge states given in brackets.  
Furthermore, the KM constant of the D-PhgAT Q300N for both L-Glu and BZF did not show 
any significant difference compared to the WT enzyme (for BZF 3.54 mM vs. 3.16 mM and 
 






for L-Glu 43.93 mM vs. 26.17 mM for Q300N and WT respectively). In contrast to the 
Q300N mutant, a significant increase (by 3-fold) in the KM towards the BZF was observed for 
the D-PhgAT Q300A. This result suggests that Gln300 may play a role in BZF binding as the 
KM for L-Glu was not dramatically affected. A comparison between the WT and the two 
mutants is shown in Table 3.5. 
 
Figure 3.34  Michaelis–Menten plot of D-PhgAT Q300N (A and B) and Q300A (C and D) for L-Glu and 
BZF. Data was analysed by non-linear regression using Graphpad Prism software.  
Table 3.5 KM comparison between the D-PhgAT WT and Q300 mutants towards the two substrate 
L-Glu and BZF. No significant changes were observed for L-Glu while an effect toward BZF was 
observed with Q300A. 
 
Enzyme Variant KM L-glu (mM) KM BZF (mM) 
D-PhgAT wt 26.17 ± 3.63 3.16 ± 0.46 
D-PhgAT Q300N 43.93 ± 7.98 3.54 ± 0.92 
D-PhgAT Q300A 43.23± 7.90 9.02± 0.95 
 
 






In conclusion, the Gln300 may play a role into the BZF binding, however is not crucial for 
the enzyme activity and/or enzyme enantioselectivity.  
3.7.2 D-PhgAT R406 mutant characterisation 
As for the other mutants, the D-PhgAT R406A was successfully expressed and purified 
according to the established procedures with yields similar to the WT enzyme. No 
significant changes were observed in the SEC profile and the pure protein was analysed by 
SDS-PAGE as shown in Figure 3.35. LC ESI-MS of D-PhgAT confirmed the presence of the 
mutation (observed mass: 50024.87 Da) in the translated sequence and further kinetic 
characterisation was therefore undertaken.  
 
Figure 3.35 A Superdex 16/60 S200 chromatogram of the D-PhgAT R406A variant. D-PhgAT elution 
volume corresponds to a dimer. (B) 12% SDS-PAGE gel of D-PhgAT purification steps. Lane 1: LMW 
marker (GE), Lane 2: D-PhgAT Q300A after nickel affinity purification, Lanes 3-8: elution fractions 
from SEC (3 mL fractions from 69-87 mL). (C) Denaturing ESI-MS spectrum of recombinant of D-
PhgAT R406A (20 μM) with a deconvoluted mass of 50024.87 ±0.21 Da which agrees with the 
 






expected one for the recombinant protein of 50024.49 Da. The values are m/z with the charge states 
given in brackets. 
The D-PhgAT R406A mutant was kinetically characterised by cHPLC, according to the 
established procedures (Figure 3.36). The mutation did not affect the enzyme 
enantioselectivity as the production of only the D-enantiomer was observed. A full 
comparison between the kinetic parameters generated in this study is show in Table 3.6. 
 
Figure 3.36 Michaelis–Menten plot of D-PhgAT R406A for L-Glu (A) and BZF (B). Data was analysed 
by non-linear regression using Graphpad Prism software 
Table 3.6 KM comparison between the D-PhgAT WT and the mutants generated in this study towards 
the two substrate L-Glu and BZF.  
The D-PhgAT R406 displays a KM constant 6-fold higher than the WT enzyme (133.5mM vs. 
26.17 mM). Affinity towards BZF is not dramatically affected with a KM ~ 2-fold lower 
compared to the WT enzyme (1.51 vs. 3.16 mM).  These results suggest that the 
hypothesized Arg406 plays a fundamental role in L-Glu recognition as the substrate affinity 
is dramatically affected when mutated.  
 
Enzyme Variant KM L-glu (mM) KM BZF (mM) 
D-PhgAT wt 26.17 ± 3.63 3.16 ± 0.46 
D-PhgAT Q300N 43.93 ± 7.98 3.54 ± 0.92 
D-PhgAT Q300A 43.23 ± 7.90 9.02± 0.95 
D-PhgAT R406A 133.5 ± 30.5 1.51 ±0.45 
 
 






3.8 D-PhgAT-D-Phg model 
After several failed attempts to trap the D-PhgAT external aldimine and inconclusive SDM 
results, substrate docking was carried out to gain insight into the R-selectivity of the D-
PhgAT.  Dr Jon Marles-Wright (Newcastle University) modelled the PLP-D-Phg external 
aldimine in the active site based on the (R)-MBA bound structure of the (S)-selective, -AT 
from Bacillus megaterium (Bm-AT, PDB code: 5G09) (Figure 3.37).161 
 The obtained model suggests that the amine group of the PMP intermediate is 
delivered to the keto substrate from only one face, since His66, His213, and Thr303 (from 
the adjacent monomer) align the substrate so that the reaction can only take place in the 
correct orientation (Figure 3.37). This suggests that the unique stereo-inverting feature of 
the enzyme is due to the enzyme architecture, that allows BZF substrate to be aminated 
from just one face and not another. The carboxylic acid group of the acceptor substrate is 
within hydrogen bonding distance of His66 and Thr303, and a positively charged ‘appendix’ 
extends to Arg34, which could accommodate the carboxylic acid group of both the donor 
and the acceptor substrates. This is in contrast to the Bm-AT, which has a tryptophan in the 
position of Arg45 and thus does not possess this structural feature. A comparison of the 
different active site architecture of the two ATs is shown in Figure 3.38.   
 
Figure 3.37 Model of D-Phg PLP external aldimine in active site tunnel of D-PhgAT. The D-Phg was 
modelled using the Bm-AT:(R)-MBA external aldimine (PDB code: 5G09) to place the substrate. D-
Phg shown as sticks with cyan carbon atoms; His66 and His213, along with Thr303 from the partner 
chain are shown with cyan and green sticks respectively. Solvent accessible surface of D-Phg shown 
in grey. 
 







Figure 3.38 Comparison of the substrate-binding tunnel of D-PhgAT:D-Phg and BM (S)-AT: (R)-MBA.  
(A) Solvent accessible surface representation of the D-PhgAT substrate-binding tunnel shown 
colored by electrostatic charge. The modelled D-Phg external aldimine is shown as cyan sticks with 
residues contributing to the substrate ‘appendix’ highlighted, with the pocket lined with His66 and 
Thr303 and terminating at Arg34. This pocket could accommodate the carboxylic acid groups of both 
the donor and acceptor substrates. (B) Solvent accessible surface representation of the B. 
megaterium AT (PDB code: 5G09) substrate-binding tunnel colored as in (A). The (R)-MBA ligand 
occupies a pocket lined with residues with hydrophobic side-chains, with no charged appendix 
capable of accepting acidic groups. 
Sequence analysis of some of the best characterised ATs belonging to the same fold (Cv-AT, 
Vf-AT and Bm-AT) revealed that the His66 and His213 residues hypothesized to be crucial 
for the correct substrate orientation are not present in other members of the class III AT 
family, confirming the uniqueness of the residues for the D-PhgAT (Figure 3.39).162  The 
His66 in P. stutzeri D-PhgAT corresponds to a conserved Leu residue in Cv-AT, Vf-AT and 
Bm-AT while the His213 corresponds to a conserve Ala residue in Cv-AT, Vf-AT and Bm-AT.  
Furthermore, the P. putida D-PhgAT homologous, displaying 82% sequence identity with 
the P. stutzeri D-PhgAT, shows the presence of the same His residues supporting 
implication of these residues in the ‘stereo-inversion’ activity of the enzyme.130 The Thr303 
residue corresponds to a serine residue in Cv-AT and Vf-AT, suggesting the importance of a 











Figure 3.39 ESPript162 alignment of P. stutzeri D-PhgAT (accession code: AAQ82900) and P. putita D-
PhgAT (AX467211) with related, well characterised (S)-selective Class III ATs. These are Bacillus 
megaterium AT (A0A1C7D190), Vibrio fluvialis AT (AEA39183), Chromobacterium violaceum AT 
(Q7NWG4).The D-PhgAT specific residues Arg34, His66,His213, Gln300 and Thr303 proposed to be 
involved in substrate orientation and D-amino acid product formation are marked with a blue 
triangle. The conserved Lys269 residue is highlighted in yellow.   
 






The Arg34 residue, suggested to be involved in the substrate recognition, is also unique to 
the stereo inverting D-PhgAT enzymes and shared with the P. putida D-PhgAT homologue. 
Based on the D-PhgAT:D-Phg model and the SDM results, a model of the dual substrate 
recognition achieved by D-PhgAT was built (Figure 3.40). According to the model the 
Arg406 residue, which was a target of SDM and Arg34, identified by substrate docking, 
recognize the carboxylic acid group of both amino donor and amino acceptor. A schematic 
representation of the substrate recognition achieved by the combination of these two 
residues is shown in Figure 3.40.   
 
        
Figure 3.40 (A) Surface view of the D-PhgAT:D-Phg model. The Arg406 and Arg34 are located at the 
entrance of the active site (B) Schematic representation of the dual substrate recognition 
mechanisms of D-PhgAT. The ‘flipping’ Arg406 is involved in the recognition of the γ carboxylic group 
of L-Glu or moves out of the active site to accommodate the benzyl ring of D-Phg. Adapted from Eliot 
et al.69 
 






According to this model, the ‘flipping’ Arg406 could either form a salt bridge to the 
glutamate γ carboxylate group or alternatively can move out of the active site to 
accommodate the benzyl ring of BZF/D-Phg. This phenomenon has been described in the 
literature as arginine ‘switch’ and was introduced in section 1.4.2.111 The other arginine 
residue, Arg34 is thought to be involved in the recognition of the α-carboxylic group of L-
Glu and BZF.113 
These comprehensive analyses suggest that the D-PhgAT unique enantioselectivity 
yielding solely (R)-products has arisen from using the Type III TA fold and incorporating 
three key amino acids: His66, His213 and Arg34. A second arginine residue, Arg406, has 
been identified as responsible for the dual substrate recognition achieved by D-PhgAT. 
Future mutagenesis of these residues will provide further insight into their role in the 
mechanism. 
3.9 D-PhgAT reaction mechanism  
A detailed reaction mechanism for the D-PhgAT catalysed reaction is shown in Figure 3.41. 
Figure 3.41 Reaction mechanism for the D-PhgAT reaction using L-Glu as amino donor and BZF as 
amino acceptor.  The L-Glu amino donor is shown in blue while the BZF is shown in red. The key step 
determining the enzyme enantioselectivity is the C4’-hydrogen transfer from the lysine to the 
quinonoid intermediate.  
 






The stereochemistry of the C-4’ hydrogen transfer to the PLP cofactor is the key step of the 
AT mechanism, determining the stereospecificity of the AT catalysed reaction. As the 
stereocentre produced by the protonation from the catalytic lysine can occur on either the 
si- or the re-face, the position of the lysine residue in comparison to PLP determines the 
chirality of the final product. As discussed in 1.4.1, (S)-ATs are reported to act from below 
the quinonoid on the si-face, while (R)-ATs act on the re-face above the quinonoid 
intermediate (Figure 1.20).106  
               Because of the ‘stereo-inverting’ nature of the D-PhgAT the 
stereochemistry could not be predicted. However, reports in the literature have 
determined that the C-4’ hydrogen transfer in D-PhgAT seems to occur on the si-face. This 
is consistent with our substrate model, which sees the Lys269 residue on the si-face of the 
cofactor and is shown in the proposed reaction mechanism (Figure 3.41).163  
 
3.10 Synthesis of 15N labelled D-Phg 
Glycopeptide antibiotics such as vancomycin contain several types of D-Phg derivatives 
including the D-Hpg and the D-3, 5-dihydroxy-phenylglycine (D-Dpg) as shown in Figure 
3.42.  
 
Figure 3.42 Vancomycin structure. The presence of different D-Phg (red) derivatives such as D-Hpg 
(in blue) and D-Dpg (in pink) can be observed. 
 






Heavy atom labelling is a useful tool in natural product biosynthesis studies, as it allows the 
position of specific precursors to be identified in complex metabolites.164,165 To this end, Dr 
Max Cryle (Monash University, Australia), interested in vancomycin biosynthesis, is actively 
searching for 15N D-Phg for feeding studies.119 D-PhgAT was therefore applied to the 
synthesis of 15N labelled D-Phg and D-Hpg by feeding commercially available 15N labelled L-
Glu as amino donor (£80 for 100 mg). The strategy used is summarized in Figure 3.43. 
 
Figure 3.43 Experimental strategy for the preparation of 15N labelled D-Phg and D-Hpg using 15N 
labelled L-Glu as the amino donor and D-PhgAT as the catalyst. 
This work was carried out with Bsc project student Fengxin Li. An analytical method for 
analysis of D-Phg/D-Hpg production was developed using reversed phase HPLC and a C18 
column (mobile phase of 5% to 95% acetonitrile (ACN) with 0.1% Trifluoroacetic acid (TFA) 
(v/v)/ water 0.1% TFA (5.12.1)). This was done as no preparative chiral columns were 
available in the department. Single enantiomers of each amino acid (0-400 mM) were used 
to build a calibration curve to relate the AUC with the amount of product formed over time 
(Appendix 8.8). 
As the AT unfavourable reaction equilibrium is usually overcome by using a large 
excess of the inexpensive unlabelled L-Glu, a compromise between conversion and usage of 
the expensive 15N labelled L-Glu was needed to obtain 15N D-Phg and 15N D-Hpg. Thus, 
parallel reactions with different concentrations of unlabelled L-Glu were carried out to find 
the best ratio of conversion to amino donor concentration at constant BZF concentration (~ 
 






66 mM, 50 mg of BZF in 5 mL reaction mixture). Samples were  withdrawn at different time 
points up to 8 h and analysed by HPLC after dilution by 40-fold in 5% ACN 0.1% TFA. A 
summary of the results is shown in Figure 3.44. Using the lowest L-Glu concentration (136 
mM) a 30% BZF conversion was observed after 8 h. A 57% BZF conversion was observed 
when using 340 mM L-Glu after 8 h of reaction.  Finally, a 62% conversion was observed 
when using the highest L-Glu concentration (680 mM) after 1 h of reaction. As the final 
yield in this model reaction at 340 mM L-Glu (57%) at 8 h was very similar to one the 
obtained with 680 mM L-Glu (62%) after 1 h, large scale synthesis of 15N D-Phg was carried 
out using 340 mM of 15N L-Glu for 8 h. Using the optimised conditions, a final 59% BZF 
conversion was observed.  A control with unlabelled L-Glu was carried out for each 
biotransformation. 

























Figure 3.44 BZF conversion over time at different L-Glu concentrations. A compromise between 
L-Glu concentration and percentage conversion was needed because of the high cost of the 15N 
L-Glu. A conversion of 30%, 57% and 62% was observed at 136 mM, 340 mM and 640 mM L-Glu 
concentration, respectively. BZF concentration was 66 mM. 
Product purification was carried out using a preparative reverse phase HPLC on a Waters 
600 with a Phenomenex Luna C18 column (5 μm, 250 × 21.2 mm) at a flow rate of 18.0 mL 
min-1. The HPLC profile of the 15N D-Phg purification is shown Figure 3.45.  
The desired product (8.9 min) was collected and freeze-dried and a white powder was 
obtained. The purity of the obtained 15N labelled D-Phg was confirmed via NMR 
spectroscopy, matching reported spectral data (section 5.12.4).166 Fourier Transform mass 
 






spectrometry (FT-MS) analysis, performed by Dr Joanna Simpson (University of Edinburgh), 
confirmed the total incorporation of 15N into the molecule (Figure 3.46, Table 3.7). An m/z 
value of 152.0712 was observed for the unlabelled compound which is consistent with the 
expected value of 152.0706. The 15N D-Phg displayed an m/z value of 153.0675 value 
matching the expected value of 153.0676. A summary of all the expected and observed m/z 
values is shown in Table 3.7. The 1 Da shift mass of the labelled D-Phg compared to the 
unlabelled confirmed the successful labelling.  
 
Figure 3.45 Preparative HPLC chromatogram of 15N D-Phg purification at 205 nm. The D-Phg elutes at 
8.9 min. The peak was collected, freeze-dried and analysed by NMR and mass spectrometry. 
Table 3.7 Observed and expected m/z values for the 15N labelled and unlabelled D-Phg/D-Hpg. 
Due to the higher cost of the HBF substrate, the optimization of the reaction conditions 
with unlabelled L-Glu was not carried out.  Thus, the same reaction conditions established 
for BZF were applied for the synthesis of 15N D-Hpg. A final HBF conversion of 20% was 
observed, ~ 3-fold lower than the conversion observed with BZF. As D-PhgAT displays high 
Compound Expected m/z Observed m/z 
D-Phg 152.0706 152.0712 
15N D-Phg 153.0676 153.0675 
D-Hpg 166.0504 166.0505 






30 min 60 min [25] 
Imidazole 
(mM) 
30 min 60 min [75] 
Imidazole 
(mM) 
30 min 60 min 
EziG1 1.12 0.84 EziG1 1.13 1.38 EziG1 0.98 1.22 
EziG2 0.54 0.09 EziG2 0.73 0.29 EziG2 0.05 0.04 
EziG3 1.32 0.43 EziG3 0.99 0.38 EziG3 0.26 0.09 
Compound Expected m/z Observed m/z 
D-Phg 152.0706 152.0712 
15N D-Phg 153.0676 153.0675 
D-Hpg 166.0504 166.0505 
15N D-Hpg 167.0477 167.0476 
 
 






catalytic efficiency (kcat/KM) towards HBF (899.15 ± 0.27 M-1 s-1), the reduced yield could be 
due to inhibition effects, typically observed in ATs.  
 
 
Figure 3.46 FT-MS of (A) the unlabelled and (B) the purified 15N D-Phg. The red dots are the 
predicted isotopic distribution for each compound. The change in the isotopic distribution of the 15N 
D-Phg substrate confirms the successful synthesis of the 15N derivative of D-Phg. Analysis was carried 
out in positive mode.  
The increased hydrophilicity of D-Hpg compared to D-Phg, caused problems in product 
purification. Using the C18 optimized method, the L-Glu substrate and the D-Phg product 
 






co-eluted. By lowering the ACN percentage in the mobile phase down to 2% a small 
separation could be observed (4.4 min vs. 4.8 min) (Figure 3.47).  
 
Figure 3.47 Preparative HPLC chromatogram of 15N D-Hpg purification at 205 nm. L-Glu shows a 
retention time of 4.4 min while D-Hpg of 4.8 min. The peak corresponding to D-Hpg was collected, 
freeze-dried and analysed by NMR and mass spectrometry. 
Fractions corresponding to the D-Hpg peak were collected and freeze dried. In this case a 
yellowish oil was obtained that was analysed via NMR and MS analysis. FT-MS analysis, 
carried out in negative mode, showed a perfect incorporation of the 15N into the D-Hpg 
molecule (Figure 3.48, Table 3.7). An m/z value of 166.0505 was observed for the 
unlabelled compound which is consistent with the expected value of 166.0504. The 15N D-
Hpg displayed an m/z value of 167.0476 value matching the expected value of 167.0477. A 
summary of all the expected and observed m/z values is shown in Table 3.7. However, NMR 
analysis indicated the presence of contaminants in the sample, corresponding to the 
substrate L-Glu (section 5.12.4).166,167 In order to obtain a pure product approaches such as 
flash chromatography may neee to be carried out to separate the two amino acids.  
Alternative purification procedures, such as using a different HPLC columns (such as the 
chirobiotic T column), may be necessary. The developed method for the synthesis of 15N D-
Phg derivatives represents a useful tool for drug feeding studies.  
 







Figure 3.48 FT-MS of (A) the unlabelled and (B) the purified 15N D-Hpg. Red dots are the predicted 
isotopic distribution for each compound. 
3.11 Enzyme immobilization  
The use of biocatalysis is increasing industrially, but is still limited to a restricted number of  
reaction types, such as the production of enantiopure alcohols, amine and esters.7,168,169 
Despite well-established enzymatic procedures, there remain many potential cases in which 
enzymes are not used. An estimate by Codexis indicates that ~ 30% of the small molecule 
compounds handled by pharmaceutical companies could benefit from the inclusion of a 
biocatalyst in the production of either the API or the final drug, but the actual usage of 
enzymes is much lower.170 One of the principle barriers for the widespread application of 
enzymes in a wider range of chemical transformation and to a larger number of products is 
the high development and applications costs of enzymes compared to traditional chemical 
 






methods. A strategy to overcome the high costs associated with enzymes consists of 
immobilizing the enzyme on a solid support, increasing the half-life of the enzyme and 
decreasing the reaction costs as the enzyme can be reused multiple times without 
additional isolation and purification.  Furthermore, immobilization allows for easy recovery 
of the product, continuous operation of the enzymatic processes and quick termination of 
reactions.171 
Immobilization techniques can be grouped into three main categories: 1) 
encapsulation/ entrapment of the enzyme in a permeable material, 2) cross-linking of the 
intact enzyme, and 3) binding to a suitable (inert) carrier.170  Approaches such as 
encapsulation and cross-linking alter the direct environment of the enzyme, affecting the 
natural structure of the enzyme. This is why the most common used method is the use of a 
suitable carrier, typically a porous plastic bead or a silica based material that binds the 
enzyme. However, despite the effort in trying to develop established immobilization 
procedures that could be generally applicable, there is still no universal immobilization 
method and screening is still required for each new process.  To this end, EnginZyme has 
developed an immobilization method, the EziG carrier, which allows the immobilization of 
potentially any enzyme with the commonly used His6-tag without requirement of having to 
drastically change immobilization conditions (http://enginzyme.com/). 
Selective binding of target protein with an affinity tag is a standard procedure in 
recombinant protein purifications such as IMAC. The same principle is applied for the EziG 
carrier, which binds the enzyme via the His6-tag using iron in ionic form (+3). Iron is used 
due to its low toxicity and stable binding as no leaching occurs from the resin. This 
immobilization method maintains the enzyme in its natural form without altering the direct 
environment and without altering the enzymes structural mobility. Because of the 
specificity of the affinity tag, immobilization can be carried out without requirement of 
prior purification. EziG is a carrier based on a specific controlled pore glass (CPG) material 
that has interconnecting pores, allowing efficient mass transfer (Figure 3.49). Three 
different EziG carriers are commercially available, all of them based on CPG but with 
different properties with regards to surface, pore diameter and bulk density: EziG-1 Opal, 
EziG-2 Coral and EziG-3 Amber.  
 
























EziG1 1.12 0.84 EziG-1 1.13 1.38 EziG1 0.98 1.22 
EziG2 0.54 0.09 EziG-2 0.73 0.29 EziG2 0.05 0.04 
EziG3 1.32 0.43 EziG-3 0.99 0.38 EziG3 0.26 0.09 
 
 
Figure 3.49 Schematic picture of the EziG enzyme carrier. The external and internal porous surface of 
CPG is covered with an organic polymer layer derivatized to chelate iron (Fe (III)) so that can bind the 
enzyme His-tag. Adapted from Cassimjee et al.170 
In collaboration with Maria Abagnale, a visiting PhD student from the Universitá degli studi 
di Napoli Federico II (Naples, Italy), EziG was tested as a suitable support to immobilize the 
D-PhgAT. All resins were tested in order to identify the most suitable carrier for D-PhgAT 
immobilization. Aiming for 10% loading (9 mg of EziG per 1 mg of purified D-PhgAT), as 
suggested by the manufacturer, the three EziG carriers were tested at different imidazole 
concentrations, a crucial factor for successful immobilization, and for different times (30 
and 60 min). Immobilization efficiency was evaluated by Bradford assay,172 a standard 
protein quantification method, carried out on the supernatant after immobilization. A 
summary of the results is shown in Table 3.8.  This experiment allowed the identification of 
the best immobilization conditions and the best carrier which was found to be EziG-2 with 
75 mM imidazole. All subsequent studies were conducted under the aforementioned 
conditions.  
Table 3.8 Bradford results on supernatant after immobilization. If the immobilization is successful no 
remaining protein would be present on the supernatant. The numbers refer to the D-PhgAT 
concentration in mg. 
Once the enzyme was successfully immobilized, BZF (10 mM) and L-Glu (300 mM) were 
added to the reaction mixture and gently shaken on an orbital shaker for 1 h at 40 rpm. The 
 






supernatant was quenched by dilution into the cHPLC mobile phase and analysed by cHPLC. 
Using this method, the enzyme activity was evaluated at different temperatures (15 °C, 37 
°C, 50 °C and 60 °C) and pH (5, 7.5, 9.5 and 11) in order to identify any difference in the 
activity of the free and immobilised forms of the enzyme. Furthermore, as EziG allows the 
direct immobilization of the cell free extract, activity was also evaluated in the free and 
immobilized cell free extract (Figure 3.50).  However, as shown in Figure 3.50, there are no 
differences between the optimum pH and temperature of the free and the immobilized 
enzyme, with the highest activity observed at pH 9.5 and at 37 °C.  
 
Figure 3.50 D-PhgAT activity of free and immobilized, pure and cell free extract D-PhgAT activity at 
(A) different temperatures (15 °C, 37 °C, 50 °C and 60 °C) and (B) different pHs (5, 7.5, 9.5 and 11).  
Recycling tests were performed at pH 9.5 and 37 °C to investigate the possibility of re-using 
the enzyme multiple times. Reactions with purified and cell free extract immobilized D-
PhgAT were carried out for 1 h (at 10 mM BZF and 300 mM L-Glu). The resin was then 
washed in buffer (0.1 M CAPS, 150 mM NaCl, 75 mM imidazole, 50 µM PLP) and stored at 4 
 






°C. After 24 h the reaction was repeated under the same conditions and this same 
procedure was repeated 9 times. At each recycling point an aliquot was taken and analysed 
by HPLC (Figure 3.51). 
Unlike the free D-PhgAT which can be used only once as it cannot be recovered 
from the reaction mixture, the immobilised enzyme is still active after 9 cycles. 
Furthermore the enzyme was immobilised directly from the cell free extract and showed 
conversion yields comparable to the purified enzyme suggesting no requirement for 
expensive purification procedures for successful catalysis prior to application in an 
industrial plant.  























 cell free extract
 free D-PhgAT
 
Figure 3.51 Recycling analysis of the free D-PhgAT, immobilized from cell-free extract and 
immobilized purified D-PhgAT. A decrease in substrate conversion is observed after 2 recycling but 
the conversion is stable at ~ 60% up to 9 recycles. 
This preliminary immobilization study show that D-PhgAT can be successfully immobilized 
using the commercial carrier EziG. These results are promising and future studies on a 
larger scale with continuous reactors will be necessary to evaluate the reaction on an 
industrial scale.  
3.12 Conclusions and future work 
The initial aims of the project have been met. The P. stutzeri D-PhgAT has been fully 
characterised and successfully applied to the biosynthesis of high value compounds starting 
 






from the natural D-Phg substrate to a wider range of products such as aromatic D-amino 
acids.   
The widespread use of PLP-dependent ATs for industrial biotechnology has been 
hindered by the unfavourable reaction equilibrium towards product formation. Approaches 
to overcome these include the use of ‘smart’ amine donors, coupled recycling systems or 
removal of the keto co-product.101–103 A wide range of amino donors was tested in order to 
identify the best amino donor, identified as L-Glu. Using a large excess of inexpensive L-glu 
(~ 20-fold KM) the equilibrium was driven towards product formation. Substrate 
concentration, time and enzyme loading have been optimised, obtaining a final conversion 
of 93%, % higher than those previously reported. Moreover, D-PhgAT has shown the 
capability to yield a range of D-amino acids such as D-Phe, D-Tyr and D-Trp.  
A recent report described the engineering of three recombinant E. coli strains that 
co-expressed four, seven and nine enzymes, including the P. stutzeri D-PhgAT as the final 
step to obtain D-Phg derivatives from racemic mandelic acid, styrene and L-Phe 
respectively.173 The D-PhgAT substrate promiscuity shown in this study suggests that similar 
cascades could be constructed to allow conversion of simple building blocks to produce a 
variety of enantiopure aromatic D-amino acids. 
The determination of the crystal structure of the D-PhgAT with its bound PLP 
cofactor has begun to shed light on the unique stereo-inverting and enantioselective 
properties of the enzyme. The broad substrate scope is explained by the large active site 
pocket and a combination of modelling and sequence analysis highlights three key active 
site residues that potentially control the exquisite (R)-selectivity of the enzyme, the His66, 
His213 and Arg34.  
These residues have been shown to be unique to the stereo-inverting enzymes and are 
shared between the two D-PhgAT homologues from P. stutzeri and P. putida. Two Arg 
residues, Arg406 and Arg34, have been identified as responsible for the recognition of the 
carboxylic group of BZF and L-Glu. Future mutagenesis of these residues will provide further 
insight into their role in the mechanism. 
The crystal structure of the PLP form of D-PhgAT paves the way for enzyme 
engineering in order to further expand the substrate scope of the enzyme. Enzyme 
 






evolution will be necessary in order to improve conversion towards desirable non-natural 
substrates such as HPPA, for which a mere 15% conversion was observed.  
Enzyme immobilization was carried out using the commercially available EziG resin 
in order to decrease the biotransformation costs, allowing reuse of the enzyme multiple 
times without the requirement to isolate and purify the enzyme. Immobilization conditions 
have been optimised and optimum pH and temperature of the immobilised enzyme has 
been determined. The enzyme has been recycled up to 9 times, displaying a stable 
conversion of 60%. These results are promising and future work will be carried out in order 
to perform in flow reactors, allowing a quick separation of the product and overcoming 
problems such as substrate inhibition.  
Moreover, D-PhgAT has also been shown to be a useful tool for the production of 
15N D-Phg derivatives that will be used for feeding studies.  
This study strengthens D-PhgAT’s place in the biocatalytic tool box and also lays down 
the foundations for future applications in the production of enantiopure natural and 
















4 The aminotransferase FumI 
The amino-pentol AT FumI, isolated from phytopathogenic filamentous fungus 
Sphingopyxis sp. MTA144, is involved in the second step of the mycotoxin fumonisin B1 
(FB1) catabolic pathway. 135,140,141,174 FB1 is carcinogenic and is a common contaminant of 
corn and corn-based products known to cause severe effects after ingestion by humans and 
animals.134,175 Studies of FB1 degradation in bacteria has led to the discovery of a class III AT 
responsible for the deamination of the hydrolysed FB1 (HFB1, 2-amino-12,16-
dimethylicosane-3,5,10,14,15-pentol) by transferring its 2-amino group to pyruvate (pyr), 
yielding 2-keto HFB1 (3,5,10,14,15-pentahydroxy-12,16-dimethylicosane-2-one) and L-Ala 
(Figure 4.1).142 The research organization BIOMIN (Austria) has investigated FumI as a 
possible food detoxification reagent and this application is covered by a patent 
(WO2004085624). However the application of FumI for biocatalysis is unexplored and its 
substrate scope in terms of both amino donor and acceptors is unknown.135 The ability of 
FumI to accept long chain alkyl substrate (C20) is a unique feature amongst the AT family 
and represents an appealing property for industrial biotechnology. 
 
 
Figure 4.1 Reaction catalysed by the amino-pentol AT FumI in fungus Sphingopyxis sp. MTA144. The 
amino donor HFB1 transfers the 2-amino group to pyruvate, yielding 2-keto HFB1 and L-Ala. 
Fatty amines, introduced in section 1.5.2, are long chain primary, secondary and tertiary 
amines from C8 to C22 used in a wide variety of applications, from cosmetic formulations to 
fabric softeners.132,133 As the global demand for these compounds is expected to grow 
finding a green biocatalytic route for their production would be of commercial interest. In 
this study FumI was explored as a biocatalytic tool for the production enantiopure alkyl 
amines from aldehydes and ketones of various chain lengths.  
 







The aim of the project is to express, purify and characterise FumI, assessing its suitability 
for the scalable biocatalytic production of high value fatty amines. The substrate scope in 
terms of both amino donor and amino acceptor will be investigated. Crystallographic 
investigations aimed to shed light on the structural determinants of the enzyme’s ability to 
accept a C20 substrate and to identify hot-spots for site directed mutagenesis.   
4.2 FumI purification, characterisation 
The fumI gene (Sphingopyxis sp. MTA144, UNIPROT code: D2D3B2),  cloned into pET30a 
(pET-30a-AT144HIS) with NdeI/SacI restriction sites to give a C-terminal His6-tag, was  
received from Dr. Wulf-Dieter Moll (BIOMIN, Austria).142 Due to the potential application of 
FumI in food detoxification, efforts have been made to optimise the expression of this 
protein. Hartinger D. et al. had developed a protocol to obtain soluble AT by expressing the 
gene in E. coli ArcticExpress (DE3) competent cells.143 Initially, a 10 L grow up in shake flasks 
was attempted following the procedure described by Hartinger et al143 by expressing in E. 
coli  ArcticExpress (DE3) with 0.1 mM IPTG at 11 °C for 24 h. However, the yield of 
recovered FumI was less than optimal (0.8 mg L-1 of culture) and ~ 2-fold less than the 
reported optimised yield (1.45 mg L-1 of culture). Hence, a 12 L fermentation was 
performed by Dr John White (University of Edinburgh) in order to increase the levels of 
protein expression. An optimization of the cell lysis method was also carried out, and lysis 
by cell disruption was found to result in a higher yield of recovered protein when compared 
to cell sonication by ~ 2-fold. Using these optimized methods typical yields were in the 
order of ~ 3 mg per litre of culture, almost 2-fold higher than the reported yield of 1.45 mg 
per litre of culture.143 
The protein was purified from the cell lysate using nickel immobilized metal affinity 
chromatography IMAC, where it eluted at a concentration of 150 mM imidazole. A second 
purification step, on a calibrated size exclusion chromatography (SEC), yielded a 
symmetrical peak at an elution volume of 75.2 mL (Figure 4.2A), corresponding to a dimer 
(Appendix 8.5). SDS-PAGE analysis showed the presence of a band at ~ 48 kDa, 
corresponding to the protein monomer (Figure 4.2B). After the two purification steps the 
 






protein is ~ 90% pure and the presence of other contaminants, including the chaperon 
Cpn10 at ~ 10 kDa involved in helping the protein folding can be observed (Figure 4.2B).   
 
Figure 4.2  (A) Chromatogram from Superdex 16/60 S200.FumI elution volume corresponds to a 
dimer (75.2 mL). (B) 12% SDS-PAGE gel of FumI SEC purification.  Lane 1: LMW marker (GE), Lane 2: 
Lanes 2-10: elution fractions from SEC (3 mL).  
To ensure the correct protein was expressed and purified, the mass of purified FumI was 
obtained using denaturing LC ESI-MS. The resulting spectrum (Figure 4.3) showed the 
presence of several peaks, representing the many charge states of the protein. The 
observed deconvoluted mass of 48136.21 ± 0.74 Da was in keeping with the expected mass 
based on the recombinant protein sequence with the loss of the starting methionine 
(48271.40 Da, Figure 4.3) , calculated from the expressed protein sequence using the 
ExPaSy ProtParam tool (https://web.expasy.org/protparam).  The loss of the initial 
methionine (131 Da) is very common as a post translational modification.146  
 
Figure 4.3 Denaturing LC ESI-MS of recombinant FumI (20 μM) with a deconvoluted mass of 
48136.21 ± 0.74 Da which agrees with the expected mass based on the expressed protein sequence 
(48140.40 Da). The values are m/z with the charge states given in brackets. 
 






4.3 UV-Vis studies 
UV-Vis spectroscopy was used to follow binding of amino acid substrates to FumI. In order 
to generate the holo-form of the enzyme, FumI was dialyzed for two h against buffer 
containing PLP (20 mM potassium phosphate (KPhos), 150 mM NaCl, 50 M PLP, pH 7.5). 
Excess PLP was then removed using a PD-10 desalting column and the resulting sample was 
analysed by UV-Vis spectroscopy.   
The enzyme in its holo-form shows a typical PLP binding profile with a max at 415 
nm and a broad shoulder at 325 nm.  When 1 mM L-Ala was added to FumI, changes in the 
UV/Vis spectrum were observed with a decrease in the absorbance maximum at 415 nm 
and concomitant increase in the 325 nm region, suggesting the formation of an external 
aldimine (Figure 4.4). By monitoring the changes in the UV-Vis spectrum at 325 nm (ΔA325) 
at different L-Ala concentrations, the apparent dissociation constant Kd was calculated 
(Figure 4.5 A and B, section 5.5.4).  The observed Kd for L-Ala (261 µM ± 0.69) is surprisingly 
low, suggesting a high affinity of FumI for the L-Ala substrate.  
 
Figure 4.4 UV-Vis profile of FumI:PLP upon L-Ala (1mM) addition over time (2 h). FumI in its holo-
form absorbs at 415 nm and 325 nm. Upon amino donor addition a decrease in the 425 nm peak and 
a concomitant increase in the 325 nm peak is observed. 
 







Figure 4.5 (A) UV-Vis spectrum of FumI with varying concentrations of L-Ala showing an increase in 
the 325 nm peak and a decrease in the 425 nm peak with increasing concentrations of L-Ala (B) Plot 
of the change in absorbance at 325 nm to calculate the Kd for L-Ala. Data was analysed by non-linear 
regression using Origin. Changes in absorbance at 325 nm were plotted against L-alanine (L-Ala) 
concentrations, and data points were fitted to a hyperbolic saturation curve. 
As deamination of HFB1 was reported not only in presence of pyruvate but also with α-
ketoglutarate, oxaloacetate, glyoxylate, and α ketobutyrate as amino acceptor,142 binding 
was tested with the corresponding amino acids ( L-Glu, L-Asp, Gly and L-2 aminobutyric acid 
(L-Aba) respectively).  FumI showed the ability to bind each of the amino acids tested. By 
varying the substrate concentrations and monitoring the ΔA325, the apparent dissociation 
constant Kd was calculated for each of them (Table 4.1, Figure 4.6). 
Table 4.1 Summary of the dissociation constant Kd for all the tested amino donors. Values have been 
obtained by plotting the ΔA325 at different substrate concentrations.   
According to the calculated dissociation constants, FumI displays the highest affinity 
towards L-Ala with a Kd of 261 µM but also showed tight binding to L-Aba and Gly with a Kd 
of 352 µM and 739 µM respectively.  Weaker binding is observed with L-Glu and L-Asp with 
Amino donor Kd  (mM) 
L-Ala 0.261 ± 0.069 
L-Aba 0.352 ± 0.042 
L-Asp 3.80 ± 1.00 
Gly 0.739 ± 0.18 
L-Glu 6.20 ± 1.60 
 
 






a calculated Kd ~ 15- and ~ 25-fold higher than the Kd for L-Ala (3.80 mM and 6.20 mM 
respectively).  
 
Figure 4.6 Plot of the change in absorbance at 325 nm to calculate the Kd for (A) L-Aba, (B) L-Asp, (C) 
Gly and (D) L-Glu. Data was analysed by non-linear regression using Origin. Changes in absorbance at 
325 nm were plotted against amino acid concentration and analysed using Origin. 
4.4 FumI/Pyruvate dehydrogenase assay (FumI/PDH) 
Kinetic parameters for the ‘forward’ reaction catalysed by FumI, have been determined by 
Hartinger et al. by using a LC ESI-MS method.142 This method relied on the peak area ratio 
of the FB1 product and HFB1 substrate in comparison with that of the internal standard 13C-
FB1. However, this method is time consuming and doesn’t allow the quick screening of a 
range of substrates. Thus, a spectrophotometric assay has been developed by coupling 
FumI with pyruvate dehydrogenase (PDH) from porcine heart, commercially available. PDH 
converts pyruvate into acetyl-CoA in the presence of CoASH and reducing NAD+. The 
production of NADH can be easily monitored at 340 nm, providing a convenient method for 
assaying FumI transamination activity (340 = 6220 M-1 cm-1).176 A scheme of the assay is 
shown in Figure 4.7. 
 







                                                                         
Figure 4.7  Reaction scheme of the FumI/PDH coupled assay. Pyr, product of the first half reaction, is 
the substrate for PDH. The conversion of NAD+ and NADH can be easily monitored 
spectrophotometrically at 340 nm (340 = 6220 M-1 cm-1).  
In order to test FumI for the capability of yielding industrially relevant alkyl amines, several 
long chain substrates that resembled the 2-keto HFB1 by-product were purchased from 
Sigma and tested as substrates. These included 2-decanone (C10-2K), 2-tridecanone (C13-
2K), 2-pentadecanone (C15-2K) and 2-heptadecanone (C17-2K) tested for the ability to 
produce 2-decanamine (C10-2A), 2-tridecanamine (C13-2A), 2-pentadecanamine (C15-2A) 
and 2-heptadecanamine (C17-2A) respectively (Figure 4.8). The convention of calling the 
substrate according to the chain length and the position of the keto or amine group will be 
adopted in this chapter. 
Figure 4.8 FumI reactions for the synthesis of long chain amines.  
 






The keto substrates were tested in order to check differences in the reaction rates at 
100µM substrate and 1 mM L-Ala (Figure 4.9). A faster rate is observed for C10-2K and C13-
2K suggesting the enzyme preference towards shorter substrates. 
 
Figure 4.9 Raw data profile of NADH appearance at 340 nm obtained with C10-2K, C13-2K, C15-2K 
and C17-2K. A concentration of 100 µM amino acceptor and 1 mM amino donor (L-Ala) was used.  
By varying the amino acceptor concentration and keeping L-Ala concentration constant 
(1 mM) it was possible to kinetically characterise the enzyme. The initial rate (over the first 
15 min) was used to determine kinetic parameters ( Table 4.3, Figure 4.10).  
 
Table 4.2 Summary of the kinetic parameters obtained using the FumI/PDH assay. The enzyme 
shows higher affinity towards 2-heptadecanone with a KM of 16.3 µM compared to shorter 
substrates. 
FumI exhibits higher affinity towards longer substrates such as C13-2K and C17-2K with a KM 
of 1.61 and 1.1 µM respectively, compared to C10-2K and C15-2K which show a KM of 22.6 
and 9.97 µM respectively. These value are within the same order of magnitude as the 
natural substrate HFB1 that has a reported KM of 1.1 µM. 
Substrate KM  (µM) kcat (10-3) (s-1) kcat/KM  (M-1 s-1) 
2-decanone (C10-2K) 22.06 ± 12.05 17.91 ± 5.6 812.14 ± 2.98 
2-tridecanone (C13-2K) 1.61 ± 0.56 3.1 ± 0.36 1754.34 ± 1.20 
2-pentadecanone (C15-2K) 9.97 ± 3.52 1.25 ± 0.30 372.67 ± 1.24 
2-heptadecanone (C17-2K) 1.1 ± 0.051 0.45 ± 0.083 539.36 ± 2.17 
L-Ala 143.9 ± 26.11 3.29 ± 0.23 22.87 ± 0.39 
 







Figure 4.10 Michaelis–Menten plot of FumI for (A) C10-2K, (B) C13-2K, (C) C15-2K and (D) C17-2K. 
Data was analysed by non-linear regression using Graphpad Prism software. 
According to the calculated kinetic parameters, the best keto substrate is C13-2K with a 
high catalytic efficiency (kcat/KM) of 1754.34 M-1 s-1, followed by C10-2K, C17-2K and finally 
C15-2K. Significantly, the reaction occurs faster with shorter substrates, with a kcat up to 40 
times higher for C10-2K compared to C17-2K. An inverse correlation between the chain 
length of the substrate and the observed turnover rate kcat was observed. A lower turnover 
rate was observed for longer alkyl chain substrates in comparison to shorter ones. As longer 
substrates more closely resemble the natural substrate HFB1, these observations are 
somewhat counter-intuitive, but this inverse correlation between the length of substrate 
and catalytic turnover could mean that the enzyme has evolved a way of downregulating 
the degradation pathway in response to a downstream product.   
Because of the low solubility of the keto substrates, 10x stock solutions of each 
amino acceptor were prepared in dimethyl sulfoxide (DMSO), resulting in a final 
concentration of 10% DMSO in the assay. Tolerance for DMSO in the reaction is an 
appealing quality for industrial application as high solvent concentrations are often used.  
 






4.5 Mass Spectrometry analysis 
4.5.1 LC ESI-MS analysis 
The FumI/PDH coupled assay directly monitors only the first half of the AT reaction and 
only indirectly fatty amine production. In order to directly monitor the amine product 
formation, an LC ESI-MS method was used. Reactions were prepared by incubating FumI 
with 100 µM amino acceptors and 1 mM L-Ala at 35 °C for 18 h in 20 mM KPhos, 150 mM 
NaCl, 50 µM PLP at pH 7.5, shaking at 250 rpm. These reactions were quenched by dilution 
into ACN 0.01% TFA and then centrifuged to remove any trace of precipitated protein. The 
samples were analysed by LC ESI-MS in positive mode. The presence of a signal at an m/z 
matching the expected m/z values for the amine products was observed for all the tested 
reactions suggesting that the enzyme is able to catalyse the formation of C10-2A, C13-2A, 
C15-2A and C17-2A. The extracted ion chromatograms of the reactions are shown in Figure 
4.11 and the expected and observed m/z values are summarised in  Table 4.3. 
 
Figure 4.11 Extracted ion chromatogram of the LC ESI-MS FumI reactions with 100 µM of C10-2K, 
C13-2K, C15-2K and C17-2K and 10 mM L-Ala. The appearance of a peak corresponding to the 
expected m/z value can be observed for each substrate confirming the formation of the amine 
products. 
The ability of FumI to turnover substrates with keto-group substitutions along the alkyl 
chain (such as 3-decanone (C10-3K) and 5-decanone (C10-5K) (Figure 4.12) was also tested 
 in order to explore the enzyme specificity towards the position of the keto group.  
 






 Table 4.3 Summary of the expected and observed m/z values for the FumI tested reactions. 
 
Figure 4.12 Tested reaction for the substrate specificity towards the position of the keto group. 
Enzyme assays were performed as described above and product formation was analysed by 
LC-MS. Surprisingly FumI was capable of utilizing C10-3K, as a peak of 158.1875 Da 
matching the expected m/z value for C10-3A was observed in the corresponding reaction 
(Figure 4.13).  
 
Figure 4.13  Extracted ion chromatogram of the LC ESI-MS from FumI reaction with 100 µM C10-3K 
and 10 mM L-Ala. An m/z value of 158.1875 Da matches the expected m/z of 158.1909 Da suggests 
the formation of the C10-3A product. 
Compound  Expected m/z Observed m/z 
C10H24N (C10-2A) 158.1909 158.1882 
C13H30N (C13-2A) 200.2378 200.2370 
C15H34N (C15-2A) 228.2691 228.2704 
C17H38N (C17-2A) 256.3004 256.3038 
 
 






However, no peak corresponding to the expected m/z value was observed for C10-5K, 
suggesting that the enzyme has relatively narrow regioselectivity.  
4.5.2 MALDI-MS analysis  
The ESI LC-MS method described above relies on a C18 column for the LC phase, 
therefore it was not ideal for testing products shorter than C10 (without significant 
adjustment of the method). Therefore, a Matrix-assisted laser desorption/ionization 
(MALDI)-MS approach was applied. By using α-cyano-4-hydroxycinnamic acid (CHCA) as the 
matrix, it was possible to detect product formation for the tested reactions in positive 
mode. This method has been successfully applied within our group for the detection of 
sphingolipid products such as 3-ketodihydrosphingosine (KDS) (developed by Dr Van Kelly, 
University of Edinburgh, data not published) and therefore tested for FumI reactions. A 
positive control with C10-2A was carried out during this experiment. 
This MALDI method was used to explore the chain length specificity of FumI in 
more detail. In particular, the ability of the enzyme to accept substrates shorter than C10 
was tested. Hence, FumI was tested with the following amino acceptors: acetone (C3-2K), 
butanone (C4-2K), hexanone (C6-2K) and octanone (C8-2K) to yield isopropylamine (C3-2A), 
2-butylamine (C4-2A), 2-aminohexane (26-2A) and 2-aminooctanone (C8-2A) respectively 
(Figure 4.14, Figure 4.15).  
 
Figure 4.14 FumI reactions for the synthesis of alkyl chain substrates shorter than C10.  The amino 
acceptor tested are: acetone (C3-2K), butanone (C4-2K), hexanone (C6-2K) and octanone (C8-2K). 
The amino acceptors were dissolved in 100% DMSO for a final concentration of 10% DMSO and used 
at a final concentration of 100 µM. L-Ala was used at a final concentration of 10 mM.  
 








Figure 4.15 MALDI-MS spectrum of the FumI reactions carried out with C3-2K, C4-2K, C6-2K C8-2K 
and C10-2K and L-Ala. The presence of a peak corresponding to the expected m/z value of the amine 
product can be observed for all the tested reactions. 
 
Surprisingly, the formation of the corresponding amine was observed for substrates down 
to C3 in length, suggesting that the enzyme is quite promiscuous and could be potentially 
 






used also for the synthesis of shorter amine products (Figure 4.15). As the natural substrate 
is 20 carbon long (FB1) such a chain length tolerance for the FumI enzyme was totally 
unexpected.  
A summary of the expected and observed m/z values is shown in Table 4.4.   
Table 4.4 Summary of the expected and observed m/z values for the FumI tested reactions. 
The unexpected promiscuity displayed by FumI in accepting substrates ranging from C3 to 
C17 represents a very interesting property for biocatalysis as it could be used for the 
production of a range of amines.   
 
4.6 Studying FumI enantioselectivity 
The enantioselectivity of FumI AT was determined by using Marfey’s reagent, 1-fluoro-2, 4-
dinitrophenyl-5-L-alanine amide (FDAA), a pre-column derivatizing reagent used for the 
separation of enantiomeric isomers of amine compounds (Figure 4.16).177–179 The use of 
Marfey’s reagent for derivatization of amino acids was firstly reported by Marfey, back in 
1984.180 FDAA reacts by nucleophilic substitution of the aromatic fluorine with the free 
amino group on the amino acid or amino target molecule. As Marfey’s reagent has a chiral 
centre in the L-Ala group (S) when a racemic mixture of an amino compound is treated with 
this compound the production of analogous diastereomers is observed. The produced 
diastereomers can be easily separated using reversed-phase high-performance liquid 
chromatography (HPLC).145 As the (R)- and (S)-standards were commercially available for 
Compound Expected m/z Observed m/z 
C3H10N (C3-2A) 60.081 60.076 
C4H12N (C4-2A) 74.097 74.131 
C6H16N (C6-2A) 102.128 102.145 
C8H20N (C8-2A) 130.159 130.161 
C10H24N (C10-2A) 158.190 158.197 
 
 






only the 2-aminooctanone (C8-2A), this was chosen to investigate FumI enantioselectivity 
(Figure 4.16). 
 
Figure 4.16 Reaction carried out with FDAA and both enantiomers of aminoctanone to check FumI 
enantioselectivity. 
By reviewing Marfey’s reagent literature it was discovered that each amine required 
optimization in order to obtain complete derivatization and enantiomeric separation. 
Different reaction times (up to 24 h) and different bases (the use of disodium tetraborate 
decahydrate in place of sodium carbonate) can be used to drive the reaction towards 
completion.176– 178,181,182 Different columns and HPLC mobile phases have been reported to 
obtain enantiomeric separation. 
1 mM (R) and (S)-C8-2A were derivatized using NaHCO3 as a base and the reaction 
was carried out for 1 h at 40 °C. The reaction was then cooled to room temperature and 
quenched by the addition of HCl and analysed by reversed phase HPLC using a C18 column. 
In order to obtain separation of the two diasteroisomers (S,S and S,R) a HPLC method was 
developed with a gradient up to 70% ACN and a method length of 50 min (section 5.10). 
Using this method the retention times for the (R) and (S)-C8-2A were 42.75 and 43.5 min 
respectively (Figure 4.17, red dash line).   
 







Figure 4.17 C18 HPLC analysis on a calibrated C18 column at  = 340 nm. The (R)- and (S)-C8-2A 
standards (1 mM, dash red line) are well resolved and the AT reaction carried out for 18 h at 35 °C 
(10 mM L-Ala, 100 µM C8-2A) shows the formation of only the (S)-C8-2A enantiomer (black line). The 
retention times are 42.75 min for (R)-C8-2A and 43.5 min for (S)-C8-2A respectively.  
A reaction was then carried out with FumI and 100 µM C8-2K and 1 mM L-Ala at 35 °C for 
18 h in 20 mM KPhos, 150 mM NaCl, 50 µM PLP at pH 7.5,shaking at 250 rpm. The 
biocatalytic reaction was subjected to the same protocol used for the (R) and (S)-C8-2A 
derivatization and analysed by C18 HPLC. Based on the presence of the peak at a retention 
time corresponding to the FDAA (S)-C8-2A enantiomer it can be concluded that the chirality 
of the final product is (S) (Figure 4.17, black line). Thus, it can be concluded that FumI 
displays (S)-enantioselectivity.  
In order to achieve complete derivatization and use this assay for quantitative 
analysis, reaction time and reagents used must be optimised. Moreover, because of the 
unavailability of commercial standards for all the amines produced using FumI as a 
catalysts, this assay is not suitable for quantitative analysis. 
4.7 Amino donor promiscuity 
Having established that FumI has a reasonably wide substrate scope in terms of amino 
acceptor, FumI was also analysed for its amino donor promiscuity. In particular, attention 
 






was focused on non-natural ‘smart’ amine donors such as ortho-xylylene diamine (OXD),102  
5-nitro-2, 3-dihydro-1H-inden-2-amine (2,3-DHIA), 4-(2-aminoethyl) benzonitrile (4-AEB) 
and  2-(4-nitrophenyl) ethan-1-amine (4-NPEA),103 introduced in section 3.3.4.2 and 3.3.4.3 
respectively. 
Changes in the UV-Vis profile of FumI were observed upon OXD addition, 
suggesting the capability of the enzyme of using it as an amino donor (Figure 4.18).  A first 
shift towards the external aldimine (325 nm) could be observed, followed, overtime, by the 
appearance of an extra peak around ~ 550 nm corresponding to an isoindole moiety, 
resulting from the production of the isoindole product. However, a very weak purple colour 
was observed suggesting a low substrate conversion. Moreover the time required to 
observe the formation of the purple colour (>8 h) suggested a slow reaction rate. 
 
Figure 4.18 FumI UV-Vis studies with OXD as amino donor at 1 mM. Over time the internal aldimine 
peak at 415 nm disappears and the external aldimine formation at ~ 325 nm is observed. 
Furthermore, an additional peak at ~ 550 nm corresponding to the isoindole formation is observed 
suggesting the occurrance of the AT reaction. The formation of a weak purple precipitate can be 
observed after ~ 8 h of reaction.  
The ‘smart’ amino donors developed by Prof. Helen Hailes (UCL), introduced in section 
3.3.4.3, were tested with a wide range of amino acceptors, from C3 to C17 ketones to 
benzaldehyde (BZALD) and butyraldehyde (NBA) (Figure 4.19).  
 







Figure 4.19 Screening of the amine donors 7 (1, 2), 3 (3, 4) and 8 (5, 6) with different amino 
acceptors such as C3-2K (lane A), C4-2K (lane B), C6-2K (lace C), C8-2K (lane D), C10-2K (lane E), C13-
2K (lane F), C15-2K (lane G), C17-2K (lane H), BZALD (lane I) and NBA  (lane J) with FumI (0.5 mg mL-
1).  Amine donors were used at final concentrations of 12.5 Mm, amino acceptors at 100 µM for the 
keto compounds from C3-2K to C17-2K for solubility reasons, and 5 mM for BZALD and NBA AS 
suggested in the literature.153 For each reaction a control with no enzyme was performed (lane 2, 4, 
6). Reactions were incubated for 18 h at 37 °C. No significant difference is observed between the 
reaction and the controls for most of the amino acceptors. A very intense colour is formed when 
BZALD and NBA are used as amino acceptor. 
The formation of a vividly coloured precipitate is observed when the amino donors 4-NPEA 
(3), 4-AEB (7) and 2,3-DHIA(8) are used with BZALD and NBA as amino acceptors. No 
significant differences are observed between the reaction (lane 1) and the negative control 
 






(lane 2) with 4-AEB (7) as amino donor and keto compounds ranging from C3 to C17 as 
amino acceptors. The formation of a pale coloured precipitate is observed when the amino 
donors 4-NPEA (3) and 2,3-DHIA(8) are incubated with a range of alkyl chain keto acceptors 
(lane 3 and lane 5). These results are quite surprising as the ketones tested (from C3-2K to 
C17-2K) were converted by the enzyme when L-Ala is used as amino donor (Figure 4.11, 
Figure 4.15). This could be due to the lower concentration of the keto acceptor used in the 
assay (1 mM), compared to the concentration of the aldehydes (5 mM), due to the low 
solubility of the keto compounds.  
The formation of coloured precipitates, observed with BZALD and NBA, suggests an 
unexpected substrate promiscuity. FumI’s capability of accepting aromatic substrates such 
as BZALD could be further explored as the formation of AT product benzylamine (BZA) can 
be easily monitored spectrophotometrically.103 
4.8 FumI and aldehydes 
FumI’s ability to use aldehyde substrates, as observed in the amino donor assay, was 
further explored. In particular, FumI was tested for the capability of converting decanal 
(C10-Al), dodecanal (C12-Al) and hexadecanal (C16-Al) into the corresponding primary 
amines decylamine (C10-1A), dodecylamine (C12-1A), and hexadecylamine (C16-1A) 
respectively (Figure 4.20).  
 
Figure 4.20 Reactions tested with C10-Al, C12-Al and C16-Al as amino acceptor and L-Ala as amino 
donor to yield C10-1A, C12-1A and C16-1A and pyruvate.  
The reactions were carried out following the protocol established for the ketone and 
product formation was analysed by LC ESI-MS. The presence of a peak matching the 
expected m/z values was observed for all the tested reactions suggesting that the enzyme 
is able to catalyse the formation of C10-1A, C12-1A and C16-1A. The extracted ion 
 






chromatogram of the reactions are shown in Figure 4.21 and the expected and observed 
m/z values are summarised in Table 4.5. 
Table 4.5 Summary of the expected and observed m/z values for the FumI tested reactions with C10-
Al, C12-Al and C16-Al.  
 
Figure 4.21 Extracted ion chromatogram of the LC ESI-MS FumI reactions with 100 µM of C10-Al, 
C12-Al, C16-Al and 10 mM L-Ala. The appearance of a peak corresponding to the expected m/z value 
can be observed. 
These results reinforce the application of FumI as a biocatalyst for the synthesis of fatty 
amines as it is able to catalyse the formation of primary amines at the first and second 
position. 
4.8.1 Development of a FumI and CAR cascade 
Carboxylic acid reductase (CAR) enzymes catalyse the reduction of carboxylic acids to the 
corresponding aldehyde via nicotinamide adenine dinucleotide phosphate (NADPH) and 
adenosine 5’ phosphate (ATP) consumption (Figure 4.22).184,185 The hydrolysis of ATP makes 
the reduction of acids into aldehydes, catalysed by CAR, thermodynamically favourable, 
Compound Expected m/z Observed m/z 
C10H24N (C10-1A) 158.1909 158.1875 
C12H28N (C12-1A) 186.2222 186.2159 
C16H36N (C16-1A) 242.2848 242.2776 
 
 






constituting a very attractive green chemical route for the production of aldehyde from 
cheap carboxylic acids under mild reaction conditions, without the requirement of harsh 
reducing agents.  
 
Figure 4.22 Generic reaction scheme for a reaction catalysed by a CAR: a fatty acid is converted into 
the corresponding aldehyde via consumption of NADPH and ATP. 
CARs are multidomain enzymes around 130 kDa, consisting of an N-terminal adenylation 
domain (A-domain) fused via a pepidyl carrier protein (PCP) to a C-terminal thioester 
reductase domain (TR-domain).186,187 
An elegant de novo route in yeasts has been reported for the biosynthesis of 
vanillin, widely used in fragrances and body care products, starting from glucose using a 
CAR enzyme from Nocardia iowensis (NiCAR) (Figure 4.23 A).188 CARs have also been 
recently applied for the production of enantiopure chiral amine building blocks in a cascade 
reaction by coupling them with an AT and an IRED (Figure 4.23 B).189 
 
Figure 4.23  Selected examples of cascades developed using CAR enzymes. (A) De novo biosynthetic 
pathway from glucose to produce vanillin. The enzyme 3-dehydroshikimate dehydratase (a) 
catalyses the conversion of 3-dehydroshikimic acid (1) into 3,4-dihydroxybenzoic acid (2) . A CAR 
enzyme from Nocardia iowensis (NiCAR) and an o-methyltransferase (b) reduce the acid to the 
aldehyde and introduce a methyl group respectively to produce vanillin (3). (B) One-pot cascade 
where the ketoacid (4) is reduced to the aldehyde (5) by Mycobacterium marinum CAR (MmCAR) (c). 
The ATA-113 (d) (Codexis) catalyses the transamination reaction of compound (5), the product 
undergoes intramolecular cyclization to imine (6). An (S)-IRED (e)produces the final (7) compound.  
Adapted from Winkler et al.185 
 






As FumI is able to accept long chain aldehydes as substrates the possibility of combining 
FumI with a CAR in a cascade process was explored, enabling the conversion of simple, 
inexpensive fatty acids into long chain fatty amines (Figure 4.24).  
 
Figure 4.24 Generic reaction scheme of the CAR-FumI cascade. The fatty acid is first converted into 
aldehyde by CAR and then further converted into the final desired fatty amine by FumI. 
In collaboration with Prof. Nick Turner (University of Manchester) and Dr. Sasha Derrington 
(University of Manchester), a library of CAR enzymes were screened against a range of 
saturated fatty acids (C6-C12) by monitoring NADPH depletion versus time at 340 nm. A CAR 
from Mycobacterium chlorophenolicum (McCAR), was identified as the most active for the 
reduction of long chain (≥C10) fatty acids.  The McCAR was previously identified by Finnigan 
W. et al. but not characterised in the study.190  
CARs require NADPH and ATP for catalysis, which would cause an increase in the 
production costs for a commercial biocatalytic process. To overcome that, whole cell 
approaches or cofactor recycling are usually applied. Recycling systems are available for 
both NADPH and ATP by utilizing the glucose dehydrogenase (GDH) and the adenylate 
kinase (AdK)/ adenosine 5’-monophosphate (AMP) phosphotransferase (PAP) enzymes, 
allowing a more sustainable process  (Figure 4.25).49 
In order to check the compatibility of the FumI/McCAR reactions several conditions 
were tested including the presence or the absence of the recycling system that could 
potentially affect the reaction efficiency. McCAR and FumI were coupled and the reactions 
were tested in a cascade process. 1 mM decanoic (C10-FA), lauric (C12-FA), myristic (C14-
FA), palmitic (C16-FA), stearic (C18-FA) and arachidic acid (C20-FA) were incubated with 10 
mM L-Ala, 2 mM NADPH, 2 mM ATP, 20 mM MgCl2, FumI (0.24 mg mL-1) and CAR (0.25 mg 
mL-1). Reactions were incubated at 30 °C for 18 h (maximum operational temperature for 
McCAR) shaking at 200 rpm. Moreover, the CAR-FumI-recycling system (AdK/PAP/GDH) was 
checked with the reaction with C10-FA as a model substrate. This reaction was carried out 
 






in one pot (all enzymes in one reaction tube) and in two steps (first CAR for 8 h and then 
FumI was added) and with and without the recycling system.  
 
Figure 4.25 Regeneration system used to recycle NADPH and ATP. The NADP+ produced by the 
reaction is converted into NADPH by GDH and conversion of D-glucose into D-gluconolactone. The 
adenosine 5’-diphosphate (ADP) generated by the reaction is converted into ATP and AMP by AdK. In 
turn, the AMP is phosphorylated by PAP to ADP. Poly (P) is the phosphoryl donor. 
For all the tested conditions a peak corresponding to the expected m/z values for the 
production of the amines (from C10-1A to C20-1A) was observed (Table 4.6). The observed 
product formation for all the tested conditions suggests that the enzymes are compatible 
to work together and that the presence of the recycling system does not affect the enzyme 
activity. Thus, for potential industrial applications, the recycling system could be used, 
avoiding the requirement of continuous addition of expensive cofactors and making it more 
attractive for industrial biocatalysis.  
These exciting preliminary data suggest that the FumI/CAR system could be used in 
a cascade, enabling the conversion of an inexpensive substrate such as a fatty acid into a 
high value fatty amine.  Substrate conversion and reaction rate will need to be determined 
in order to identify the best reaction conditions and scale up the reaction to an industrially 
relevant level. The possibility of coupling the enzymes using a whole cell approach could be 
explored in order to reduce the reaction costs and the requirement of cofactor 
regeneration systems.  
 






Table 4.6  Summary of the expected and observed m/z values for the FumI/McCAR tested reactions 
with C10-FA, C12-FA, C14-FA, C16-FA, C18-FA and C20-FA  to yield C10-1A, C12-1A, C14-1A, C16-1A,  
C18-1A and C20-1A respectively.  
 
Figure 4.26 Extracted ion chromatogram of the LC ESI-MS coupled reactions with FumI and McCAR 
exploring different conditions. The appearance of a peaks with the expected m/z value 
corresponding to the production of C10-1A, C12-1A, C14-1A, C16-1A, C18-1A and C20-1A can be 
observed.  
4.9 High resolution structural studies of FumI 
To aid rational modification and the understanding of the substrate scope of FumI, the 
determination of the 3D structure of the enzyme is crucial. In collaboration with Dr. Jon 
Marles-Wright (Newcastle University), crystal screening with purified FumI (8.1 mg mL-1) in 
20 mM KPhos, 500 mM NaCl, 50 µM PLP, pH 7.5 were performed using a wide range of 
Compound Expected m/z Observed m/z 
C10H24N (C10-1A) 158.1909 158.1930 
C12H28N (C12-1A) 186.2222 186.2240 
C14H32N (C14-1A) 214.2535 214.2550 
C16H36N (C16-1A) 242.2848 242.2855 
C18H40N (C18-1A) 270.3161 270.3111 
C20H44N (C20-1A) 298.3474 298.3409 
 
 






commercial screens (MIDAS, PEG/Ion, STRUCTURE, JCSG+) in 96 well plates using a Gryphon 
robot. Crystals were observed under only a few conditions (A4 JCSG+, B4 PEG/ION, C10 
MIDAS). The most suitable crystals for X-ray diffraction resulted from C10 MIDAS (30% w/v 
polyacrylate 2100, sodium salt, 0.2 M ammonium sulfate, 0.1 M HEPES pH 6). These crystals 
were fished, frozen in cryoprotectant and shot at the Diamond Light synchrotron, Harwell 
for X-ray diffraction analysis (Figure 4.27).  
Several diffraction-quality datasets were collected (Diamond Light) with the highest 
resolution of 1.60 Å undergoing full refinement to generate structural information 
(Appendix 8.9). The solving of the FumI structure was carried out by Dr Jon Marles-Wright 
(Newcastle University) by molecular replacement using the structure of the glutamate 1-
semialdehyde AT from Bacillus subtilis (PDB code: 3BS8), displaying 29% sequence identity. 
The final refined model contains one homodimer of FumI with the PLP cofactor present as 
an internal aldimine with residue Lys256 in each chain. The refined protein structure is 
deposited under the PDB code 6HBS.  
 
Figure 4.27 (A) Crystal morphology of yellow crystals produced by adding 1 µL of 8.7 mg mL-1 FumI in 
20 mM KPhos, 500 mM NaCl, 50 µM PLP, pH 7.5, to 1 µL of 30% w/v polyacrylate 2100, sodium salt, 
0.2 M ammonium sulfate, 0.1 M HEPES pH 6 (B) Electron density map of the active site containing 
the PLP cofactor contoured at 1 σ. 
The overall fold of FumI is typical of the class III AT family (PLP fold type I). FumI is a 
homodimer (Figure 4.28 A) where each monomer consists of a small and large subunit with 
the PLP lying at the dimer interface. The monomeric FumI structure can be subdivided into 
two distinct domains: a small discontinuous domain comprising the residues 1-59 and 308-
 






417; and a large domain formed by residues 60 to 307 (Figure 4.28 B). The N-terminal 
portion of the small domain consists of an α-helix followed by a three-stranded antiparallel 
β-sheet, whilst the C- terminal part consists of an α-helix followed by two antiparallel β-
strands, an extended loop interrupted with a short α-helix, followed by a longer α-helix. 
The large domain consists of the typical central seven- β-strands, with five parallel strands 
and two in an anti-parallel orientation. The β-strands are connected by α-helices, with the 
cofactor binding site at the dimerization interface. 
The active sites of FumI are located at the dimeric subunit interface, containing 
amino acids from both subunits. Each active site contains a PLP-binding pocket and a 
substrate binding region. The cofactor is bound by a covalent Schiff base linkage to the ε-
amino group of the catalytic Lys256.  The presence of residues involved in PLP stabilization 
is highlighted in Figure 4.29. The PLP pyridine ring is sandwiched between Tyr143, opposite 
edge-on against the PLP ring, and Val230, as common in ATs. The nitrogen of the pyridine 
ring is coordinated by a hydrogen bond to Asp229, acting to maintain the cofactor in the 
protonated form.191  The phosphate group of the cofactor is coordinated by a series of 
hydrogen bonds with Gly117 and Ser118 from one monomer (monomer A) and Thr283, 
Gly284 and Ser285 from the other one (monomer B), directly or through water molecules, 
providing a very stable anchoring point for PLP (‘phosphate cup’).118 An Arg residue, Arg231 
coordinates the hydroxyl group of PLP, which is unusual for ATs. 
 
Figure 4.28  (A) Crystal structure of the FumI internal aldimine at 1.75 Å resolution Monomer A is 
shown in red, monomer B in blue. (B) Large and small domain of monomer A are highlighted in 
bright and pale blue. PLP is shown as sticks and highlighted in yellow. 
 







Figure 4.29 (A) Zoom into the active site of the FumI PLP internal aldimine. The PLP internal aldimine 
and residues involved in cofactor stabilisation are shown as stick representations, with carbon atoms 
shown in red and blue for the two monomers in the active dimer, oxygens are shown in red, nitrogen 
in blue and phosphorous in orange. The aromatic ring of PLP is sandwiched between Val230 and 
Tyr143. The nitrogen of the pyridine ring is fixed by hydrogen bond coordination to Asp229 as is 
common in AT enzymes. The phosphate group is stabilized by a network of interactions with Ser117, 
from Monomer A; and Gly284, and Thr283 and Ser285 from monomer B. Unusually, Arg231 interacts 
with the hydroxyl group of the PLP ring. (B) Hydrogen bonds, direct or through water molecules, are 
shown as dotted lines and distances (Å) in grey. 
A long (~ 20 Å) hydrophobic tunnel is observed that leads from the surface down into the 
PLP-binding site (Figure 4.30).  
 
Figure 4.30 (A) FumI surface coloured by electrostatic potential. The presence of a large tunnel to 
accommodate the HFB1 substrate can be observed. (B) Zoom in of the large hydrophobic 20 Å 
tunnel. 
 






The hydrophobic nature of this tunnel suggests that it accommodates the long HFB1 
substrate. Moreover, this feature provides insight into the FumI alkyl-chain substrate 
promiscuity observed in biochemical assays. However, without a co-crystallisation structure 
of FumI with a bound substrate it is difficult to predict where different substrate functional 
groups will interact with the FumI structure, which makes the rational design of enzyme 
modifications somewhat more challenging. 
The unusual Arg231 residue interacting with the hydroxyl group of the PLP cofactor 
is unique amongst the AT class III family.  Bioinformatic analysis with the some of the best 
characterised members of this family such as Cv-AT and Vf-AT and the just characterised D-
PhgAT (displaying 22%, 24% and 26% sequence identity respectively) highlight the unusual 
nature of this residue (Figure 4.31). From the sequence alignment it can be noticed that a 
DEVI motif is highly conserved in a loop region of the large domain of class III ATs. In FumI 
the DEVI motif is replaced by DDVR. The usually conserved aliphatic isoleucine residue, a 
key residue in the large domain, is substituted to the basic Arg231 suggesting that the 
arginine residue may play a role in substrate recognition and catalysis.  
Site directed mutagenesis (SDM) experiments were performed whereby Arg231 
was mutated to an alanine.  Unfortunately, the R231A mutant was completely insoluble 
and no protein was recovered after protein purification. As such, no characterization could 
be performed. This suggests that the interaction of Arg231 with the PLP is crucial for the 
correct protein folding.  
The obtainment of an external aldimine structure could further highlight the role of 
the Arg residue, known to play a crucial role in AT substrate recognition.111,113 Thus, 
substrate soaking experiments have been performed with the natural substrate HFB1 
(kindly supplied from Dr. Moll (BIOMIN, Austria)), to attempt to trap the external aldimine 
structure. Unfortunately, very low occupancy of the substrate was observed, even after 
prolonged soaking of HFB1 (up to 1 h). This is possibly due to the highly hydrophobic nature 
of the substrate that cannot penetrate the crystal. Alternative approaches, such as 
substrate docking or molecular dynamics could be performed in the future in order to 
identify further residues involved in substrate recognition and eventually identify hot-spots 
for mutations.  
 
 







Figure 4.31 ESPript162 alignment of Sphingopyxis FumI with Vf-AT (F2XBU9), Cv-AT (Q7NWG4) and P. 
stutzeri D-PhgAT. The conserved residues involved in cofactor stabilisation (Lys, Asp, Tyr) involved in 
substrate orientation are marked with a blue triangle and are conserved amongst the AT family. The 
unique FumI Arg231 residue is shown with a green triangle and is not conserved amongst the AT 
family. The residues numbering refers to the Cv-AT.  
 
 






4.10 Conclusions and future work 
Recombinant Sphingopyxis FumI AT has been successfully expressed, purified and 
characterised. The FumI substrate scope has been widely explored suggesting an enzyme 
promiscuity that could be exploited for industrial biocatalysis. FumI was able to 
transaminate long alkyl chain keto substrates (from C3 to C20) and long chain aldehydes 
(from C10 to C20). Conversion of substrates with bulkier substituents such as bromo-, fluoro- 
as well as unsaturated keto compounds will be interesting to be explored to further 
characterise the enzyme scope. 
A coupled spectrophotometric assay, as well as an LC-MS method, have been 
developed to determine kinetic parameters and observe the product formation 
respectively. 
The enzyme enantioselectivity has been determined by Marfey’s derivatization, highlighting 
the (S)-selectivity of FumI. 
The possibility of using FumI in a cascade process, by coupling it with a CAR enzyme 
has been explored and promising preliminary results suggest that the conversion from fatty 
acid to fatty amine using this coupled system is achievable.  Further work will be necessary 
in order to optimise the reaction conditions and obtain substrates conversion from fatty 
acid to fatty amines. Whole cells biotransformation could be explored to avoid the 
requirement of cofactor regeneration systems. 
The 3D structure of the FumI: PLP internal aldimine has been solved at 1.6 Å 
resolution by molecular replacement with a B. subtilis AT that displayed 29% sequence 
identity. The structure highlighted the presence of a wide hydrophobic tunnel that provides 
some insight into the ability of the enzyme to accept long chain substrates. An unusual 
Arg231 residue has been identified as potentially important for substrate recognition and 
catalysis and mutagenesis (R231A) led to the production of insoluble protein. Obtaining the 
structure of a PLP:substrate or product external aldimine, by crystals soaks or 
modelling/docking, will be crucial to identify residues for future directed evolution studies 
which may expand the substrate scope.  
 






Exploring the possibility of immobilising FumI, alone or in the cascade process, 
using commercial resins such as EziG will have to be explored to reduce the cost of the 
process and the requirement for using purified enzyme. 
Natural product biosynthetic pathways are a source of enzymes that have become 
attractive candidates for biocatalysis, by using them for the generation of ‘unnatural’ 
natural products. In this study, the FB1 degradation pathway from Sphingopyxis sp. 
MTA144, has provided an attractive biocatalyst, FumI, previously unexplored. FumI 
represent a very useful addition to the biocatalytic tool box as it can be applied for the 
biosynthesis of long chain amines from both aldehyde and ketones, providing a much more 





























5 Materials and methods 
5.1 Materials and reagents 
All reagents, chemicals and media were purchased from Sigma-Aldrich, Thermo Fisher 
Scientific or Bio-Rad unless otherwise stated. All primers were purchased from Sigma 
Genosys and competent cells, pET plasmids and restriction enzymes from New England 
Biolabs (NEB), Novagen and Life Technologies. Chromatography columns were purchased 
from GE Healthcare. The dpga gene was purchased from GenScript.  
5.1.1 Culture media 
Growth media and Luria Bertani (LB) agar plates were prepared by dissolving the 
components in deionised water and sterilising by autoclaving for 20 min at 120 °C. 40% 
Glucose and 1 M MgCl2 stock solutions were prepared separately and sterilised by filtration 
through a 0.22 µm filter. They were then stored at 4 °C and used within one week and 
added to the Modified ZB media when cooled down. 
• LB: tryptone (10 g L-1), yeast extract (5 g L-1) and NaCl (10 g L-1) 
• 2YT broth: tryptone (16 g L-1), yeast extract (10 g L-1) and sodium chloride (5 g L-1) 
• Super optimal broth with catabolite repression (SOC): tryptone (20 g L-1), yeast 
extract (5 g L-1), sodium chloride (10 mM), potassium chloride (2.5 mM), 
magnesium chloride (10 mM), magnesium sulphate (10 mM), glucose (2% w/v) 
• M9 10X: Na2HPO4 (75.2 g L-1), KH2PO4 (30 g L-1), NaCl (5 g L-1), NH4Cl (10 g L-1) 
• Modified M9ZB medium, 1 X M9 salts solution, tryptone (10 g L-1), yeast extract (5 
g L- 1) 
5.1.2 Antibiotic 
When growing cell lines harbouring plasmid an appropriate antibiotic was added to cool 
growth media after sterilisation.  Antibiotic solutions were prepared in deionised water, 
filtered through a 0.22 µm filter and stored at -20 °C. 
 






• Ampicillin (Amp100): 100 mg mL-1 stock solution prepared and added to media to give 
a final concentration of 100 μg mL-1 (1:1000) 
• Kanamycin (Kan30):  30 mg mL-1 stock solution prepared and added to media to give a 
final concentration of 30 μg mL-1 (1:1000) 
• Gentamicin (Gen20): 20 mg mL-1 stocks were prepared and added to the media to give 
a final concentration of 20 μg mL-1 (1:1000) 
5.1.3 Induction  
Isopropyl β-D-1-thiogalactopyranoside (IPTG): 0.1 M stock solution was freshly prepared on 
the same day as used and stored at 4 °C. It was added to a final concentration ranging from 
0.05 -1 mM encompassing test expression conditions and large scale inductions. 
5.1.4 Cell lines 
The different cell lines used in this study for cloning processes and protein expression:  
Species Cell  line Application 
E. coli DH5α™ (Invitrogen) Transformation – subcloning plasmid amplification etc. 
E. coli C2987 (NEB ) Transformation - PCR product-vector ligations. 
E. coli BL21 (DE3) (Novagen) Transformation- protein expression. 
E. coli ArcticExpress (Agilent) Transformation- FumI expression 
Table 5.1 E. coli strains used in this study. 
5.1.5 LB agar 
Agar powder was dissolved in deionised water and melted by autoclaving.  Appropriate 
antibiotic was added once cooled to below 50 °C. All plates were stored at 4 ˚C and used 
within 1 week of preparation. 
• LB agar: tryptone (10 g L-1), yeast extract (5 g L-1), sodium chloride (5 g L-1), agar 
(15 g L-1) 
 







All buffers were prepared by dissolving components in deionised water and adjusting to 
correct pH using either hydrochloric acid (HCl) or sodium hydroxide (NaOH). These were 
filtered through a 0.22 µm filter and degassed by sonication before chromatography. 
 
Table 5.2 List of buffers used in this study.  
5.2 Molecular Biology 
5.2.1 DNA and plasmids  
Full-length, codon optimized dpgA (Pseudomonas stutzeri ST-201, UNIPROT code: Q6VY99) 
was purchased from GenScript. After cutting with BspHI/BamHI, dpgA was sub-cloned into 
NcoI/BamHI digested pET-15b plasmid to give recombinant D-PhgAT with a non-cleavable 
N-terminal His6-tag (pET15b-dpgA) (Appendix 8.1, Appendix 8.2).  
The full-length fumI gene (Sphingopyxis sp. MTA144, UNIPROT code: D2D3B2) was kindly 
received from Dr Wulf-Dieter Moll from BIOMIN Research Center in Tulln, Austria through a 
material transfer agreement (MTA). The received clone contains the fumI gene cloned into 
a pET-30a vector with a non-cleavable C-terminal His6-tag (pET-30a-AT144HIS) as described 
in Hartinger et al. (Appendix 8.3, Appendix 8.4). 143 
Buffer Components 
A 0.1 M CAPS, 150 mM NaCl, 20 mM Imidazole, 50 M PLP pH 9.5 
B 0.1 M CAPS, 150 mM NaCl, 500 mM Imidazole, 50 M PLP, pH 9.5 
C 0.1 M CAPS, 150 mM NaCl, 50 M PLP, pH 9.5 
D 0.1 M CAPS, 150 mM NaCl, 75 mM Imidazole, 50 M PLP, pH 9.5 
E 20 mM KPhos, 500 mM NaCl 40 mM Imidazole, 50 M PLP, pH 7.5 
F 20 mM KPhos, 500 mM NaCl 500 mM Imidazole, 50 M PLP, pH 7.5 
G 20 mM KPhos, 500 mM NaCl, 50 M PLP, pH 7.5 
H 20 mM KPhos, 150 mM NaCl, 50 M PLP, pH 7.5 
I 50 mM Tris, 150 mM NaCl, 50 M PLP, pH 7.5 
L 100 mM Tris, pH 7.5, 50 µM PLP 
 






5.2.2 Site directed mutagenesis  
5.2.2.1 Primers 
The D-PhgAT Q300N, Q300A, R406A and the fumI R231A were constructed according to the 
overlapping primer site-directed mutagenesis (SDM) method (Table 5.3).160  
Primer Sequence 
Dpga Q300N Fw GTGCTGCACAACGGTACCTTCACCGG 
Dpga Q300N Rev AAGGTACCGTTGTGCAGCACTTTACGAT 
Dpga Q300A Fw GTGCTGCACGCGGGTACCTTCACCGG 
Dpga Q300A Rev AAGGTACCCTCCGCGTGCAGCACTTTACGAT 
Dpga R406A Fw CATCGGTGGCGCTGGCAGCGTTTTTCTGAGCGCG 
Dpga R406A Rev AAAACGCTGCCAGCGCCACCGATGTCCACACCTT 
FumI R231A Fw ACGATGTGGCGGCAGGTTTCCGGGTGG 
FumI R231A Rev AACCTGCCGCCACATCGTCAACGACCAG 
Table 5.3 List of oligonucleotides used in this study. The changed sequence is highlighted in bold. 
5.2.2.2 Polymerase Chain Reaction (PCR) 
The reactions were set up as shown in Table 5.4. 
Component Volume (µL) 
5X Phusion Buffer 10 
10 mM DNTPs 1 
10 uM Rev Primer 2.5 
10 uM Fw Primer 2.5 
DNA (100 ng) 1-2 
DMSO 1.5 
H20 29.5-30.5 
DNA Polymerase (Phusion polymerase, NEB) 1 
Table 5.4  Volumes and concentrations of the reagents used in the PCR reaction experiments. 
The PCR was carried out under the following conditions:  
 
 
PCR step Temp (°C) Time (s) Cycles 
Initial denaturation 98 30 1 
Denaturation 98 10 30 
Annealing Tm -5ºC 30 30 
 






Table 5.5 Reaction conditions used during the SDM PCR experiments. 
5 µL of the reaction of the SDM PCR reaction was loaded into the agarose gel (1 µL of 5x 
loading buffer) and checked for correct amplification.  5 µL of 10x CutSmart buffer (NEB) 
and 2 µL of DpnI enzyme (20 U) were added to the reaction and incubated at 37 ˚C 
overnight (ON). This reaction mixture was used to transform E. coli C2987 cells.  
5.2.3 Agarose gel electrophoresis 
1% w/v agarose gels were prepared as described below according to the number of 
samples and the size of equipment being used. 0.6 g or 1.5 g agarose powder was added to 
60 mL or 150 mL of Tris, acetic acid and EDTA (TAE buffer, Biorad) and heated in a 
microwave oven until dissolved. This was cooled down and 6 µL or 15 µL of Gelred (Biotum) 
were added (1:10000 dilution). The gel solution was poured and allowed to set and the 
appropriate volume of 1x TAE buffer was poured over the gel to cover it. Samples were 
loaded after addition of 5x loading buffer (NEB) and gels were run at a constant voltage of 
100V for around 50 min. Hyperladder I (Bioline) was used as a marker and the gels 
visualised using UV trans-illumination.  
5.2.4 Plasmid DNA purification  
Plasmid DNA was purified from cells by picking transformed colonies (DH5α) into 5 mL of LB 
media containing appropriate antibiotic for selection (Kan30 or Amp100). These were grown 
ON at 37 °C with shaking (220 rpm) with cell pellets harvested by centrifugation at 3,500 x g 
for 10 min at 4 °C. DNA was isolated using the Qiaprep Spin Miniprep Kit (QIAGEN) using 
the associated protocols and eluted into 30 µL of deionized water.  
Extension 72 210-240 30 
Final extension 72 600 1 
Hold 4 ∞ -- 
 






5.2.5 Sequencing reaction  
The sequence of the recombinant protein was checked by sequencing reaction. 20 µL of 





Table 5.6 Sequence of the primers used for sequencing reactions. 
5.3 Protein Expression 
5.3.1 Transformation of BL21 (DE3) 
Plasmid DNA (~ 100 ng) was added to an aliquot of competent E. coli cells (10-25 µL) and 
incubated on ice for 20-30 min. The cells were subsequently heat shocked at 42 °C for 30 
sec and cooled on ice for 2 min. SOC (100 µL) was added to the cells and these were 
recovered with shaking at 37 °C for 1 h. The recovered cells were plated on LB agar + 
appropriate antibiotic and grown at 37 °C ON. Colonies were stored at 4 °C and used within 
2 weeks. 
5.3.2 Transformation of ArcticExpress 
E. coli ArcticExpress (DE3) competent cells were defrosted and kept on ice at all times while 
aliquoting. Once thawed, the cells were gently mixed and transferred (100 μL) into a 
prechilled 14- mL BD Falcon polypropylene round-bottom tube. A 1:10 dilution of XL10 Gold 
β-mercaptoethanol (Agilent) was added (2 μL) to the cells. The content of the tube was 
mixed gently and incubated on ice for 10 min, swirling gently every 2 min. Plasmid DNA (~ 
100 ng) was added to the aliquot and incubated on ice for 30 min. After incubation, cells 
were heat-shocked in a 42 °C water bath for 20 sec and cooled on ice for 2 min. Preheated 
(37 °C) SOC medium (900 μL) was added to the cells and subsequently incubated at 37 °C 
for 1 h with shaking at 230 rpm. Finally, cells were spread onto an LB agar plate containing 
Kan30 and left to grow ON at 37 °C. Colonies were stored at 4 °C and used within 2 weeks. 
 






5.3.3 Small scale test expression in BL21 (DE3) 
Test expressions were carried out on small scale to determine optimal conditions for D-
PhgAT prior to large scale expression. A single colony of E. coli cells harbouring the pet15b-
dpgA plasmid was inoculated in LB broth with Amp100 and grown ON at 37 °C. In the 
morning, the optical density at 600nm (OD600) of the cells was taken and this culture added 
to fresh LB + antibiotic for a final OD600 of 0.1. The new culture was grown to an OD600 of 
approximately 0.6-0.9 at 37 °C. 0.5 M solution of IPTG was added to the cells for a final 
concentration of 0.1 mM, 0.5 mM and 1 mM. The cultures were incubated further at 16 °C 
and 30 °C for 3 h, 5 h and ON. Time points were collected at those times by centrifugation 
at 3,500 x g for 10min. Protein expression was analysed after cell lysis and separation of 
pellet and supernatant by denaturing 12% SDS-PAGE gel run at 200 V. 
5.3.4 Large scale expression in BL21 (DE3) 
The pet15b-dpgA construct was used to transform E. coli BL21 (DE3) competent cells and 
selection was carried out on agar plates containing Amp100. A single colony was used to 
inoculate 250 mL of LB/Amp100 broth and the ON culture was grown at 37 °C with shaking at 
250 rpm. The ON culture was used to inoculate 1 L of fresh LB/Amp100 broth and grown to 
an OD600 of 0.6–0.9. Protein expression was induced by addition of IPTG to a final 
concentration of 0.1 mM and growth was continued for 16 h h at 20 °C. Cells were 
harvested by centrifugation (Thermo Scientific Multifuge X3R) at 4,000 x g for 30 min at 4 
°C. 
5.3.5 Large scale expression in ArcticExpress 
Protein expression was carried out as previously described by Hartinger et al.143 One colony 
of ArcticExpress (DE3) harbouring pET-30a-AT144HIS derived plasmid was used to inoculate 
LB broth (250 mL) containing Gen20 and the appropriate antibiotic for the pET vector (Kan30) 
and grown ON at 37 °C with shaking at 250 rpm. The next morning, the inoculant was 
diluted 50-fold into M9ZB modified medium (10 x 1000 mL) containing M9 salts, 1mM 
MgCl2 and 0.4% glucose without antibiotics and incubated for 3 h at 37 °C with shaking at 
250 rpm (Excella E25 Incubator, New Brunswick Scientific). Cells were allowed to grow to an 
 






OD600 of 0.8 before the temperature was lowered to 11 °C. After the temperature was 
equilibrated, protein expression was induced by the addition of 1 mM IPTG. Protein 
expression was carried out for 24 h at 11 °C with shaking at 250 rpm. 
5.3.6 Cells harvesting 
After the appropriate time of induction, bacterial cells were harvested by centrifugation 
(Thermo Scientific Multifuge X3R) at 4,000 x g for 30 min at 4 °C. The supernatant was 
discarded and the cell pellet was resuspended in a minimal amount of PBS buffer and 
further centrifuged for 30 min at 3,500 x g at 4 °C. Finally, the supernatant was discarded 
and the bacterial cell pellet containing the protein of interest was stored at -20 °C for 
further protein purification. 
5.3.7 Fermentation of ArcticExpress 
Fermentation of FumI was carried out by Dr. John White at the University of Edinburgh on a 
12 L scale in a BioFlo 4500 Fermentor.  The starting colture was carried out as previously 
described and diluted by 50-fold in the 12 L fermentor. Cells were allowed to grow to an 
OD600 of 1.0 at 37 °C before lowering the temperature down to 11 °C. Protein expression 
was induced by the addition of 1 mM IPTG for 24 h at 11 °C, harvested and stored at -20 °C. 
5.4 Protein Purification 
5.4.1 Cell Lysis by sonication 
All purification steps were carried out at 4 °C. Cells were resuspended in buffer A/E with 
addition of DNase (0.2 mg per 10 mL buffer) and lysed by sonication for 15 cycles (30 sec 
on, 30 sec off). The lysed cell suspension was clarified by centrifugation (Thermo Scientific 
Multifuge X3R) at 14,000 x g for 40 min at 4 °C. The cell-free extract was loaded onto a 1 mL 
HisTrap nickel affinity column (GE Healthcare). Samples (50 µL) from all stages were 
retained for SDS-PAGE analysis. 
 






5.4.2 Cell lysis by high-pressure homogenization 
Cell pellets were resuspended in buffer E and particulates were removed via filtration 
through 1 mm sieve. A cell disruptor (Constant Systems) was equilibrated with buffer E and 
then the resuspended pellet was passed through at a pressure of 20.1 kpsi. The lysed cell 
suspension was cleared by centrifugation (Thermo Scientific Multifuge X3R) at 14,000 x g 
for 40 min at 4 °C. 
5.4.3 Nickel NTA purification 
The cell-free extract was loaded onto a 1 mL HisTrap nickel affinity column (GE Healthcare). 
The column was washed with binding buffer (buffer A/E) for 20 column volumes (CVs) , 
then the protein eluted with an imidazole gradient (20 to 500 mM)(buffer B/F) over 30 CVs. 
Protein containing fractions were analysed by 12% SDS-PAGE and concentrated to 1 mL 
using a Vivaspin 20 MWCO 30,000 (Sartorius). 
5.4.4 Size exclusion chromatography 
The concentrated D-PhgAT/FumI (1 mL) was loaded onto a pre-equilibrated (Buffer C/G) 
HiPrep™ 16/600 Superdex™ S-200 size exclusion column (120 mL). Recombinant protein 
was eluted at a flow rate of 1 mL min-1 monitoring at 280 nm and 420 nm. The purity of the 
recombinant proteins was analysed by 12% SDS-PAGE. The fractions containing clean 
protein of interest were combined and frozen at -80 °C with 20% glycerol. 
5.5 Protein characterisation 
5.5.1 SDS-PAGE protein analysis 
An average gel (16 mL) consisted of a 12% running gel (6.9 mL H20, 4.8 mL of 40% 
acrylamide, 4 mL of 1.5 M Tris pH 8.8, 150 μL of 10% w/v SDS, 300 μL of 50 mg mL-1 
ammonium peroxodisulfate and 20 μL TEMED) and a 4% stacking gel (2.9 mL H20, 0.75 mL 
of 40% acrylamide, 1.25 mL of 0.5 M Tris pH 6.8, 50 μL of 10% w/v SDS, 100 μL of 50 mg mL-
1 ammonium peroxodisulfate and 5 μL TEMED). Polyacrylamide gel electrophoresis (PAGE) 
 






of purification stage samples was performed using the BioRad Mini Protean II system and 
12% acrylamide gels. 50 µL of each samples were boiled for 5-10 min in 2x SDS loading 
buffer (2.5 mL Tris, 0.5 M pH 6.8, 2 mL glycerol, 4Ml of 10% w/v SDS, 1 mL β-
mercaptoethanol and 0.5 Ml of 0.1% w/v bromophenol blue) with 10 µL loaded onto the 
gel and run for ~ 50 min at 200V/180mA. Protein was visualised by InstantBlue Coomassie 
Stain (Expedeon Ltd) and mass estimated using LMW marker (GE Healthcare). 
5.5.2 Determination of enzyme concentration 
5.5.2.1 Bradford assay  
The Bradford protein assay is a method used to quantify the protein concentration in a 
sample. It is based on the principle that the Coomassie Brilliant Blue G-250 dye (Figure 5.1) 
changes colour from brown to blue under acidic conditions, measuring in this way the 
presence of basic amino acids (lysine, arginine and histidine).172 
 
Figure 5.1 Coomassie Brilliant Blue G-250 dye structure 
As first,50 µL of four serum albumin bovine (BSA) standard solutions (0.25 mg mL-1, 0.5 mg 
mL-1, 1 mg mL-1, 1.4 mg mL-1) were mixed with 1500 mL of Bradford reagent (Sigma). The 
absorbance was read at 595 nm and used to build a calibration curve. 50 µL of the purified 
protein at different dilutions (1:2, 1:5) were then mixed with 1.5 mL of Bradford reagent 
and the absorbance at 595 nm was recorded.  
5.5.2.2 Beer-Lambert Law 
Relevant size exclusion fractions were pooled together and scanned between 200-800 nm 
wavelengths using a Varian Cary-50 UV-Vis spectrophotometer. Extinction coefficients were 
 






calculated using ProtParam tool (https://web.expasy.org/protparam/) and subsequent 
protein concentrations determined using the scanned A280 absorbance and the Beer-
Lambert equation A = εcl.192  
5.5.3 UV/Vis spectroscopy 
All UV-Vis spectra were recorded on a single-beam Hewlett-Packard 8452A diode array 
spectrophotometer and analysed using UV-Vis ChemStation software (Agilent). To convert 
the apo-D-PhgAT/FumI to holo-D-PhgAT/FumI the enzyme was dialyzed for 2 h at 4 °C 
against buffer C/H with 50 μM PLP. Excess PLP was removed by passing the protein through 
a PD-10 (Sephadex G- 25M) desalting column (GE Healthcare) before any 
spectrophotometric measurements were taken. The concentration of recombinant protein 
was 20 μM and the spectrophotometer was blanked with buffer C/H without 50 M PLP.  
 
5.5.4 Measuring enzyme dissociation constants for amino acids 
To convert the apo- FumI to holo- FumI the enzyme was dialyzed for 2 h at 4 °C against 
buffer H with 50 μM PLP and excess of PLP was removed by buffer exchange as previously 
described. 10 X stock solutions were prepared for each tested amino donor at each 
concentration (0-200 mM). The spectrum was recorded immediately prior to the addition 
and immediately following the addition of the amino donor and left at 35 °C for 18 h. The 
morning after the spectrum was recorded and the Δ325nm used to calculate the dissociation 
constant.  
Data was analysed by non-linear regression using Origin. Changes in absorbance at 325 nm 
were plotted against L-alanine (L-Ala) concentrations, and data points were fitted to a 
hyperbolic saturation curve using Sigma Plot software: 
The ΔAobs is the observed change in absorbance at 325 nm and the ΔAmax is the maximal 
absorbance change, [Ala] is the L-Ala concentration, and Kd is the dissociation constant. 
ΔAobs 
ΔAmax [Ala] 










5.6 Amino benzenes as ‘smart’ amino donors 
5.6.1 D-PhgAT 
The amines 5-nitro-2, 3-dihydro-1H-inden-2-amine (2,3-DHIA), 4-(2-Aminoethyl) 
benzonitrile 
(4-AEB) and 2-(4-nitrophenyl) ethan-1-amine(4-NPEA) were dissolved in buffer D and tested 
with different amino acceptors (benzoylformate (BZF), α-ketoglutarate (AKG), 
benzaldehyde (BZALD) and N-butyraldehyde (NBA)) at 0.5 mg mL-1 D-PhgAT. Amine donor 
were used at a final concentrations of 25 mM while amino acceptors at 10 mM, as 
suggested in the literature116. For each reaction a control with no enzyme was performed. 
Reactions were incubated for 18 h at 37 °C. 
5.6.2 FumI 
The amine donors 2,3-DHIA, 4-AEB and 4-NPEA were tested with different amino acceptors 
(from C3 to C20 and BZALD and NBA) at 0.5 mg mL-1 FumI. Amine donor were used at a final 
concentrations of 12.5 mM while amino acceptors at 5mM/1mM final concentration 
according to their solubility. The keto compounds were dissolved in 100% DMSO and 
prepared as 10x stock solutions to achieve a final concentration of 10% DMSO.  For each 
reaction a control with no enzyme was performed. Reactions were incubated for 18 h at 
37 °C.153  
5.7 Ortho-xylylene diamine (OXD) assay 
5.7.1 UV/Vis studies 
A solution of 10 mM of ortho-xylylene diamine (OXD) was made up in the appropriate 
buffer (C/H) and added to the enzyme (20 µM), appropriately loaded with PLP and 
desalted, for a final concentration of 1 mM. The spectrum was recorded from 200 to 800 
nm as described above. Overtime the formation of a purple precipitate could be observed.  
 






5.7.2 Solid phase assay 
The solid phase assay was performed as described by Anthony P. Green et al.152,102 A 
glycerol stock of E. coli BL21 (DE3) harbouring pET-15b-dpgA was diluted 1/10,000 in sterile 
H2O and plated onto a Hybond-N membrane on the surface of LB-agar supplemented with 
Amp100. Plates were incubated at 30 °C ON. As a control, untransformed E. coli BL21 (DE3) 
cells were grown in parallel. The recombinant protein expression was induced by the 
addition of 2 mM IPTG to the surface of the LB-agar plates, replacing the membrane and 
incubating for further 6 h at 30 °C. Blotting paper was then soaked in a solution of OXD (5 
mM) in KPhos buffer (100 mM, pH 7.5) and the excess liquid was drained. The membranes 
were placed on top of the blotting paper and incubated at 30 °C for ON. After 1 h the 
formation of a purple precipitate could be observed.  
5.8 Spectrophotometric assays 
5.8.1 Measuring enzyme kinetics with the coupled assay AKGDH/D-PhgAT 
The D-PhgAT activity was monitored by coupling the reaction with the α-ketoglutarate 
dehydrogenase (AKGDH), being AKG the product of the first half reaction. The final volume 
of the reactions was 250 μL and contained 0.1 M CAPS pH 9.5, 150 mM NaCl, 1mM MgCl2, 1 
mM CaCl2, 0.05 mM EDTA, 50 uM PLP, 1 mM CoASH, 3 mM NAD+ , 0.2 U KGDH, 0 to 50 mM 
L-Glu, 0 to 20 mM BZF. These reagents were pre-incubated at 35 °C and the reaction was 
blanked. The reaction was initiated by adding 1 µM D-PhgAT. The increase in absorbance at 
340 nm resulting from the enzymatic conversion of NAD+ to NADH was monitored over 1h 
on a BioTek Synergy HT plate reader with Costar 96-well plate. The data from the first 15 
min were analysed using the Michaelis–Menten model and a nonlinear regression fit on 
GraphPad gave values of KM and kcat (εNADH = 6220 M-1 cm-1). 
 
5.8.2 Measuring enzyme kinetics with the coupled assay FumI/PDH 
The FumI activity was monitored by coupling the reaction with the pyruvate dehydrogenase 
(PDH), being pyruvate the product of the first half reaction. The final volume of the 
reactions was 200 μl and contained 50 mM Tris, 700 mM MgCl2, 35 mM CaCl2, 50 µM,  0.32 
 






mM thiamine pyrophosphate (TPP), 200 µM CoASH, 2 mM NAD 0.2 U PDH, 0 to 100 µM 
keto substrate, 10 mM L-Ala. These reagents were pre-incubated at 35 °C and the reaction 
was blanked. The reaction was initiated by adding 1 µM FumI. The increase in absorbance 
at 340 nm resulting from the enzymatic conversion of NAD+ to NADH after pyruvate 
production by the FumI was monitored over 1 h on a BioTek Synergy HT plate reader with a 
Costar 96-well plate. The data from the first 15 min were analysed using the Michaelis–
Menten model and a nonlinear regression fit on GraphPad gave values of KM and kcat (εNADH 
= 6220 M-1 cm-1). 
5.9 Chiral HPLC 
For kinetic parameters calculations, reactions containing 0.51 mg mL-1 D-PhgAT, , 0-200 mM 
L-Glu, 0-20 mM BZF/HBZF/IPA/PPA/HPA in 0.1 M CAPS pH 9.5, 150 mM NaCl, 50 µM PLP 
buffer were incubated at 37 °C before being terminated at 15 min by diluting 40-fold in the 
chiral mobile phase: 0.025%   triethylammonium acetate (TEAA):MeOH (50:50). Reactions 
were then analysed by chiral HPLC using a Chirobiotic T column (Astec, chiral phase 
Teicoplanin, 5 μm, 250 mm × 4.6 mm) under the following isocratic conditions: mobile 
phase: 0.025%  TEAA:MeOH (50:50, v/v), flow rate: 1 mL min−1 , detection λ: 205 nm, 
temperature: RT, run time: 30 min. The column was calibrated with single enantiomers of 
the amino acids. The conversion was used to measure enzyme activity (Appendix 8.6). The 
same procedure was applied for the non-natural products such as D-phenylalanine, D-
tyrosine and D-tryptophan. Lab solution sofwtare (Shimadzu) was used to measure the area 
under product peaks. 
5.9.1 Determination of the % enantiomeric excess (ee) 
Enantiomeric excess (ee) was calculated for each biotransformation.   
The% ee was calculated as follows: 
 
 
Where (R)- and (S)- are the AUC for each enantiomer.  
 






5.9.2 Amino donor screening D-PhgAT 
A D-PhgAT aliquot was thawed and incubated on ice with 50 µM PLP for ~ 2h in order to be 
fully loaded with fresh PLP.  Reactions containing 0.51 mg mL-1 D-PhgAT, 10 mM L/D amino 
donor, 10 mM BZF in buffer C were incubated at 37 °C before being terminated at 18 h by 
diluting 40-fold in the chiral mobile phase. Reactions were then analysed by cHPLC using a 
Chirobiotic T column as stated before. Percentage of conversions were normalized by L-Glu 
conversion which resulted to be the best amino donor. 
5.9.3 Large scale biotransformation conditions D-PhgAT 
Large scale biotransformation (1g) was performed in 100 mL conical flask with a final 
volume of 50 mL. For each component of the reaction the pH was adjusted to 9.5 before 
being added to the reaction mixture. A fresh purified D-PhgAT was added at a final 
concentration of 0.2 mg mL-1, 0.4 mg mL-1or 1 mg mL-1 (4 µM, 8 µM, 20 µM)  in buffer C 
containing 1 g of BZF (~ 133 mM) and 500 mM L- Glu. The biotransformation was carried 
out at 37 °C at 120 rpm. A negative control with all the reagents but the enzyme was 
performed at the same time. Time points were collected at time 0, 15 min, 30 min, 1 h, 2 h, 
3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 24 h, 36 h. Each time point was collected in triplicated and 
processed as described above. At each time point reactions were quenched by diluting 40-
fold in the chiral mobile phase and analysed by cHPLC. 
5.9.4 Small scale biotransformation D-PhgAT 
Small scale biotransformation was performed in 50 mL conical Falcon tube with a final 
volume of 5 mL. For each component of the reaction the pH was adjusted to 9.5 before 
being added to the reaction mixture. A fresh purified D-PhgAT was added at a final 
concentration of mg mL- in buffer C containing 100 mg of BZF, HBF, IPA, PPA, HPPA and 500 
mM L- Glu. The biotransformation was carried out at 37 °C at 120 rpm. A negative control 
with all the reagents but the enzyme was performed at the same time. Time points were 
collected at time 0, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 24 h. Each time 
point was collected in triplicated and processed as described above. At each time point 
 






reactions were terminated by diluting 40-fold in the chiral mobile phase and analysed by 
cHPLC. 
5.9.5 FumI reactions to be analysed by MS 
A FumI aliquot was thawed and incubated on ice with 50 µM PLP for ~ 2h in order to be 
fully loaded with fresh PLP.  Reactions containing 0.4 mg mL-1 FumI, 10 mM L-Ala, 100 µM 
keto acceptor (dissolved in DMSO for a final 10%  concentration) in buffer H were 
incubated at 35 °C at 250 rpm using a Thermo Shaker (PCTM) for 18 h. Reactions were 
terminated by diluting 1:1 with ACN, 0.1%  v/v formic acid. Samples were clarified by 
centrifugation at 16,000 x g for 10 min and analysed by mass spectrometry.  
5.9.6 FumI-CAR cascade 
The FumI-CAR cascade was set up with C10-FA, C12-FA, C-14-FA, C16-FA, C18-FA and C20-
FA in buffer L as follows: 
 
Reagent Final concentration (mM) 
1M MgCl2 20 
100 mM ATP 2 
100 mM NADPH 2 
50 mM FA 1 
500 mM Alanine 10 
CAR 0.25 mg mL-1 
FumI 0.24 mg mL-1 
Table 5.7 FumI-CAR couple reaction conditions without the recycling system. 
Each fatty acid was dissolved in 100% DMSO. When using the NADH/ATP recycling system 
the same conditions were applied with the addition of 10 mM Glucose, 4 mg mL-1 Poly (P), 
0.3 mg mL-1 GDH, AdK and PAP.  
5.10 Marfey’s (FDAA) reagent derivatization 
50 µL of 1 mM (R)-/(S)-C8-2A were mixed with 100 µL of FDAA (dissolved in Acetone) and 
20 µL of 1 M NaHCO3. The sample was heated at 40 °C for 1 h in a Thermo Shaker (PCMT). 
After the sample cooled down to room temperature (RT), 20 µL of 2M HCl were added.  
 






The sample (10 µL) was injected onto Luna 5u C18 RP-HPLC column (100 Å, 250 x 4.60 mm, 
Phenomenex). The LC gradient ran from 10%   ACN and 80% water with 0.1% TFA to 70% 
ACN 0.1% TFA over 40 min, flow rate 1.0 mL min-1, temperature: RT, detection at 340 nm. 
A reaction containing 0.4 mg mL-1 FumI, 10 mM L-Ala, 100 µM C8-2K (dissolved in DMSO for 
a final 10% concentration) in buffer H was incubated at 35 °C at 250 rpm using a Thermo 
Shaker for 18 h. The reaction was derivatized with Marfey’s reagent following the protocol 
described above. 
5.11 Mass Spectrometry  
5.11.1 Protein LC-MS 
Bradford assay was used to determine protein concentration for LC-MS. Protein was diluted 
to a concentration of 20 µM and centrifuged for 10 min at 17,000 x g. 5 µL of the 
supernatant was injected into LC-MS on a Synapt G2-Si Q-TOF (Waters) instrument with 
Phenomenex C4 3.6 µm LC column coupled to an electrospray ionisation (ESI) source. The 
LC gradient ran from 5% ACN and 95% water with 0.1% FA to 95% ACN over 15 min. The MS 
source was set at 120 °C, backing pressure 2 mbar and sampling cone voltage of 54 V. 
Protein spectra are presented after subtraction using MassLynx V4.1 software. Peak m/z 
annotations were extracted from smoothed and centroided data which was also used in the 
component algorithm to extract the protein average masses. 
5.11.2 FumI reactions LC-MS 
FumI reactions (50 μL) with different keto substrates (C3 to C20) and 10 mM alanine were 
mixed with ACN, 0.1% v/v formic acid (50 μL) and clarified by centrifugation at 16,000 x g 
for 10 min. 5 µL of supernatant was subjected to LC-MS on a Synapt G2-Si Q-TOF (Waters) 
instrument with Phenomenex Jupiter C18 5 µm 300 Å LC column coupled to an ESI source. 
The LC gradient ran from 5% ACN and 95% water with 0.1% FA to 95% ACN over 30 min. 
The MS source was set at 120 °C, backing pressure 2 mbar and sampling cone voltage of 54 
V. Extracted ion chromatograms (EICs) and masses were determined on MassLynx V4.1 
software. A lockmass correction was applied once at the beginning of each analysis against 
leucine enkephalin peptide. 
 






5.11.3 FumI reactions MALDI 
For MALDI sample preparation a volume of 1 μL of FumI reaction sample solution was 
spotted on a ground steel MALDI target plate, followed by 1 μL of α-cyano-4-
hydroxycinnamic acid (CHCA) matrix solution (1% in 50% ACN/0.1% TFA (w/v/v)). The 
sample and the matrix solutions were mixed together on the plate and allowed to air-dry. 
Each sample was spotted on to the MALDI target plate in triplicate. For analysis using the 
ultraflex the data was acquired using FlexControl software version 3.3 (Bruker Daltonics). 
Positive-ion MALDI mass spectra were obtained using a Bruker ultraflex III in reflectron 
mode, equipped with a Nd:YAG smart beam laser. Spectra were acquired over a range of 
50-500 m/z. Final mass spectra were externally calibrated against an adjacent spot 
containing 6 peptides (des-Arg1-Bradykinin, 904.681; Angiotensin I, 1296.685; Glu1-
Fibrinopeptide B, 1750.677; ACTH (1-17 clip), 2093.086; ACTH (18-39 clip), 2465.198; ACTH 
(7-38 clip), 3657.929). Monoisotopic masses were obtained using a SNAP averaging 
algorithm (C 4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) and a S/N threshold of 2. . 
Fragmentation was performed in LIFT mode without the introduction of a collision gas. The 
default calibration was used for MS/MS spectra, which were baseline-subtracted and 
smoothed (Savitsky-Golay, width 0.15 m/z, cycles 4); monoisotopic peak detection used a 
SNAP averaging algorithm (C 4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) with a 
minimum S/N of 6. Bruker flexAnalysis software (version 3.3) was used to perform spectral 
processing and peak list generation.  
Before starting the run the laser intensity was first optimised so that maximum signal 
intensity was obtained, without compromising the baseline of the spectrum. The average 
laser intensity used was around 43%, however this changed depending on the sample type, 
with extracts of low concentration typically requiring a higher laser intensity than 
concentrated extracts. The optimum number of laser shots was investigated at the 
beginning of each sample run with an average of 800 shots used. It was found that when 
analysing majority of the samples, the spectra obtained did not increase above 800 laser 
shots. In addition, before each run, the plate was aligned so that the laser started in the 
centre of each of each spot with the spot movement for each sample set to random.  
 






5.12 N15 D-Phg and N15 D-Hpg biosynthesis  
5.12.1 C18 HPLC method 
Reactions were then analyzed by HPLC using a Luna 5μ C18 (2) RP-HPLC column (100Å, 
250×4.60mm, Phenomenex) and the following conditions:  5% to 95% ACN (0.1% TFA, 
v/v)/water (0.1% TFA, v/v) in 20 min, flow rate: 1mL min-1, detection at λ= 274 nm, 
temperature: RT. Samples were diluted by 40-fold into 5% ACN (0.1% TFA, v/v) before being 
analysed by HPLC. A calibration curve of D-Phg and D-Hpg was used to relate the area 
under the curve (AUC) with the amount of product synthesised. 
5.12.2 Synthesis of N15 D-Phg and N15 D-Hpg 
For the preparation of N15 D-Phg the reaction mixture consisted of: 66 mM BZF, 340 
mM N15-L-Glu and 1 mg mL-1 D-PhgAT in a 5 mL scale. Same procedure was followed for the 
synthesis of 15N-D-Hpg but using a lower concentration of the amino acceptor HBF (33 
mM). Reactions were incubated at 37 °C at 250 rpm. The real time conversion of BZF and 
HBZF into D-Phg and D-Hpg was monitored by C18 HPLC as described above.  
5.12.3 Purification by reversed-phase HPLC  
Reaction mixtures were acidified by adding few drops of pure trifluoroacetic acid (TFA). 
Precipitate generated at this stage was removed by centrifugation.  Analytical HPLC anaylsis 
were conducted as described in 5.12.1. Preparative reverse phase HPLC was conducted on 
a Waters® 600 (225 μL) system using a 486 tuneable absorbance detector recording at 205 
nm equipped with a Phenomenex® Luna C18(2) column (5 μm, 250 × 21.2 mm) using 97% 
water (0.1% TFA) and 3% ACN (0.1% TFA) as eluent at a flow rate of 18.0 mL min-1. Column 
was pre-equilibrated (3% ACN, 0.1% TFA) before injecting reaction mixtures (2mL in every 
run) and washed with 97% ACN (0.1% TFA) for approximately 10min after the desired 
product peaks were collected. Elute fractions were collected and freeze-dried.  Due to 
higher hydrophilicity of D-Hpg than D-Phg, D-Hpg was purified via a modified method with 
lower ratio of ACN in the mobile phase, using 98% water (0.1% TFA) and 2% ACN (0.1% 
 






TFA). Elute fractions were combined and freeze-dried which afforded the product as 
yellowish oil.  
5.12.4 NMR analysis  
Nuclear magnetic resonance (NMR) spectra were recorded at 298 K on Bruker PRO500 or 
AVA500 spectrometers running at 500 MHz (1H spectra). The solvent used was deuterium 
oxide (D2O). Coupling constants J, were calculated using MestreNova (version 9). The 
following abbreviations (and their combinations) are used to label the multiplicities: s 
(singlet), d (doublet), m (multiplet). 
D-Phg 1H NMR (500 MHz, D2O): δH 7.51-7.47 (5H, m).166  
D-Hpg 1H NMR (500 MHz, D2O): δH 6.88 (2H, d, J = 8.5 Hz), 7.25 (2H, d, J = 8.5 Hz).193 
L-Glu 1H NMR (500 MHz, D2O): δH 1.95-2.11 (2H, m), 2.31-2.28 (2H, m), 3.71-3.68 (1H, m).167 
5.12.5 Mass Spec Analysis  
Samples were cleaned prior to analysis using C18 solid-phase tips (Millipore ZipTips). After 
loading, the tips were washed with 0.1% formic acid and eluted in 50:50(v/v) ACN: 0.1% 
formic acid). Samples were analysed on the SolariX FT-ICR-MS using direct infusion by 
nanomate in positive ion mode for  N15 D-Phg and in negative mode of N15 D-Hpg. Spectra 
were acquired using the solariXcontrol software and processed with DataAnalysis version 
4.2 (Bruker Daltonics). The following setting were applied. D-Phg and 15N D-Phg was 
isolated using the quadrapole set at either 152 (with a 7 Da window) or 153 (with a 5 Da 
window). For each analysis 100 scans were collected from m/z 100-1000 with an 
accumulation time of 2 sec. This was carried out by Dr Joanna Simpson and Dr Faye 
Cruikshank (University of Edinburgh). 
5.13 X-ray Crystallography 
5.13.1 D-PhgAT robot screening and optimization 
This work was carried out in collaboration with Dr. Jon Marles-Wright (Newcastle, 
University). Recombinant purified P. stutzeri D-PhgAT at 9.1 mg mL-1 was crystallised by 
 






hanging-drop vapour diffusion at 18 °C. Crystallisation experiments were set up in 96 well 
MRC plates with commercially available screens from Molecular Dimensions Limited with 
100 nL drops of protein and 100 nL well solution and equilibrated against 70 μL of well 
solution. Crystals grew in few conditions (C3/H10 PEG/Ion, B8 JCSG+, H4 MIDAS) that were 
further optimised. Diffracting quality crystals were obtained by adding 1 µL of 9.1 mg mL-1 
D-PhgAT in buffer C to 1 µL of 0.1 M Tris (pH 7.5), 0.2 M MgCl2, 10% (v/v) polyethylene 
glycol 8000. Crystals were cryoprotected with a solution containing 0.1 M Tris (pH 7.5), 0.2 
M MgCl2, 10% (w/v)  polypropylene glycol 8000, 20% (v/v) polypropylene glycol 200 PEG 
and then flash-cooled by immersion in liquid nitrogen. Datasets were collected on beamline 
I03 at the Diamond Light Source (Didcot, UK) at 100 K using a Pilatus 6M detector. 
Diffraction data were integrated and scaled using XDS194 and symmetry-related reflections 
were merged with Aimless.195 The resolution cut off used for structure determination and 
refinement was determined based on the CC1/2 criterion proposed by Karplus and 
Diederichs.196 The structure of D-PhgAT was determined by molecular replacement using 
the D-PhgAT incomplete structure with the PDB code 2CY8. A single solution comprising 
three dimers in the asymmetric unit was found using Phaser.197  The initial model was 
rebuilt using Phenix.autobuild198 followed by cycles of refinement with Phenix.refine199 and 
manual rebuilding in Coot.200 The final model was refined with automatically determined 
TLS groups and isotropic B-factors. The model was validated using MolProbity.201 Structural 
superimpositions were calculated using Coot. Crystallographic figures were generated with 
PyMOL (Schrodinger LLC). Data collection and refinement statistics are shown in Appendix 
8.7. X-ray diffraction images are available online at Zendo (doi:10.5281/zenodo.1059413). 
The structure is deposited at the PDB with PDB code 6G1F. 
5.13.2 FumI robot screening and optimization 
This work was carried out in collaboration with Dr. Jon Marles-Wright (Newcastle, 
University). Crystal screening with recombinant purified Sphingopyxis FumI (8.1 mg mL-1) in 
20 mM KPhos, 500 mM NaCl,50 µM PLP, pH 7.5 was performed using a wide range of 
commercial screens (MIDAS, PEG/Ion, STRUCTURE, JCSG+) in 96 well plate using the 
Gryphon robot. The C10 MIDAS condition (35% w/v polyacrylate 2100 sodium salt, 0.2 M 
ammonium sulfate, HEPES pH 7.5) was further optimised. The best crystals were produced 
 






by adding 1 µL of 8.1 mg mL-1 FumI in buffer G to 1 µL of 100 mM HEPES pH 6, 30% 
Polyacrilate 2100 sodium salt (v/v), 0.2 M ammonium sulfate. Crystals were cryoprotected 
with a solution containing 100 mM HEPES pH 6, 30%(w/v)  Polyacrilate sodium salt 
polypropylene glycol 200 PEG and then flash-cooled by immersion in liquid nitrogen. The 
FumI 3D structure was solved by molecular replacement using the structure of the 
glutamate 1-semialdehyde AT from Bacillus subtilis (PDB code: 3BS8), displaying 29% 
sequence identity. A single solution comprising one dimer in the asymmetric unit was found 
using Phaser.197 Crystallographic figures were generated with PyMOL (Schrodinger LLC). 
Data collection and refinement statistics are shown in Appendix 8.7.  The structure is 
deposited at the PDB with the PDB code: 6HBS. 
5.14 Enzyme immobilization 
5.14.1 Optimization 
EziG resins were kindly sent by EnginZyme and tested for D-PhgAT immobilization. Three 
different EziG carriers are commercially available with different properties with regards to 
surface, pore diameter and bulk density: EziG1 Opal, EziG2Coral and EziG3 Amber. 
All resins were tested in order to identify the most suitable carrier for D-PhgAT 
immobilization. Aiming for 10% loading (9 mg of EziG per 1 mg of purified D-PhgAT), as 
suggested by the manufacturer, the three EziG carriers were tested at different imidazole 
concentrations, a crucial factor for successful immobilization. 1 mg of D-PhgAT was mixed 
with 9 mg of carrier and left under orbital shaking for different times (30 and 60 min) at 37 
°C. A volume of 200 µL was kept constant in buffer C (0-75 mM imidazole).  The amount of 
immobilized enzyme was evaluated by Bradford assay on the supernatant. This experiment 
allowed the identification of the best immobilization conditions and the best carrier which 
was found to be EziG2 with 75 mM imidazole and 30 min. All subsequent studies were 
conducted under the aforementioned conditions. 
5.14.2 Immobilization reactions  
1 mg of purified/cell free extract D-PhgAT was mixed with 9 mg of EziG2 in buffer D, left 
under orbital shaking for 30 min at 37 °C. Reactions were left standing for 10 min to allow 
 






sedimentation. A Bradford assay on the supernatant was carried out to check that the 
immobilization was successful. The supernatant was then removed and reaction 
components (10 mM BZF, 300 mM L-Glu) were added to the carrier for a final volume of 
200 µL. These reactions were incubated at 37 °C under orbital shaking for 1 h. An aliquot of 
20 µL was withdrawn from the reaction, diluted 1:40 in the cHPLC mobile phase and 
analysed by cHPLC. The amount of D-Phg produced was determined by relating the area 
under the curve with the amount of D-Phg through a calibration curve. A positive control 
with the wild enzyme (not immobilized) was always done in parallel in order to compare 
the enzyme performances.  
5.14.3 Optimum of pH and Temperature 
Different pH and temperature were tested to identify differences between the immobilized 
and wild enzyme. The immobilization was carried out under the optimized conditions (pH 
9.5, 37 °C). After successfully immobilization the reactions (10 mM BZF, 300 mM L-Glu) 
were tested at 15 °C, 37 °C, 50 °C and 60 °C in buffer D. Analogously, reactions were carried 
out at pH 5, 7.5, 9.5 and 11 at 37 °C. The amount of D-Phg produced was evaluated by 
cHPLC.  
5.14.4 Recycling cycles  
To test the possibility of using multiple times the immobilized D-PhgAT, recycling tests were 
performed. Purified/cell free extract D-PhgAT was firstly immobilized according to 
optimised conditions and 1 h reactions were carried out as previously described. After 
withdrawing a sample for cHPLC analysis, the supernatant was removed and replaced with 
1 mL of buffer D. The samples were orbitally shaken for 30 min at 37 °C. After 
sedimentation, a Bradford assay was performed to check eventual protein loss and stored 
at 4 °C. After 24 h the same procedure was repeated. This procedure was repeated for 9 













6 Conclusions and future work 
The aim of this thesis was to explore the biocatalytic potential of two very interesting, 
distantly-related class III aminotransferases (ATs): D-Phenylglycine aminotransferase (D-
PhgAT) from P. stutzeri and amino-pentol AT (FumI) from Sphingopyxis sp. MTA144. 
D-PhgAT is a unique member of the AT family as the amino donors in the ‘forward’ 
and ‘backward’ reaction exhibit opposite absolute stereochemical configuration. Thus, D-
PhgAT is referred as ‘stereo inverting’ and is a very appealing target for the production of 
high value D-amino acids from inexpensive L-amino acids. D-PhgAT was successfully 
expressed, purified and kinetically characterised. Two different methods, a 
spectrophotometric method and a high-performance liquid chromatography (HPLC) based 
method, have been developed to determine the enzyme kinetic parameters and the 
enantioselectivity. The D-PhgAT amino donor substrate scope has been widely explored 
identifying L-Glu as the best amino donor. Thus, a large scale biotransformation has been 
carried out using L-Glu as amino donor and benzoyl formate (BZF) (1 g) as the model 
substrate and the percentage conversion and ee has been determined. A large excess of the 
amino donor L-Glu (~ 20-fold KM) is enough to drive the reaction towards product formation 
and obtain 93% conversion of BZF after 3 h of reaction with an enzyme loading of 1 mg mL-
1. Moreover, the bioconversion has been extended to non-natural substrates to yield a wide 
range of aromatic D-amino acids: D-Phe, D-Tyr and D-Trp exhibiting promising conversions 
(from 15% to 57%).   
The successful determination of the crystal structure of the D-PhgAT at 2.25 Å 
resolution with its bound PLP cofactor has begun to shed light on the unique stereo-
inverting and enantioselective properties of the enzyme. An in depth structural and 
sequence analysis has highlighted three key active site residues that potentially control the 
exquisite (R)-selectivity of the enzyme; His66, His 213 and Arg34. These residues are shared 
between the two D-PhgAT homologues from P. stutzeri and P. putida. Site-directed 
mutagenesis on these residues will further clarify their role in the substrate recognition.  
A strategy to overcome the high costs associated with enzymes consists of 
immobilizing an enzyme on a solid support to allow the reuse of an enzyme multiple times 
 






without additional isolation and purification. Preliminary studies using a commercial resin, 
EziG, have been carried out and D-PhgAT was successfully immobilized and recycled up to 9 
times. This could be further explored to make the process industrially relevant. All these 
findings strengthen the D-PhgAT position in the biocatalytic toolbox of the ATs for the 
production of a wide range of D-aminoacids.  
The amino-pentol AT FumI is a very attractive target for biocatalysis as its natural 
substrate is 20 carbons long, suggesting that it could be potentially applied for the 
production of long chain amines which are broadly used in detergents, surfactants and 
cosmetic formulations. 
Surprisingly, FumI was able to accept a wide range of ketones and aldehydes of 
various chain length (from C3 to C20) yielding the corresponding amines. A coupled assay 
and an LC ESI-MS method have been developed for the determination of the kinetic 
parameters and the detection of the product. Derivatisation using the widely used Marfey’s 
reagent has been carried out to check the enzyme enantioselectivity (S).  
The determination of the FumI 3D structure with its cofactor at 1.6 Å resolution 
revealed a potential hydrophobic binding site for the long chain substrates.  Moreover, an 
unsual arginine residue, Arg231 directly interacts with the hydroxyl group of the PLP 
cofactor. Site-directed mutagenesis results were inconclusive as the substitution of the Arg 
residue to an Ala residue (Q231A) resulted in insoluble protein. The determination of an 
external aldimine structure with the natural substrate HFB1 or Ala bound could provide 
further insight into the residues involved in substrate recognition and highlight hot spots 
for site directed mutagenesis. 
Moreover, the possibility of coupling FumI with a carboxylic acid reductase (CAR) 
enzyme from Mycobacterium chlorophenolicum (McCAR) for the production of fatty amines 
from fatty acids has been explored. Very promising preliminary results suggest that the two 
enzymes are compatible and catalyse the production of primary amines from C10 to C20. The 
determination of the % conversions for all the tested substrates will be crucial to optimize 
the reaction conditions and bring it to industrial level. 
Until now, the application of FumI has been limited to detoxification of maize 
contaminants. In this work FumI is presented in a new light as a promising addition to the 
biocatalytic toolbox for the production of a wide range of fatty amines.  
 







(1)  Wenda, S.; Illner, S.; Mell, A.; Kragl, U. Industrial Biotechnology—the Future of 
Green Chemistry? Green Chem. 2011, 13 (11), 3007. 
(2)  Laird, T. Biocatalysis and Biotransformations. Org. Process Res. Dev. 2005, 9 (5), 521. 
(3)  Meyer, H.-P.; Eichhorn, E.; Hanlon, S.; Lütz, S.; Schürmann, M.; Wohlgemuth, R.; 
Coppolecchia, R. The Use of Enzymes in Organic Synthesis and the Life Sciences: 
Perspectives from the Swiss Industrial Biocatalysis Consortium (SIBC). Catal. Sci. 
Technol. 2013, 3 (1), 29–40. 
(4)  Pollard, D. J.; Woodley, J. M. Biocatalysis for Pharmaceutical Intermediates: The 
Future Is Now. Trends Biotechnol. 2007, 25 (2), 66–73. 
(5)  Sheldon, R. A. Biocatalysis and Green Chemistry. Green Biocatal. 2016, 1–15. 
(6)  Sethi, M. K.; Chakraborty, P.; Shukla, R. Biocatalysis – A Greener Alternative in 
Synthetic Chemistry; The Royal Society of Chemistry, 2017. 
(7)  Sheldon, R. A.; Pereira, P. C. Biocatalysis Engineering: The Big Picture. Chem. Soc. 
Rev. 2017. 
(8)  Johannes, T. W.; Simurdiak, M. R.; Zhao, H. Biocatalysis. Encycl. Chem. Process. 2006, 
101–110. 
(9)  Bornscheuer, U. T.; Huisman, G. W.; Kazlauskas, R. J.; Lutz, S.; Moore, J. C.; Robins, K. 
Engineering the Third Wave of Biocatalysis. Nature 2012, 485 (7397), 185–194. 
(10)  Sedlaczek, L.; Smith, L. L. Biotransformations of Steroids. Crit. Rev. Biotechnol. 1988, 
7 (3), 187–236. 
(11)  Arnold, F. H. Directed Evolution: Bringing New Chemistry to Life. Angew. Chemie - 
Int. Ed. 2018, 57 (16), 4143–4148. 
(12)  Packer, M. S.; Liu, D. R. Methods for the Directed Evolution of Proteins. Nat. Rev. 
 






Genet. 2015, 16 (7), 379–394. 
(13)  Bornscheuer, U. T. The Fourth Wave of Biocatalysis Is Approaching. Philos. Trans. A. 
Math. Phys. Eng. Sci. 2018, 376 (2110), 20170063. 
(14)  Liese, J. (Alex) T. L. Biocatalysis for the Pharmaceutical Industry; Tao, J. (Alex), Lin, 
G.-Q., Liese, A., Eds.; John Wiley & Sons, Ltd: Chichester, UK, 2009. 
(15)  Albarrán-Velo, J.; González-Martínez, D.; Gotor-Fernández, V. Stereoselective 
Biocatalysis: A Mature Technology for the Asymmetric Synthesis of Pharmaceutical 
Building Blocks. Biocatal. Biotransformation 2018, 36 (2), 102–130. 
(16)  Gardossi, L.; Molinari, F. Biocatalytic Process. Catalysis 2009, No. 32, 516–538. 
(17)  Sánchez-Carrón, G.; Campopiano, D. J. Contemporary Catalysis: Science, Technology, 
and Applications; The Royal Society of Chemistry, 2017. 
(18)  Davis, B. G.; Boyer, V. Biocatalysis and Enzymes in Organic Synthesis. Nat. Prod. Rep. 
2001, 18 (6), 618–640. 
(19)  Choi, J. M.; Han, S. S.; Kim, H. S. Industrial Applications of Enzyme Biocatalysis: 
Current Status and Future Aspects. Biotechnol. Adv. 2015, 33 (7), 1443–1454. 
(20)  Yamada, H.; Kobayashi, M. Nitrile Hydratase and Its Application to Industrial 
Production of Acrylamide. Biosci. Biotechnol. Biochem. 1996, 60 (9), 1391–1400. 
(21)  Arshad, R.; Farooq, S.; Ali, S. S. 6-Aminopenicillanic Acid Production by Intact Cells of 
E. Coli Containing Penicillin G Acylase (PGA). Pakistan J. Biol. Sci. 2007, 10 (18), 
3190–3194. 
(22)  Liu, Z. Q.; Zheng, W.; Huang, J. F.; Jin, L. Q.; Jia, D. X.; Zhou, H. Y.; Xu, J. M.; Liao, C. J.; 
Cheng, X. P.; Mao, B. X.; et al. Improvement and Characterization of a 
Hyperthermophilic Glucose Isomerase from Thermoanaerobacter Ethanolicus and 
Its Application in Production of High Fructose Corn Syrup. J. Ind. Microbiol. 
Biotechnol. 2015, 42 (8), 1091–1103. 
(23)  Schmid, A.; Dordick, J. S.; Hauer, B.; Kiener, A.; Wubbolts, M.; Witholt, B. Industrial 
 






Biocatalysis Today and Tomorrow. Nature 2001, 409 (6817), 258–268. 
(24)  Bommarius, A. S.; Paye, M. F. Stabilizing Biocatalysts. Chem. Soc. Rev. 2013, 42 (15), 
6534–6565. 
(25)  Datta, S.; Christena, L. R.; Rajaram, Y. R. S. Enzyme Immobilization: An Overview on 
Techniques and Support Materials. 3 Biotech 2013, 3 (1), 1–9. 
(26)  Turner, N. J. Directed Evolution Drives the next Generation of Biocatalysts. Nat. 
Chem. Biol. 2009, 5 (8), 567–573. 
(27)  Savile, C. K.; Janey, J. M.; Mundorff, E. C.; Moore, J. C.; Tam, S.; Jarvis, W. R.; 
Colbeck, J. C.; Krebber, A.; Fleitz, F. J.; Brands, J.; et al. Biocatalytic Asymmetric 
Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture. Science 
(80-. ). 2010, 329 (5989), 305–309. 
(28)  Desai, A. A. Sitagliptin Manufacture: A Compelling Tale of Green Chemistry, Process 
Intensification, and Industrial Asymmetric Catalysis. Angew. Chemie - Int. Ed. 2011, 
50 (9), 1974–1976. 
(29)  Reetz, M. T. What Are the Limitations of Enzymes in Synthetic Organic Chemistry? 
Chem. Rec. 2016, 16 (6), 2449–2459. 
(30)  Sheldon, R. A.; Brady, D. The Limits to Biocatalysis : Pushing the Envelope. Chem. 
Commun. 2018, 54, 6088–6104. 
(31)  Capelli, R.; Marchetti, F.; Tiana, G.; Colombo, G. SAGE: A Fast Computational Tool for 
Linear Epitope Grafting onto a Foreign Protein Scaffold. J. Chem. Inf. Model. 2017, 57 
(1), 6–10. 
(32)  Lalonde, J. Highly Engineered Biocatalysts for Efficient Small Molecule 
Pharmaceutical Synthesis. Curr. Opin. Biotechnol. 2016, 42, 152–158. 
(33)  Bencivenni, G. Organocatalytic Strategies for the Synthesis of Axially Chiral 
Compounds. Synlett 2015, 26 (14), 1915–1922. 
(34)  Andrushko, V.; Andrushko, N. Principles, Concepts and Strategies of Stereoselective 
 






Synthesis. In Stereoselective Synthesis of Drugs and Natural Products; John Wiley & 
Sons, Inc.: Hoboken, NJ, USA, 2013; pp 1–42. 
(35)  Nguyen, L. A.; He, H.; Pham-Huy, C. Chiral Drugs: An Overview. Int. J. Biomed. Sci. 
2006, 2 (2), 85–100. 
(36)  Chhabra, N.; Aseri, M.; Padmanabhan, D. A Review of Drug Isomerism and Its 
Significance. Int. J. Appl. Basic Med. Res. 2013, 3 (1), 16. 
(37)  Vargesson, N. Thalidomide-Induced Teratogenesis: History and Mechanisms. Birth 
Defects Res. Part C - Embryo Today Rev. 2015, 105 (2), 140–156. 
(38)  Calcaterra, A.; D’Acquarica, I. The Market of Chiral Drugs: Chiral Switches versus de 
Novo Enantiomerically Pure Compounds. J. Pharm. Biomed. Anal. 2018, 147, 323–
340. 
(39)  Nugent, T. C.; El-Shazly, M. Chiral Amine Synthesis - Recent Developments and 
Trends for Enamide Reduction, Reductive Amination, and Imine Reduction. Adv. 
Synth. Catal. 2010, 352 (5), 753–819. 
(40)  Schrittwieser, J. H.; Velikogne, S.; Kroutil, W. Biocatalytic Imine Reduction and 
Reductive Amination of Ketones. Adv. Synth. Catal. 2015, 357 (8), 1655–1685. 
(41)  Ghislieri, D.; Turner, N. J. Biocatalytic Approaches to the Synthesis of 
Enantiomerically Pure Chiral Amines. Top. Catal. 2014, 57 (5), 284–300. 
(42)  Wu, H.; West, A. R.; Vickers, M.; Apperley, D. C.; Jones, A. G. Synthesis, 
Crystallization and Characterization of Diastereomeric Salts Formed by Ephedrine 
and Malic Acid in Water. Chem. Eng. Sci. 2012, 77, 47–56. 
(43)  Xue, Y.-P.; Cao, C.-H.; Zheng, Y.-G. Enzymatic Asymmetric Synthesis of Chiral Amino 
Acids. Chem. Soc. Rev. 2018, 47, 1516–1561. 
(44)  Ismail, H.; Lau, R. M.; Van Rantwijk, F.; Sheldon, R. A. Fully Enzymatic Resolution of 
Chiral Amines: Acylation and Deacylation in the Presence of Candida Antarctica 
Lipase B. Adv. Synth. Catal. 2008, 350 (10), 1511–1516. 
 






(45)  Gotor-Fernández, V.; Brieva, R.; Gotor, V. Lipases: Useful Biocatalysts for the 
Preparation of Pharmaceuticals. J. Mol. Catal. B Enzym. 2006, 40 (3–4), 111–120. 
(46)  Grogan, G. Synthesis of Chiral Amines Using Redox Biocatalysis. Curr. Opin. Chem. 
Biol. 2018, 43, 15–22. 
(47)  Jeon, H.; Yoon, S.; Ahsan, M.; Sung, S.; Kim, G.-H.; Sundaramoorthy, U.; Rhee, S.-K.; 
Yun, H. The Kinetic Resolution of Racemic Amines Using a Whole-Cell Biocatalyst Co-
Expressing Amine Dehydrogenase and NADH Oxidase. Catalysts 2017, 7 (9), 251. 
(48)  Abrahamson, M. J.; Vázquez-Figueroa, E.; Woodall, N. B.; Moore, J. C.; Bommarius, 
A. S. Development of an Amine Dehydrogenase for Synthesis of Chiral Amines. 
Angew. Chemie - Int. Ed. 2012, 51 (16), 3969–3972. 
(49)  Zhao, H.; Van Der Donk, W. A. Regeneration of Cofactors for Use in Biocatalysis. 
Curr. Opin. Biotechnol. 2003, 14 (6), 583–589. 
(50)  Aleku, G. A.; France, S. P.; Man, H.; Mangas-Sanchez, J.; Montgomery, S. L.; Sharma, 
M.; Leipold, F.; Hussain, S.; Grogan, G.; Turner, N. J. A Reductive Aminase from 
Aspergillus Oryzae. Nat. Chem. 2017, 9 (10), 961–969. 
(51)  Cosgrove, S. C.; Brzezniak, A.; France, S. P.; Ramsden, J. I.; Mangas-Sanchez, J.; 
Montgomery, S. L.; Heath, R. S.; Turner, N. J. Imine Reductases, Reductive Aminases, 
and Amine Oxidases for the Synthesis of Chiral Amines: Discovery, Characterization, 
and Synthetic Applications. In Methods in Enzymology; Elsevier Inc., 2018; pp 1–19. 
(52)  Gomm, A.; O’Reilly, E. Transaminases for Chiral Amine Synthesis. Curr. Opin. Chem. 
Biol. 2018, 43, 106–112. 
(53)  Malik, M. S.; Park, E. S.; Shin, J. S. Features and Technical Applications of ω-
Transaminases. Appl. Microbiol. Biotechnol. 2012, 94 (5), 1163–1171. 
(54)  Holden, M. Pyridoxamine Phosphate-Oxidase and Pyridoxal Phosphate- Phosphatase 
Activities in Escherichia Coli. 1961, No. 1930, 364–372. 
(55)  Schneider, G.; Käck, H.; Lindqvist, Y. The Manifold of Vitamin B6 Dependent 
 






Enzymes. Structure 2000, 8 (1), R1–R6. 
(56)  Heyl, D.; Harris, S. A.; Folkers, K. The Chemistry of Vitamin B6. VI. Pyridoxylamino 
Acids. J. Am. Chem. Soc. 1948, 70 (10), 3429–3431. 
(57)  Richard, J. P.; Amyes, T. L.; Crugeiras, J.; Rios, A. The PLP Cofactor : Lessons from 
Studies on Model Reactions ☆. BBA - Proteins Proteomics 2011, 1814 (11), 1419–
1425. 
(58)  Bugg, T. D. H. Introduction to Enzyme and Coenzyme Chemistry; John Wiley & Sons, 
Ltd: Chichester, UK, 2012. 
(59)  Percudani, R.; Peracchi, A. A Genomic Overview of Pyridoxal-Phosphate-Dependent 
Enzymes. EMBO Rep. 2003, 4 (9), 850–854. 
(60)  Percudani, R.; Peracchi, A. The B6 Database: A Tool for the Description and 
Classification of Vitamin B6-Dependent Enzymatic Activities and of the 
Corresponding Protein Families. BMC Bioinformatics 2009, 10, 273. 
(61)  Paiardini, A.; Contestabile, R.; Buckle, A. M.; Cellini, B. PLP-Dependent Enzymes. 
Biomed Res. Int. 2014, 2014, 1–2. 
(62)  Mascarenhas, R.; Le, H. V.; Clevenger, K. D.; Lehrer, H. J.; Ringe, D.; Kelleher, N. L.; 
Silverman, R. B.; Liu, D. Selective Targeting by a Mechanism-Based Inactivator 
against Pyridoxal 5ʹ-Phosphate-Dependent Enzymes: Mechanisms of Inactivation 
and Alternative Turnover. Biochemistry 2017, 56 (37), 4951–4961. 
(63)  Clayton, P. T. B6-Responsive Disorders: A Model of Vitamin Dependency. J. Inherit. 
Metab. Dis. 2006, 29 (2–3), 317–326. 
(64)  Harrison, P. J.; Dunn, T. M.; Campopiano, D. J. Sphingolipid Biosynthesis in Man and 
Microbes. Nat. Prod. Rep. 2018. 
(65)  Chen, J.; Gong, X.; Li, J.; Li, Y.; Ma, J.; Hou, C.; Zhao, G.; Yuan, W.; Zhao, B. Carbonyl 
Catalysis Enables a Biomimetic Asymmetric Mannich Reaction. Science (80-. ). 2018, 
360 (6396), 1438–1442. 
 






(66)  John R. A. Pyridoxal Phosphate-Dependent Enzymes. Biochim. Biophys. Acta 1995, 
1248, 81–96. 
(67)  Metzler, D. E.; Ikawa, M.; Snell, E. E. A General Mechanism for Vitamin B6-Catalyzed 
Reactions. J. Am. Chem. Soc. 1954, 76 (3), 648–652. 
(68)  Tidwell, T. T. Hugo (Ugo) Schiff, Schiff Bases, and a Century of β-Lactam Synthesis. 
Angew. Chemie - Int. Ed. 2008, 47 (6), 1016–1020. 
(69)  Eliot, A. C.; Kirsch, J. F. Pyridoxal Phosphate Enzymes: Mechanistic, Structural, and 
Evolutionary Considerations. Annu. Rev. Biochem. 2004, 73 (1), 383–415. 
(70)  Eliot, A. C.; Kirsch, J. F. Pyridoxal Phosphate Enzymes: Mechanistic, Structural, and 
Evolutionary Considerations. Annu. Rev. Biochem. 2004, 73 (1), 383–415. 
(71)  Raman, M. C. C.; Johnson, K. a.; Yard, B. a.; Lowther, J.; Carter, L. G.; Naismith, J. H.; 
Campopiano, D. J. The External Aldimine Form of Serine Palmitoyltransferase: 
Structural, Kinetic and Spectroscopic Analysis of the Wild-Type Enzyme and HSAN1 
Mutant Mimics. J. Biol. Chem. 2009, 284 (25), 17328–17339. 
(72)  Phillips, R. S. Chemistry and Diversity of Pyridoxal-5ʹ-Phosphate Dependent 
Enzymes. Biochim. Biophys. Acta - Proteins Proteomics 2015, 1854 (9), 1167–1174. 
(73)  Dunathan, H. C. Conformation and Reaction Specificity in Pyridoxal Phosphate 
Enzymes. Proc. Natl. Acad. Sci. 1966, 55 (4), 712–716. 
(74)  Yoshimura, T.; Jhee, K.-H.; Soda, K. Stereospecificity for the Hydrogen Transfer and 
Molecular Evolution of Pyridoxal Enzymes. Biosci. Biotechnol. Biochem. 1996, 60 (2), 
181–187. 
(75)  Di Salvo, M. L.; Contestabile, R.; Safo, M. K. Vitamin B6salvage Enzymes: Mechanism, 
Structure and Regulation. Biochim. Biophys. Acta - Proteins Proteomics 2011, 1814 
(11), 1597–1608. 
(76)  Toney, M. D. Reaction Specificity in Pyridoxal Phosphate Enzymes. Arch. Biochem. 
Biophys. 2005, 433 (1), 279–287. 
 






(77)  Toney, M. D. Controlling Reaction Specificity in Pyridoxal Phosphate Enzymes. 
Biochim. Biophys. Acta - Proteins Proteomics 2011, 1814 (11), 1407–1418. 
(78)  Ro, H. S.; Jeon, C. O.; Kim, H. S.; Sung, M. H. Stabilization of Quinonoid Intermediate 
E-Q by Glu32 of D-Amino Acid Transaminase. J. Microbiol. Biotechnol. 2006, 16 (9), 
1434–1440. 
(79)  Hirayama, A.; Miyanaga, A.; Kudo, F.; Eguchi, T. Mechanism-Based Trapping of the 
Quinonoid Intermediate by Using the K276R Mutant of PLP-Dependent 3-
Aminobenzoate Synthase PctV in the Biosynthesis of Pactamycin. ChemBioChem 
2015, 16 (17), 2484–2490. 
(80)  Alexander, F. W.; Sandmeier, E.; Mehta, P. K.; Christen, P. Evolutionary Relationships 
Enzymes Regio-Specific a , P and Y Families. Eur. J. Biochem. 1994, 219 (3), 953–960. 
(81)  Grishin, N. V; Phillips, M. a; Goldsmith, E. J. Modeling of the Spatial Structure of 
Eukaryotic Ornithine Decarboxylases. Protein Sci. 1995, 4 (7), 1291–1304. 
(82)  Mehta, P. K.; Hale, T. I.; Christen, P. Aminotransferases: Demonstration of Homology 
and Division into Evolutionary Subgroups. Eur. J. Biochem. 1993, 214 (2), 549–561. 
(83)  Slabu, I.; Galman, J. L.; Lloyd, R. C.; Turner, N. J. Discovery, Engineering, and 
Synthetic Application of Transaminase Biocatalysts. ACS Catal. 2017, 7 (12), 8263–
8284. 
(84)  Soda, K.; Yoshimura, T.; Esaki, N. Stereospecificity for the Hydrogen Transfer of 
Pyridoxal Enzyme Reactions. Chem. Rec. 2001, 1 (5), 373–384. 
(85)  Berkovitch, F.; Behshad, E.; Tang, K.-H.; Enns, E. A.; Frey, P. A.; Drennan, C. L. A 
Locking Mechanism Preventing Radical Damage in the Absence of Substrate, as 
Revealed by the X-Ray Structure of Lysine 5,6-Aminomutase. Proc. Natl. Acad. Sci. 
2004, 101 (45), 15870–15875. 
(86)  Lepore, B. W.; Ruzicka, F. J.; Frey, P. A.; Ringe, D. The X-Ray Crystal Structure of 
Lysine-2,3-Aminomutase from Clostridium Subterminale. Proc. Natl. Acad. Sci. 2005, 
102 (39), 13819–13824. 
 






(87)  Graf von Stosch, A. Aspartate Aminotransferase Complexed with Erythro -β-
Hydroxyaspartate: Crystallographic and Spectroscopic Identification of the 
Carbinolamine Intermediate. Biochemistry 1996, 35 (48), 15260–15268. 
(88)  Shaw, J. P.; Petsko, G. A.; Ringe, D. Determination of the Structure of Alanine 
Racemase from Bacillus Stearothermophilus at 1.9-Å Resolution. Biochemistry 1997, 
36 (6), 1329–1342. 
(89)  Sugio, S.; Petsko, G. a.; Manning, J. M.; Soda, K.; Ringe, D. Crystal Structure of a D-
Amino Acid Aminotransferase: How the Protein Controls Stereoselectivity. 
Biochemistry 1995, 34 (Figure 1), 9661–9669. 
(90)  Barford, D.; Hu, S. H.; Johnson, L. N. Structural Mechanism for Glycogen 
Phosphorylase Control by Phosphorylation and AMP. J. Mol. Biol. 1991, 218 (1), 233–
260. 
(91)  Łyskowski, A.; Gruber, C.; Steinkellner, G.; Schürmann, M.; Schwab, H.; Gruber, K.; 
Steiner, K. Crystal Structure of an (R)-Selective ω-Transaminase from Aspergillus 
Terreus. PLoS One 2014, 9 (1). 
(92)  Shin, J. S.; Kim, B. G. Comparison of the Omega-Transaminases from Different 
Microorganisms and Application to Production of Chiral Amines. Bioscience, 
biotechnology, and biochemistry. 2001, pp 1782–1788. 
(93)  Wybenga, G. G.; Crismaru, C. G.; Janssen, D. B.; Dijkstra, B. W. Structural 
Determinants of the β-Selectivity of a Bacterial Aminotransferase. J. Biol. Chem. 
2012, 287 (34), 28495–28502. 
(94)  Koszelewski, D.; Tauber, K.; Faber, K.; Kroutil, W. ω-Transaminases for the Synthesis 
of Non-Racemic α-Chiral Primary Amines. Trends Biotechnol. 2010, 28 (6), 324–332. 
(95)  Truppo, M. D.; Rozzell, J. D.; Turner, N. J. Efficient Production of Enantiomerically 
Pure Chiral Amine at Conc 50 g/L Using Transaminase. Org. Process Res. Dev. 2010, 
14 (1), 234–237. 
(96)  Fuchs, C. S.; Simon, R. C.; Riethorst, W.; Zepeck, F.; Kroutil, W. Synthesis of (R)- or 
 






(S)-Valinol Using ω-Transaminases in Aqueous and Organic Media. Bioorg. Med. 
Chem. 2014, 22 (20), 5558–5562. 
(97)  Ward, J.; Wohlgemuth, R. High-Yield Biocatalytic Amination Reactions in Organic 
Synthesis. Curr. Org. Chem. 2010, 14 (17), 1914–1927. 
(98)  O’Reilly, E.; Turner, N. J. Enzymatic Cascades for the Regio- and Stereoselective 
Synthesis of Chiral Amines. Perspect. Sci. 2015, 4, 55–61. 
(99)  Slabu, I.; Galman, J. L.; Lloyd, R. C.; Turner, N. J. Discovery, Engineering, and 
Synthetic Application of Transaminase Biocatalysts. ACS Catal. 2017, 7 (12), 8263–
8284. 
(100)  Höhne, M.; Kühl, S.; Robins, K.; Bornscheuer, U. T. Efficient Asymmetric Synthesis of 
Chiral Amines by Combining Transaminase and Pyruvate Decarboxylase. 
ChemBioChem 2008, 9 (3), 363–365. 
(101)  Gomm, A.; Lewis, W.; Green, A. P.; O’Reilly, E. A New Generation of Smart Amine 
Donors for Transaminase-Mediated Biotransformations. Chem. - A Eur. J. 2016, 22 
(36), 12692–12695. 
(102)  Green, A. P.; Turner, N. J.; O’Reilly, E. Chiral Amine Synthesis Using ω-
Transaminases: An Amine Donor That Displaces Equilibria and Enables High-
Throughput Screening. Angew. Chemie - Int. Ed. 2014, 10714–10717. 
(103)  Hailes, H.; Baud, D.; Ladkau, N.; Moody, T.; Ward, J. M. A Rapid, Sensitive 
Colorimetric Assay for the High-Throughput Screening of Transaminases in Liquid or 
Solid-Phase. Chem. Commun. 2015, 51, 17225–17228. 
(104)  Guan, L.-J.; Ohtsuka, J.; Okai, M.; Miyakawa, T.; Mase, T.; Zhi, Y.; Hou, F.; Ito, N.; 
Iwasaki, A.; Yasohara, Y.; et al. A New Target Region for Changing the Substrate 
Specificity of Amine Transaminases. Sci. Rep. 2015, 5, 10753. 
(105)  Genz, M.; Vickers, C.; van den Bergh, T.; Joosten, H. J.; Dörr, M.; Höhne, M.; 
Bornscheuer, U. T. Alteration of the Donor/acceptor Spectrum of the (S)-Amine 
Transaminase from Vibrio Fluvialis. Int. J. Mol. Sci. 2015, 16 (11), 26953–26963. 
 






(106)  Berglund, P.; Humble, M. S.; Branneby, C. C–X Bond Formation: Transaminases as 
Chiral Catalysts: Mechanism, Engineering, and Applications. In Comprehensive 
Chirality; Elsevier, 2012; Vol. 7, pp 390–401. 
(107)  Hwang, B. Y.; Cho, B. K.; Yun, H.; Koteshwar, K.; Kim, B. G. Revisit of 
Aminotransferase in the Genomic Era and Its Application to Biocatalysis. J. Mol. 
Catal. B Enzym. 2005, 37 (1–6), 47–55. 
(108)  Steffen-Munsberg, F.; Vickers, C.; Kohls, H.; Land, H.; Mallin, H.; Nobili, A.; Skalden, 
L.; van den Bergh, T.; Joosten, H.-J.; Berglund, P.; et al. Bioinformatic Analysis of a 
PLP-Dependent Enzyme Superfamily Suitable for Biocatalytic Applications. 
Biotechnol. Adv. 2015, 33 (5), 566–604. 
(109)  Morrison, J. L.; Breitling, R.; Higham, D. J.; Gilbert, D. R. A Lock-and-Key Model for 
Protein-Protein Interactions. Bioinformatics 2006, 22 (16), 2012–2019. 
(110)  Hirotsu, K.; Goto, M.; Okamoto, A.; Miyahara, I. Dual Substrate Recognition of 
Aminotransferases. Chem. Rec. 2005, 5 (3), 160–172. 
(111)  Malashkevish, V.; Onuffer; Kirsch; Jansonius, J. Alternating Arginine -Modulated 
Substrate Specificity in an Engineered Tyrosinase Aminotransferase. Nat. sturctural 
Biol. 1995, 2 (7), 548–553. 
(112)  Kamitori, S.; Okamoto, A.; Hirotsu, K.; Higuchi, T.; Kuramitsu, S.; Kagamiyama, H.; 
Matsuura, Y.; Katsube, Y. Three-Dimensional Structures of Aspartate 
Aminotransferase from Escherichia Coli and Its Mutant Enzyme at 2.5 A Resolution. 
J. Biochem. 1990, 108 (2), 175–184. 
(113)  Steffen-Munsberg, F.; Vickers, C.; Thontowi, A.; Schätzle, S.; Meinhardt, T.; 
SvedendahlHumble, M.; Land, H.; Berglund, P.; Bornscheuer, U. T.; Höhne, M. 
Revealing the Structural Basis of Promiscuous Amine Transaminase Activity. 
ChemCatChem 2013, 5 (1), 154–157. 
(114)  Park, E.-S.; Kim, M.; Shin, J.-S. Molecular Determinants for Substrate Selectivity of ω-
Transaminases. Appl. Microbiol. Biotechnol. 2012, 93 (6), 2425–2435. 
 






(115)  Humble, M. S.; Cassimjee, K. E.; Hãkansson, M.; Kimbung, Y. R.; Walse, B.; Abedi, V.; 
Federsel, H. J.; Berglund, P.; Logan, D. T. Crystal Structures of the Chromobacterium 
Violaceumω-Transaminase Reveal Major Structural Rearrangements upon Binding of 
Coenzyme PLP. FEBS J. 2012, 279 (5), 779–792. 
(116)  Kaulmann, U.; Smithies, K.; Smith, M. E. B.; Hailes, H. C.; Ward, J. M. Substrate 
Spectrum of ω-Transaminase from Chromobacterium Violaceum DSM30191 and Its 
Potential for Biocatalysis. Enzyme Microb. Technol. 2007, 41 (5), 628–637. 
(117)  Rausch, C.; Lerchner, A.; Schiefner, A.; Skerra, A. Crystal Structure of the ω-
Aminotransferase from Paracoccus Denitrificans and Its Phylogenetic Relationship 
with Other Class III Amino- Transferases That Have Biotechnological Potential. 
Proteins Struct. Funct. Bioinforma. 2013, 81 (5), 774–787. 
(118)  Denesyuk, A. I.; Denessiouk, K. a; Korpela, T.; Johnson, M. S. Functional Attributes of 
the Phosphate Group Binding Cup of Pyridoxal Phosphate-Dependent Enzymes. J. 
Mol. Biol. 2002, 316 (1), 155–172. 
(119)  Al Toma, R. S.; Brieke, C.; Cryle, M. J.; Süssmuth, R. D. Structural Aspects of 
Phenylglycines, Their Biosynthesis and Occurrence in Peptide Natural Products. Nat. 
Prod. Rep. 2015, 32 (8), 1207–1235. 
(120)  Mast, Y. J.; Wohlleben, W.; Schinko, E. Identification and Functional Characterization 
of Phenylglycine Biosynthetic Genes Involved in Pristinamycin Biosynthesis in 
Streptomyces Pristinaespiralis. J. Biotechnol. 2011, 155 (1), 63–67. 
(121)  Al Toma, R. S.; Brieke, C.; Cryle, M. J.; Süssmuth, R. D. Structural Aspects of 
Phenylglycines, Their Biosynthesis and Occurrence in Peptide Natural Products. Nat. 
Prod. Rep. 2015, 32 (8), 1207–1235. 
(122)  van Wageningen, A. M. A.; Kirkpatrick, P. N.; Williams, D. H.; Harris, B. R.; Kershaw, J. 
K.; Lennard, N. J.; Jones, M.; Jones, S. J. M.; Solenberg, P. J. Sequencing and Analysis 
of Genes Involved in the Biosynthesis of a Vancomycin Group Antibiotic. Chem. Biol. 
1998, 5 (3), 155–162. 
 






(123)  Hubbard, B. K.; Thomas, M. G.; Walsh, C. T. Biosynthesis of L-P-
Hydroxyphenylglycine, a Non-Proteinogenic Amino Acid Constituent of Peptide 
Antibiotics. Chem. Biol. 2000, 7 (12), 931–942. 
(124)  Wegman, M. A.; Janssen, M. H. A.; van Rantwijk, F.; Sheldon, R. A. Towards 
Biocatalytic Synthesis of β-Lactam Antibiotics. Adv. Synth. Catal. 2001, 343 (6–7), 
559–576. 
(125)  Leuchtenberger, W.; Huthmacher, K.; Drauz, K. Biotechnological Production of 
Amino Acids and Derivatives: Current Status and Prospects. Appl. Microbiol. 
Biotechnol. 2005, 69 (1), 1–8. 
(126)  Guo, F.; Berglund, P. Transaminase Biocatalysis: Optimization and Application. Green 
Chem. 2017, 19 (2), 333–360. 
(127)  Wiyakrutta, S.; Meevootisom, V. A Stereo-Inverting D-Phenylglycine 
Aminotransferase from Pseudomonas Stutzeri ST-201: Purification, Characterization 
and Application for D-Phenylglycine Synthesis. J. Biotechnol. 1997, 55 (3), 193–203. 
(128)  Rojanarata, T.; Opanasopit, P.; Ngawhirunpat, T.; Saehuan, C.; Wiyakrutta, S.; 
Meevootisom, V. A Simple, Sensitive and Green Bienzymatic UV-Spectrophotometric 
Assay of Amoxicillin Formulations. Enzyme Microb. Technol. 2010, 46 (3–4), 292–
296. 
(129)  Khampha, W.; Meevootisom, V.; Wiyakrutta, S. Spectrophotometric Enzymatic 
Cycling Method Using L-Glutamate Dehydrogenase and D-Phenylglycine 
Aminotransferase for Determination of L-Glutamate in Foods. Anal. Chim. Acta 
2004, 520 (1–2), 133–139. 
(130)  Müller, U.; van Assema, F.; Gunsior, M.; Orf, S.; Kremer, S.; Schipper, D.; Wagemans, 
A.; Townsend, C. A.; Sonke, T.; Bovenberg, R.; et al. Metabolic Engineering of the E. 
Coli L-Phenylalanine Pathway for the Production of D-Phenylglycine (D-Phg). Metab. 
Eng. 2006, 8 (3), 196–208. 
(131)  Kongsaeree, P.; Samanchart, C.; Laowanapiban, P.; Wiyakrutta, S.; Meevootisom, V. 
 






Crystallization and Preliminary X-Ray Crystallographic Analysis of D-Phenylglycine 
Aminotransferase from Pseudomonas Stutzeri ST201. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 2003, 59 (5), 953–954. 
(132)  Visek, K. Amines, Fatty. In Kirk-Othmer Encyclopedia of Chemical Technology; John 
Wiley & Sons, Inc.: Hoboken, NJ, USA, 2003; Vol. 2, pp 518–537. 
(133)  Barrault, J.; Pouilloux, Y. Synthesis of Fatty Amines. Selectivity Control in Presence of 
Multifunctional Catalysts. Catal. Today 1997, 37 (2), 137–153. 
(134)  Nelson, P. E.; Desjardins, A. E.; Plattner, R. D. Fumonisins, Mycotoxins Produced by 
Fusarium Species: Biology, Chemistry, and Significance. Annu. Rev. Phytopathol. 
1993, 31 (1), 233–252. 
(135)  Hartinger, D.; Moll, W. Fumonisin Elimination and Prospects for Detoxification by 
Enzymatic Transformation. World Mycotoxin J. 2011, 4 (3), 271–283. 
(136)  Zitomer, N. C.; Mitchell, T.; Voss, K. a.; Bondy, G. S.; Pruett, S. T.; Garnier-Amblard, E. 
C.; Liebeskind, L. S.; Park, H.; Wang, E.; Sulllards, M. C.; et al. Ceramide Synthase 
Inhibition by Fumonisin B1 Causes Accumulation of 1-Deoxysphinganine. A Novel 
Category of Bioactive 1-Deoxysphingoid Bases and 1-Deoxydihydroceramides 
Biosynthesized by Mammalian Cell Lines and Animals. J. Biol. Chem. 2009, 284 (8), 
4786–4795. 
(137)  Marasas, W. F. O.; Riley, R. T.; Hendricks, K. A.; Stevens, V. L.; Sadler, T. W.; 
Gelineau-van Waes, J.; Missmer, S. A.; Cabrera, J.; Torres, O.; Gelderblom, W. C. A.; 
et al. Fumonisins Disrupt Sphingolipid Metabolism, Folate Transport, and Neural 
Tube Development in Embryo Culture and In Vivo: A Potential Risk Factor for Human 
Neural Tube Defects among Populations Consuming Fumonisin-Contaminated 
Maize. J. Nutr. 2004, 134 (4), 711–716. 
(138)  Dragan, Y. P.; Bidlack, W. R.; Cohen, S. M.; Goldsworthy, T. L.; Hard, G. C.; Howard, P. 
C.; Riley, R. T.; Voss, K. A. Implications of Apoptosis for Toxicity, Carcinogenicity and 
Risk Assessment: Fumonisin B1 as an Example. Toxicol. Sci. 2001, 61 (1), 6–17. 
 






(139)  Gelderblom, W. C. A.; Marasas, W. F. O.; Jaskiewicz, K.; Combrinck, S.; 
Vanschalkwyk, D. J. Cancer Promoting Potential of Different Strains of Fusarium-
Moniliforme in a Short-Term Cancer Initiation Promotion Assay. Carcinogenesis 
1988, 9 (8), 1405–1409. 
(140)  Heinl, S.; Hartinger, D.; Thamhesl, M.; Vekiru, E.; Krska, R.; Schatzmayr, G.; Moll, W. 
D.; Grabherr, R. Degradation of Fumonisin B1 by the Consecutive Action of Two 
Bacterial Enzymes. J. Biotechnol. 2010, 145 (2), 120–129. 
(141)  Heinl, S.; Hartinger, D.; Thamhesl, M.; Schatzmayr, G.; Moll, W. D.; Grabherr, R. An 
Aminotransferase from Bacterium ATCC 55552 Deaminates Hydrolyzed Fumonisin 
B1. Biodegradation 2011, 22 (1), 25–30. 
(142)  Hartinger, D.; Schwartz, H.; Hametner, C.; Schatzmayr, G.; Haltrich, D.; Moll, W. D. 
Enzyme Characteristics of Aminotransferase FumI of Sphingopyxis Sp. MTA144 for 
Deamination of Hydrolyzed Fumonisin B 1. Appl. Microbiol. Biotechnol. 2011, 91 (3), 
757–768. 
(143)  Hartinger, D.; Heinl, S.; Schwartz, H. E.; Grabherr, R.; Schatzmayr, G.; Haltrich, D.; 
Moll, W. Enhancement of Solubility in Escherichia Coli and Purification of an 
Aminotransferase from Sphingopyxis Sp. MTA144 for Deamination of Hydrolyzed 
Fumonisin B(1). Microb. Cell Fact. 2010, 9, 62. 
(144)  Chantarasiri, A.; Meevootisom, V.; Isarangkul, D.; Wiyakrutta, S. Effective 
Improvement of D-Phenylglycine Aminotransferase Solubility by Protein Crystal 
Contact Engineering. J. Mol. Microbiol. Biotechnol. 2012, 22 (3), 147–155. 
(145)  Jariyachawalid, K.; Laowanapiban, P.; Meevootisom, V.; Wiyakrutta, S. Effective 
Enhancement of Pseudomonas Stutzeri D-Phenylglycine Aminotransferase 
Functional Expression in Pichia Pastoris by Co-Expressing Escherichia Coli GroEL-
GroES. Microb. Cell Fact. 2012, 11 (1), 47. 
(146)  Bonissone, S.; Gupta, N.; Romine, M.; Bradshaw, R. A.; Pevzner, P. A. N-Terminal 
Protein Processing: A Comparative Proteogenomic Analysis. Mol. Cell. Proteomics 
2013, 12 (1), 14–28. 
 






(147)  Geoghegan, K. F.; Dixon, H. B. F.; Rosner, P. J.; Hoth, L. R.; Lanzetti, A. J.; Borzilleri, K. 
A.; Marr, E. S.; Pezzullo, L. H.; Martin, L. B.; LeMotte, P. K.; et al. Spontaneous α-N-6-
Phosphogluconoylation of a “His Tag” inEscherichia coli:The Cause of Extra Mass of 
258 or 178 Da in Fusion Proteins. Anal. Biochem. 1999, 267 (1), 169–184. 
(148)  Baxter, S.; Royer, S.; Grogan, G.; Brown, F.; Holt-Tiffin, K. E.; Taylor, I. N.; 
Fotheringham, I. G.; Campopiano, D. J. An Improved Racemase/acylase 
Biotransformation for the Preparation of Enantiomerically Pure Amino Acids. J. Am. 
Chem. Soc. 2012, 134 (47), 19310–19313. 
(149)  Faber, K. Biotransformations in Organic Chemistry; Springer International Publishing: 
Cham, 2018. 
(150)  Truppo, M. D.; Rozzell, J. D.; Moore, J. C.; Turner, N. J. Rapid Screening and Scale-up 
of Transaminase Catalysed Reactions. Org. Biomol. Chem. 2009, 7 (2), 395–398. 
(151)  Truppo, M. D.; David Rozzell, J.; Turner, N. J. Efficient Production of Enantiomerically 
Pure Chiral Amines at Concentrations of 50 g/L Using Transaminases. Org. Process 
Res. Dev. 2010, 14 (1), 234–237. 
(152)  Green, A. P.; Turner, N. J.; O’Reilly, E. Chiral Amine Synthesis Using ω-
Transaminases: An Amine Donor That Displaces Equilibria and Enables High-
Throughput Screening. Angew. Chemie Int. Ed. 2014, 53 (40), 10714–10717. 
(153)  Hailes, H.; Baud, D.; Ladkau, N.; Moody, T.; Ward, J. M. A Rapid, Sensitive 
Colorimetric Assay for the High-Throughput Screening of Transaminases in Liquid or 
Solid-Phase. Chem. Commun. 2015, 51, 17225–17228. 
(154)  Zhou, Y.; Wu, S.; Li, Z. One-Pot Enantioselective Synthesis of D-Phenylglycines from 
Racemic Mandelic Acids, Styrenes, or Biobased L-Phenylalanine via Cascade 
Biocatalysis. Adv. Synth. Catal. 2017, 359 (24), 4305–4316. 
(155)  Breuer, M.; Ditrich, K.; Habicher, T.; Hauer, B.; Keßeler, M.; Stürmer, R.; Zelinski, T. 
Industrial Methods for the Production of Optically Active Intermediates. Angew. 
Chemie Int. Ed. 2004, 43 (7), 788–824. 
 






(156)  Tentolouris, N.; Voulgari, C.; Katsilambros, N. A Review of Nateglinide in the 
Management of Patients with Type 2 Diabetes. Vasc. Health Risk Manag. 2007, 3 (6), 
797–807. 
(157)  Kepert, I.; Fonseca, J.; Müller, C.; Milger, K.; Hochwind, K.; Kostric, M.; Fedoseeva, 
M.; Ohnmacht, C.; Dehmel, S.; Nathan, P.; et al. D-Tryptophan from Probiotic 
Bacteria Influences the Gut Microbiome and Allergic Airway Disease. J. Allergy Clin. 
Immunol. 2017, 139 (5), 1525–1535. 
(158)  Hansford, K. A.; Reid, R. C.; Clark, C. I.; Tyndall, J. D. A.; Whitehouse, M. W.; Guthrie, 
T.; McGeary, R. P.; Schafer, K.; Martin, J. L.; Fairlie, D. P. D-Tyrosine as a Chiral 
Precusor to Potent Inhibitors of Human Nonpancreatic Secretory Phospholipase A2 
(IIa) with Antiinflammatory Activity. ChemBioChem 2003, 4 (2–3), 181–185. 
(159)  Qiu, J.; Su, E.; Wang, W.; Wei, D. High Yield Synthesis of D-Phenylglycine and Its 
Derivatives by Nitrilase Mediated Dynamic Kinetic Resolution in Aqueous-1-Octanol 
Biphasic System. Tetrahedron Lett. 2014, 55 (8), 1448–1451. 
(160)  Liu, H.; Naismith, J. H. An Efficient One-Step Site-Directed Deletion, Insertion, Single 
and Multiple-Site Plasmid Mutagenesis Protocol. BMC Biotechnol. 2008, 8, 91. 
(161)  van Oosterwijk, N.; Willies, S.; Hekelaar, J.; Terwisscha van Scheltinga, A. C.; Turner, 
N. J.; Dijkstra, B. W. Structural Basis of the Substrate Range and Enantioselectivity of 
Two ( S )-Selective ω-Transaminases. Biochemistry 2016, 55 (31), 4422–4431. 
(162)  Robert, X.; Gouet, P. Deciphering Key Features in Protein Structures with the New 
ENDscript Server. Nucleic Acids Res. 2014, 42 (W1), 320–324. 
(163)  Jomrit, J.; Summpunn, P.; Meevootisom, V.; Wiyakrutta, S. Sensitive Non-
Radioactive Determination of Aminotransferase Stereospecificity for C-4’ Hydrogen 
Transfer on the Coenzyme. Biochem. Biophys. Res. Commun. 2011, 405 (4), 626–631. 
(164)  Dickschat, J. S. Modern Aspects of Isotopic Labellings in Terpene Biosynthesis. 
European J. Org. Chem. 2017, 2017 (33), 4872–4882. 
(165)  Rinkel, J.; Dickschat, J. S. Recent Highlights in Biosynthesis Research Using Stable 
 






Isotopes. Beilstein J. Org. Chem. 2015, 11, 2493–2508. 
(166)  Thiverny, M.; Farran, D.; Philouze, C.; Blandin, V.; Chavant, P. Y. Totally 
Diastereoselective Addition of Aryl Grignard Reagents to the Nitrone-Based Chiral 
Glycine Equivalent MiPNO. Tetrahedron: Asymmetry 2011, 22 (12), 1274–1281. 
(167)  Govindaraju, V.; Basus, V. J.; Matson, G. B.; Maudsley, A. A. Measurement of 
Chemical Shifts and Coupling Constants for Glutamate and Glutamine. Magn. Reson. 
Med. 1998, 39 (6), 1011–1013. 
(168)  Ghisalba, O.; Meyer, H.-P.; Wohlgemuth, R. Industrial Biotransformation. Encycl. Ind. 
Biotechnol. Bioprocess, Biosep. Cell Technol. 2009, 4 (1–2), 1–18. 
(169)  Straathof, A. J. J.; Panke, S.; Schmid, A. The Production of Fine Chemicals by 
Biotransformations. Curr. Opin. Biotechnol. 2002, 13 (6), 548–556. 
(170)  Cassimjee, K. E.; Federsel, H.-J. CHAPTER 13. EziG: A Universal Platform for Enzyme 
Immobilisation. In Biocatalysis: An Industrial Perspective; The Royal Society of 
Chemistry, 2017; pp 345–362. 
(171)  Homaei, A. A.; Sariri, R.; Vianello, F.; Stevanato, R. Enzyme Immobilization: An 
Update. J. Chem. Biol. 2013, 6 (4), 185–205. 
(172)  Bradford, M. M. A Rapid and Sensitive Method for the Quantitation of Microgram 
Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal. Biochem. 
1976, 72 (1–2), 248–254. 
(173)  Zhou, Y.; Wu, S.; Li, Z. One-Pot Enantioselective Synthesis of D -Phenylglycines from 
Racemic Mandelic Acids , Styrenes , or Biobased L -Phenylalanine via Cascade 
Biocatalysis. 2017. 
(174)  Benedetti, R.; Nazzi, F.; Locci, R.; Firrao, G. Degradation of Fumonisin B1 by a 
Bacterial Strain Isolated from Soil. Biodegradation 2006, 17 (1), 31–38. 
(175)  Marasa, W.; Miller, J.; RIley, R.; Visconti, A.; Marasas, W.; Miller, J.; RIley, R.; 
Visconti, A. Fumonisin B1. Environ. Heal. Criteria 2000, 150. 
 






(176)  Walker, J. M. Mitochondrial Disorders; Wong, Ph.D., L.-J. C., Ed.; Methods in 
Molecular Biology; Humana Press: Totowa, NJ, 2012; Vol. 837. 
(177)  Bhushan, R.; Brückner, H. Marfey’s Reagent for Chiral Amino Acid Analysis: A 
Review. Amino Acids 2004, 27 (3–4), 231–247. 
(178)  Bhushan, R.; Brückner, H. Use of Marfey’s Reagent and Analogs for Chiral Amino 
Acid Analysis: Assessment and Applications to Natural Products and Biological 
Systems. J. Chromatogr. B 2011, 879 (29), 3148–3161. 
(179)  B’Hymer, C.; Montes-Bayon, M.; Caruso, J. A. Marfey’s Reagent: Past, Present, and 
Future Uses of 1-Fluoro-2,4-Dinitrophenyl-5-L-Alanine Amide. J. Sep. Sci. 2003, 26 
(1–2), 7–19. 
(180)  Marfey, P. Determination of D-Amino Acids. II. Use of a Bifunctional Reagent, 1,5-
Difluoro-2,4-Dinitrobenzene. Carlsberg Res. Commun. 1984, 49 (6), 591–596. 
(181)  Bhushan, R.; Tanwar, S. RP-LC Resolution of (R,S)-Atenolol via Diastereomerization 
with Marfey’s Reagent and Its Structural Variants Under Conventional and 
Microwave Heating. Chromatographia 2008, 68 (9–10), 849–853. 
(182)  Hess, S.; Gustafson, K. R.; Milanowski, D. J.; Alvira, E.; Lipton, M. A.; Pannell, L. K. 
Chirality Determination of Unusual Amino Acids Using Precolumn Derivatization and 
Liquid Chromatography-Electrospray Ionization Mass Spectrometry. J. Chromatogr. 
A 2004, 1035 (2), 211–219. 
(183)  Del Pozo, A. M.; Merola, M.; Ueno, H.; Manning, J. M.; Tanizawa, K.; Nishimura, K.; 
Soda, K.; Ringe, D. Stereospecificity of Reactions Catalyzed by Bacterial D-Amino 
Acid Transaminase. J. Biol. Chem. 1989, 264 (30), 17784–17789. 
(184)  Akhtar, M. K.; Turner, N. J.; Jones, P. R. Carboxylic Acid Reductase Is a Versatile 
Enzyme for the Conversion of Fatty Acids into Fuels and Chemical Commodities. 
Proc. Natl. Acad. Sci. 2013, 110 (1), 87–92. 
(185)  Winkler, M. Carboxylic Acid Reductase Enzymes (CARs). Curr. Opin. Chem. Biol. 2018, 
43 (2), 23–29. 
 






(186)  Gahloth, D.; Dunstan, M. S.; Quaglia, D.; Klumbys, E.; Lockhart-Cairns, M. P.; Hill, A. 
M.; Derrington, S. R.; Scrutton, N. S.; Turner, N. J.; Leys, D. Structures of Carboxylic 
Acid Reductase Reveal Domain Dynamics Underlying Catalysis. Nat. Chem. Biol. 
2017, 13 (9), 975–981. 
(187)  Stolterfoht, H.; Steinkellner, G.; Schwendenwein, D.; Pavkov-Keller, T.; Gruber, K.; 
Winkler, M. Identification of Key Residues for Enzymatic Carboxylate Reduction. 
Front. Microbiol. 2018, 9 (2), 1–15. 
(188)  Hansen, E. H.; Møller, B. L.; Kock, G. R.; Bünner, C. M.; Kristensen, C.; Jensen, O. R.; 
Okkels, F. T.; Olsen, C. E.; Motawia, M. S.; Hansen, J. De Novo Biosynthesis of Vanillin 
in Fission Yeast (Schizosaccharomyces Pombe) and Baker’s Yeast (Saccharomyces 
Cerevisiae). Appl. Environ. Microbiol. 2009, 75 (9), 2765–2774. 
(189)  France, S. P.; Hussain, S.; Hill, A. M.; Hepworth, L. J.; Howard, R. M.; Mulholland, K. 
R.; Flitsch, S. L.; Turner, N. J. One-Pot Cascade Synthesis of Mono- and Disubstituted 
Piperidines and Pyrrolidines Using Carboxylic Acid Reductase (CAR), ω-Transaminase 
(ω-TA), and Imine Reductase (IRED) Biocatalysts. ACS Catal. 2016, 6 (6), 3753–3759. 
(190)  Finnigan, W.; Thomas, A.; Cromar, H.; Gough, B.; Snajdrova, R.; Adams, J. P.; 
Littlechild, J. A.; Harmer, N. J. Characterization of Carboxylic Acid Reductases as 
Enzymes in the Toolbox for Synthetic Chemistry. ChemCatChem 2017, 9 (6), 1005–
1017. 
(191)  Griswold, W. R.; Toney, M. D. Role of the Pyridine Nitrogen in Pyridoxal 5ʹ-
Phosphate Catalysis: Activity of Three Classes of PLP Enzymes Reconstituted with 
Deazapyridoxal 5ʹ-Phosphate. J. Am. Chem. Soc. 2011, 133 (37), 14823–14830. 
(192)  Swinehart, D. F. The Beer-Lambert Law. J. Chem. Educ. 1962, 39 (7), 333. 
(193)  Liu, C.; Molinski, T. F. Preparation of α-Amino Acids by Oxidative Oxazoline-
Oxazinone Rearrangement-Hydrogenation (OOOH). Scope and Limitations. Chem. - 
An Asian J. 2011, 6 (8), 2022–2027. 
(194)  Kabsch, W. Integration, Scaling, Space-Group Assignment and Post-Refinement. Acta 
 






Crystallogr. Sect. D Biol. Crystallogr. 2010, 66 (2), 133–144. 
(195)  Evans, P. R.; Murshudov, G. N. How Good Are My Data and What Is the Resolution? 
Acta Crystallogr. Sect. D Biol. Crystallogr. 2013, 69 (7), 1204–1214. 
(196)  Karplus, P. A.; Diederichs, K. Linking Crystallographic Model and Data Quality. 
Science (80-. ). 2012, 336 (6084), 1030–1033. 
(197)  McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; 
Read, R. J. Phaser Crystallographic Software. J. Appl. Crystallogr. 2007, 40 (Pt 4), 
658–674. 
(198)  McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; 
Read, R. J. Phaser Crystallographic Software. J. Appl. Crystallogr. 2007, 40 (4), 658–
674. 
(199)  Afonine, P. V.; Grosse-Kunstleve, R. W.; Echols, N.; Headd, J. J.; Moriarty, N. W.; 
Mustyakimov, M.; Terwilliger, T. C.; Urzhumtsev, A.; Zwart, P. H.; Adams, P. D. 
Towards Automated Crystallographic Structure Refinement with Phenix.refine. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 2012, 68 (4), 352–367. 
(200)  Nicholls, R. A. Ligand Fitting with CCP 4. Acta Crystallogr. Sect. D Struct. Biol. 2017, 
73 (2), 158–170. 
(201)  Chen, V. B.; Arendall, W. B.; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. 
J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity : All-Atom Structure 
Validation for Macromolecular Crystallography. Acta Crystallogr. Sect. D Biol. 






















































































































































































Appendix 8.5  Calibration curve for the HiLoad 16/600 Superdex 200 column (GE Healthcare) used to 
estimate the molecular weight of the protein based on its retention volume. 
The MW of the protein is estimated as follows: 
  Where   
 
Where: 
MW is measured in Da 
Ve = elution volume 
Vo = Void volume (41.94 mL) 


















Appendix 8.6 Chiral HPLC calibration curves of: (A) D-phenylgylcine (B) D-4 hydroxyphenylglycine (C) 
D- phenylalanine (D) D- tyrosine (E) D-tryptophan. Each amino acid concentration (0 – 800 mM) was 
analysed using the following solvents (0.025% triethylammonium acetate (TEAA):MeOH (50:50). The 
flow rate was 1 min mL-1 with elution monitored at   = 205 nm. Data was analysed by non-linear 





















Wavelength (Å) 0.9795 
Resolution range (Å) 49.47 - 2.248 (2.329 - 2.248) 
Space group C 1 2 1 
Unit cell (Å) a = 329.28, b = 83.90, c = 133.42 
Unit cell ()  = 111.56 
Total reflections 60,0728 (56,842) 
Unique reflections 160,521 (15,800) 
Multiplicity 3.7 (3.6) 
Completeness (%) 99.76 (98.19) 
Mean I/sigma(I) 12.70 (1.39) 
Wilson B-factor (Å2) 48.16 
Rmerge 0.062 (0.869) 
Rmeas 0.072 (1.018) 
Rpim 0.037 (0.522) 
CC1/2 0.998 (0.609) 
CC* 1 (0.87) 
Diffraction images (DOI) 10.5281/zenodo.1059413 
Refinement 
Reflections used in refinement 160,770 (15,797) 
Reflections used for Rfree 8,144 (782) 
Rwork 0.1828 (0.2874) 
Rfree 0.2106 (0.3125) 
CC(work) 0.963 (0.794) 
CC(free) 0.952 (0.763) 
Number of non-hydrogen atoms 20,642 
Macromolecules 20,233 
solvent 409 
Protein residues 2641 
RMS (bonds) (Å) 0.004 
RMS (angles) () 0.97 
Ramachandran favored (%) 97.13 
Ramachandran allowed (%) 2.80 
Ramachandran outliers (%) 0.08 
Rotamer outliers (%) 2.20 
Clashscore 1.92 
Average B-factor (Å2) 60.63 
Macromolecules (Å2) 60.80 
Solvent (Å2) 52.36 
Number of TLS groups 32 
PDB code 6G1F 
 
Appendix 8.7 D-PhgAT X-ray crystallographic data collection and refinement statistics. Statistics for 
the highest-resolution shell are shown in parentheses. 
 







Appendix 8.8 C18 HPLC calibration curves of (A) D-phenylgylcine (B) D-4 hydroxyphenylglycine. Each 
amino acid concentration (0 – 800 mM) was analysed using a C18 column. The flow rate was 1min 























Wavelength (Å) 0.976 
Resolution range (Å) 46.79  - 1.65 (1.709  - 1.65) 
Space group P 1 21 1 
Unit cell (Å) 63.18 104.419 65.25 90 109.264 90 
Unit cell () 303657 (28488) 
Total reflections 95437 (9514) 
Unique reflections 3.2 (3.0) 
Multiplicity 99.56 (99.09) 
Completeness (%) 12.40 (1.57) 
Mean I/sigma(I) 20.90 
Wilson B-factor (Å2) 0.05703 (0.6757) 
Rmerge 0.06848 (0.8182) 
Rmeas 0.03749 (0.4555) 
Rpim 0.999 (0.712) 
CC1/2 1 (0.912) 
Refinement 
Reflections used in refinement 95418 (9512) 
Reflections used for Rfree 4734 (430) 
Rwork 0.1751 (0.3584) 
Rfree 0.2031 (0.3419) 
CC(work) 0.970 (0.830) 
CC(free) 0.968 (0.866) 
Number of non-hydrogen atoms 7041 
Macromolecules 6406 
solvent 32 
Protein residues 603 
RMS (bonds) (Å) 826 
RMS (angles) () 0.013 
Ramachandran favored (%) 1.50 
Ramachandran allowed (%) 97.08 
Ramachandran outliers (%) 2.68 
Rotamer outliers (%) 0.24 
Clashscore 1.24 
Average B-factor (Å2) 1.35 
Macromolecules (Å2) 25.98 
Solvent (Å2) 25.29 
Reflections used in refinement 22.56 
Reflections used for Rfree 33.44 
PDB code 6HBS 
 
Appendix 8.9  FumI X-ray crystallographic data collection and refinement statistics. Statistics for the 
highest-resolution shell are shown in parentheses. 
